Skip to search.

Breaking News Visit Yahoo! News for the latest.

×Close this window

saathii

The Yahoo! Groups Product Blog

Check it out!

Group Information

  • Members: 3263
  • Category: AIDS-HIV
  • Founded: Feb 19, 2000
  • Language: English
? Already a member? Sign in to Yahoo!

Yahoo! Groups Tips

Did you know...
Real people. Real stories. See how Yahoo! Groups impacts members worldwide.

Messages

Advanced
Messages Help
Messages 4767 - 4796 of 4842   Oldest  |  < Older  |  Newer >  |  Newest
Messages: Show Message Summaries Sort by Date ^  
#4767 From: Sughis Muhammad <sughism@...>
Date: Tue Dec 13, 2011 9:53 am
Subject: (No subject)
sughism
Send Email Send Email
 
Dear Professionals, 

We are pleased to inform you that, the Volume 2, Issue 4 of theHealth is available online (ahead of print). theHealth has open access policy and so all the content is available online without any registration fee. However, print version is available by paid subscription. To subscribe, please visit the website.

Call for articles for March 2012 Issue
theHealth entertains manuscripts from all domains of health sciences from pilot studies to review articles, from public health to health economics. You are invited to submit your scholarly work for upcoming issues.

Deadline for article submission for March issue is 15 January, 2012.
 
Volume 2, Issue 4, December 2011
CURRENT ISSUE
Table of Contents
ci
fbjn
 
Editorials
Automated blood sampling in drug discovery and development
Deferme S
Full Text [pdf]
Cervical cancer screening - A recent approach
Agrawal R
Full Text [pdf]
Research
A study of dental hygiene and decayed, missed, and filled status among patients attending dental OPD of Bankura Sammilani Medical College, India
Soren AB, Mundle M, Das D, Chattachapadhyay S, Ray SK, et al.
Full Text [pdf]
Comparison of respiratory outcome among small for gestational age and appropriate for gestational age premature infants
Gharehbaghi MM, Peirovifar A, Gharabaghi PM, Hamzei V
Full Text [pdf]
Overseas Pakistanis seeking medical education in Pakistan
Mahmood A, Ejaz S, Ali M, Khatoon F, Syed AA, et al.
Full Text [pdf]
Short stature in children: Experience from a tertiary care hospital in Kolkata, India
Chowdhury SP, Sarkar TK, Haldar D, Taraphdar P, Naskar TK, et al.
Full Text [pdf]
Prescribing and dispensing pattern: Implication in the right of access to essential medicines
Haldar D, Naskar TK, Sarkar TK, Ray SK, Taraphdar P, et al.
Full Text [pdf]
Review
Virulence traits of Shiga toxin producing Escherichia coli
Khan AB, Naim A
Full Text [pdf]
From Our Correspondents
A commendable health initiative: The roll back malaria programme in Ghana - Part I
Danso-Abeam D
The National Health Service feeling the credit crunch
Hashim Z
Mortality due to environmental pollution in Italy
Casale A
Full Text [pdf]
LIPhealth Updates
CRPH focused for international recognition
CRPH plan to organize a series of symposium for high school graduates in Lahore, Pakistan
theHealth is indexed in the Directory of Open Access Journals (DOAJ)
HEAL Pakistan and IEC4Change to support flood victims
LIPhealth and Public Health Agency of Barcelona
Full Text [pdf]

For the editorial board.
_______________
Muhammad Sughis
Skype: sughis
________________________________________
For social and professional interaction,
Join Pakistani Students Abroad (PSA)
http://groups.google.com/group/psabroad

#4768 From: SAATHII Jobs <jobs@...>
Date: Tue Dec 20, 2011 10:31 am
Subject: Socio-Economic and Legal Protection: vacancies in Orissa and Rajasthan
jobs@...
Send Email Send Email
 
SAATHII seeks to fill program and accounts/admin vacancies in its Orissa and Rajasthan offices. These are for a UNDP-supported initiative promote access and uptake of inclusive socio-economic and legal services for marginalized groups such as MSM, transgender people, sex workers, injecting drug users and people living with HIV. The team will work in partnership with State AIDS Control Societies, with communities affected by HIV/AIDS and other organizations from the civil society and for-profit sectors. Besides state-level advocacy, the project will focus on Ajmer, Alwar, Barmer, Jaipur, Udaipur and Jodhpur in Rajasthan; and Angul, Bolangir, Bhadrak, Ganjam, Baleswar, and Khordha in Orissa.

The duration of the project is one year. Successful candidates will enter a probationary period of three months prior to confirmation based on performance.  All positions require strong oral and written communication skills, ability to plan and organize, a strong work ethic, and willingness to travel.  Remuneration is competitive and will be commensurate with skill-set, and experience.

Interested candidates are requested to send a cover letter detailing their eligibility for the position, an updated resume, salary last earned and expect, and two references (including a recent/current employer to jobs@... on or before December 27, 2011.

Please specify the Position and State you are applying for in your e-mail subject. 
POSITION 1: Team Lead JOB CODE: SAATHII-ASP-TL-1211
POSITION 2: Program Officer – Socio-Economic Protection and Inclusion JOB CODE: SAATHII-ASP-PO-Social-1211
POSITION 3: Program Officer – Legal Protection and Literacy JOB CODE: SAATHII-ASP-PO-Legal-1211
POSITION 4:  Finance and Administrative Officer JOB CODE: SAATHII-ASP-FAO-1211

Details are below:
----------------------------------------------------------------------------
POSITION 1: Team Lead (at level of Senior Project Manager or Associate Director, depending on credentials)
JOB CODE: SAATHII-ASP-TL-1211


No. of posts  - Two, one each for Orissa and Rajasthan
Office location: Jaipur  and Bhubaneswar
Travel: Focal districts in the respective states, with occasional travel to Delhi and Chennai

Role: The candidates will be expected to lead the projects in the respective states; ensure adherence to timelines, documentation and reporting; bring about synergies among related initiatives in the state, and help design state-specific strategies and sustainability plans. They will also need to provide supportive mentorship to project staff for quality enhancement.

Qualifications and Experience

• Post graduate in social sciences / public health / development, or  equivalent with a minimum of five years experience in the field of  HIV/AIDS prevention and / or care, support and treatment
• Experience and proven skills in project management
• Self-starter with demonstrated skills in leadership
• Community public health knowledge
• Proven ability to develop and maintain working relationship with partners from the government, non-government and academic sectors.
• Familiarity with issues of sex, gender and sexuality; and awareness of key issues facing PLHIV communities, sexual minorities, sex workers and IDUs
• Commitment to meaningful involvement of HIV-affected communities in interventions, planning and capacity-building
• Experience in training and technical assistance
• Qualitative and quantitative analytical skills and research experience and plus
• Good command over English and Hindi, with at least a working knowledge of Marwari (for Rajasthan position) or Oriya (Orissa)

----------------------------------------------------------------------------
POSITION 2: Program Officer – Socio-Economic Protection and Inclusion
JOB CODE: SAATHII-ASP-PO-Social-1211


No. of posts  - Two, one each for Orissa and Rajasthan
Office location: Jaipur  and Bhubaneswar
Travel: Focal districts in the respective states, with occasional travel to Delhi and Chennai

Role: The candidates will work to increase access to social protection services for PLHIV and sexual minorities, sex workers and IDUs. This will include access to government schemes at state level and in the focal districts, access to income generation programs. Processes will include baseline/endline research, rapport-building and sensitization of key government departments on issues pertaining to marginalized groups, building on previous work already carried out  on PLHIV issues. He/she will work with PLHIV, sexual minority and sex worker communities in the sensitization and advocacy of stakeholders from government, business and civil society.

Qualifications and Experience

• Post graduate in social sciences/public health/ development, or equivalent with a minimum of three years experience in the field of  HIV/AIDS prevention and/or care, support and treatment
• Strong communication skills in English and the local language are critical.
• Experience in networking and advocacy with diverse stakeholders
• Familiarity with issues of sex, gender and sexuality; and awareness of key issues facing PLHIV communities, sexual minorities, sex workers and IDUs
• Experience with community mobilization and coalition building a plus
• Ability to work in a large and diverse team
• Crisis management and troubleshooting skills 
. Computer skills, including use of Internet and MS Office

----------------------------------------------------------------------------
POSITION 3: Program Officer – Legal Protection and Literacy
JOB CODE: SAATHII-ASP-PO-Legal-1211


No. of posts  - Two, one each for Orissa and Rajasthan

Office location: Jaipur  and Bhubaneswar

Travel: Focal districts in the respective states, with occasional travel to Delhi and Chennai

Role: The candidates will work to increase access to legal aid for PLHIV, sexual minorities, sex workers and IDUs,  enhance legal literacy of these focal groups, sensitize members of bar associations, legal services authorities and law enforcement, and on issues HIV, sexuality and the law. He/she will also be involved in baseline and endline research.

Qualifications and Experience

• Bachelors degree in Law
OR
Post graduate in social sciences/public health/ development with a minimum of three years experience in the field of  HIV, gender and/or sexuality
• Knowledge of legal issues facing PLHIV and members of marginalized and at-risk groups such as MSM, Hijras, sex workers and IDUs
• Strong communication skills in English and the local language are critical.
• Experience in working with law and law enforcement authorities a plus
 Computer skills, including use of Internet and MS Office
• Ability to work in a large and diverse team
• Crisis management and troubleshooting skills 

----------------------------------------------------------------------------
POSITION 4:  Finance and Administrative Officer
JOB CODE: SAATHII-ASP-FAO-1211

No. of posts  - Two, one each for Orissa and Rajasthan
Office location: Jaipur  and Bhubaneswar
Travel: Focal districts in the respective states, with occasional travel to Delhi and Chennai

Role: The candidates will support the project and respective offices in Jaipur and Bhubaneswar in finance and administration. Activities will include:
  • Oversight of accounts and administration relating to the project
  • Day-to-day management of accounts
  • Preparation and submission of project MIS on monthly basis
  • Managing petty cash
  • Preparation of vouchers
  • Assistance in payroll processing
  • Updating and maintaining of administrative registers
  •  Ensuring compliance with organization procurement procedures
Qualifications and Experience
  • Graduate or Post Graduate in Commerce/Accounts with at least 3 years of experience in accounts, preferably with exposure to non-profit sector.
  • Good written and oral communication in English
  • Excellent knowledge of Tally (TM)
  •  Computer skills, including use of Internet and MS Office (TM)
  • Ability to work in a team
  • Office administration skills
Interested candidates are requested to send a cover letter detailing their eligibility for the position, an updated resume, salary last earned and expect, and two references (including a recent/current employer to jobs@... on or before December 27, 2011.

SAATHII provides a secular working environment and does not discriminate based on HIV/AIDS, religious or community affiliations, gender or sexual orientation. 
---------

#4769 From: SAATHII Jobs <jobs@...>
Date: Tue Dec 20, 2011 11:23 am
Subject: vacancy: Webmaster and Content Developer (Chennai or Hyderabad)
jobs@...
Send Email Send Email
 
JOB TITLE Webmaster and Content Developer
JOB CODE: SAATHII-WebCD-1211

No. of posts  - One
Location: Chennai or Hyderabad

Role: The candidate will be expected to maintain and update SAATHII’s
website saathii.org and project-specific websites, and develop content
related to SAATHII’s projects

Specific tasks include, but are not limited to:
- Plan and execute re-organization of the website saathii.org
(including a Joomla to Wordpress conversion)
- Develop content relating to HIV/AIDS projects of SAATHII to populate
new pages, augment existing ones
- Develop e-learning modules and online training needs/impact
assessment in partnership with technical teams
- Document website changes and analyze web-traffic for program
evaluation purposes.
- Design and implement program-specific websites/pages
- Verify submitted links for suitability based on content provided by
other program staff
- Followup with program and admin teams across SAATHII’s seven offices
on a weekly basis for content development and updating
- Compile newsletters of media coverage on HIV/AIDS.

Qualifications and Experience
- Professional degree and/or appropriate diploma/certificate in relevant  area.
- Proven track record of designing and maintaining websites.
- Prior exposure or work in public health issues a plus
- Ability to develop online content based on SAATHII’s documents and
communication with program teams
- Desirable: experience with database-driven pages such as content
management systems, and with tools such as Adobe Creative Suite.
- Excellent written, spoken and editing skills in English.
- Attention to detail in both format and content.
- Ability to follow up diligently with program and staff teams across
SAATHII's offices to obtain updated information

Interested and suitably qualified candidates are requested to send a
cover letter detailing their eligibility for the position, resume, and
two references (including a recent/current employer) to
jobs@... on or before December 27, 2011. Please specify
preferred location (Chennai or Hyderabad) in your application.

Remuneration is competitive and will be commensurate with skill-set,
and experience.

SAATHII provides a secular working environment and does not
discriminate based on HIV/AIDS, religious or community
affiliations,gender or sexual orientation.

--
SAATHII: Solidarity and Action Against the HIV Infection in India
www.saathii.org
Job inquiries: jobs@...

#4770 From: "amitie.trust" <amitie.trust@...>
Date: Tue Dec 20, 2011 11:02 am
Subject: Situations Vacant
amitie.trust
Send Email Send Email
 

Job Titles:

  1. Programme Officer – 1,
  2. Counsellor – 1,
  3. Administration & Accounts Officer – 1,
  4. Outreach Workers – 2,
  5. Peer Educators – 4.

 

Employing Agency: Amitié Trust

 

Name of the Programme: Project Pehchan – Community Systems Strengthening for Men who have Sex with Men (MSM), Hijra and Transgender Communities in India

 

Location: Western parts of Hooghly District – Singur, Tarakeswar, Arambagh etc.

 

Date of Issue: December 20, 2011

 

Closing Date: December 26, 2011

 

The Organisation: Amitié Trust is a community based organization of, by and for people marginalized because of their non-conventional sexualities and/ or gender non-conformities. Continuing with the works started by Amitié Society in 2003, Amitié Trust got registered on April 01, 2009 and working in the districts of Howrah, Hooghly of West Bengal as a network of individuals celebrating diverse non-conventional sexualities (gays, homosexuals, lesbians, bisexual men and women, people practising same-sex behaviour without any identities etc.) and/ or gender identities (kothis, duplis, parikhs, transpersons, Hijras etc.) not appreciated by social norms, to improve the quality and standard of their lives and towards restoring unto them their human rights and human dignity.

 

The Programme: Amitié Trust has been empanelled as a sub-sub-recipient (SSR) to implement Project Pehchan – Community Systems Strengthening for Men who have Sex with Men (MSM), Hijra and Transgender Communities in India in collaboration with Alliance India (Principal Recipient – PR) and Solidarity and Action Against The HIV Infection in India (SAATHII) Kolkata Office (Sub Recipient – SR) in the above-mentioned areas in the district of Hooghly with funding support from The Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM).

 

Main objectives of this intervention are:
a) To strengthen community systems that reach MSM, Hijra and Transgender communities;
b) To increase the number of beneficiaries reached by such systems;
c) To strengthen the relevant health system resources and
d) To increase knowledge and advocacy for MSM, Hijra and Transgender communities.

 

Amitié Trust invites applications from suitable candidates for the following vacancies:

 

  1. Programme Officer

a)      No. of vacancies – 1

b)      Approximate monthly salary – ` 6500/-

c)      Educational qualification – Master in Social Work/ M. A. in Sociology, knowledge of MS Office and internet.

d)      Desired qualities – Fluency in written and spoken Bengali and English, good communication skills, good documentation skills, good leadership qualities, sound knowledge in sexual health issues especially HIV/ AIDS and gender and sexuality issues, ability to work with people marginalized because of their non-conventional sexualities and/ or gender non-conformities as well as sexual health issues.

e)      Experiences in the relevant field will be considered to be an advantage.

 

  1. Counsellor

a)      No. of vacancies – 1

b)      Approximate monthly salary – ` 5500/-

c)      Educational qualification – M. A. in Psychology/ Master in Social Work/ M. A. in Sociology/ Post Graduate Degree in any social sciences with Diploma or Certificate in Counselling from a reputed and recognized institute, knowledge of MS Office and internet.

d)      Desired qualities – Fluency in written and spoken Bengali and English, good communication skills, good documentation skills, good motivational skills, sound knowledge in sexual health issues especially HIV/ AIDS and gender and sexuality issues, ability to work with people marginalized because of their non-conventional sexualities and/ or gender non-conformities as well as sexual health issues.

e)      Experiences in the relevant field will be considered to be an advantage.

 

  1. Administration and Accounts Officer

a)      No. of vacancies – 1

b)      Approximate monthly salary - ` 5000/-

c)      Educational qualification – Degree in Commerce – preferably with major in Accounts. Should be efficient in using Tally accounting software.

d)      Desired qualities - Fluency in written and oral Bengali and English, good communication skills, good documentation skills, ability to work with people marginalized because of their non-conventional sexualities and/ or gender non-conformities as well as sexual health issues.

e)      Experiences in the relevant field will be considered to be an advantage.

 

  1. Outreach Workers

a)      No. of vacancies – 2

b)      Approximate monthly salary – ` 4500/-

c)      Essential factor – Should be from the MTH communities with proven track record of working among the MTH communities with wide visibility and acceptability.

d)      Educational qualifications – Preferably graduate in any discipline and fluency in written and spoken Bengali.

e)      Desired qualities – Fluency in written and spoken English, good communication skill, good motivational skills, ability to work in a team, basic knowledge in sexual health issues especially HIV/ AIDS and gender and sexuality issues, basic knowledge of computer handling.

f)        Experiences in the relevant field will be considered to be an advantage.

 

  1. Peer Educators

a)      No. of vacancies – 4

b)      Monthly volunteer compensation – ` 1500/-

c)      Essential factor – Should be from the MTH communities with visibility and acceptance in the local MTH communities.

d)      Educational qualifications – Preferably Madhyamik passed and fluency in written and spoken Bengali.

e)      Desired qualities – Good communication skill, motivational skills, ability to work in a team, basic knowledge in sexual health issues especially HIV/ AIDS and gender and sexuality issues.

 

For vacancies no. 1, 2 & 3: Applications addressed to the Settlor Trustee, Amitié Trust and clearly marked as "Application for the post of ……" along with a comprehensive CV in English including the names of two referees and mentioning the last pay drawn should be mailed to amitie.trust@... on or before midnight of December 26, 2011. Applications sent to any other mail address or delivered through any other channel will not be entertained.

 

For vacancies no. 3 & 4: Applications addressed to the Settlor Trustee, Amitié Trust along with a comprehensive CV in Bengali or English could be mailed to amitie.trust@... or delivered by post or courier or in person to the Registered Office at Amitie' Trust, Flat no. – 112, 1st Floor, Rear Block, Sonali Complex, 4, Lalababu Shire Road, P.O. Belurmath, Dist. Howrah, West Bengal, India – 711202 or to Aparna Banerjee, c/o Mukul Roy, 12 C, Provashnagar, Srirampore, Hooghly – 712249 on or before midnight of December 26, 2011.

 

N. B. –

 

  • All vacancies are announced tentatively on basis of the empanelment. Confirmation of selected candidates is subject to signing of final contract between SAATHII and Amitié Trust.
  • All vacancies are contractual by nature for the period of the contract to be signed between SAATHII and Amitié Trust and subject to renewal on basis of extension of the contract period.
  • Final monthly salaries will be fixed according to the contract to be signed between SAATHII and Amitié Trust and subject to fluctuation in accordance with the rate of conversion between US $ and `.
  • Encouragement relaxations in educational qualifications permissible for otherwise exceptionally suitable PLHIV and/ or persons from MTH communities in vacancies no. 1, 2 and 3.
  • If shortlisted, the candidates will be informed over telephone as well as e-mail for the date, time and venue of the interview.
  • Only those able to join immediately are required to apply.

#4771 From: Amitava Sarkar <amitava_123in@...>
Date: Tue Dec 20, 2011 1:42 pm
Subject: Re: Vacancy announcement for the post of Community Mobiliser - Odisha, Project Pehchan
amitava_123in
Send Email Send Email
 

Job title:

Community Mobiliser - Odisha, Project Pehchan (Job code BBSR-PEH-CMO-1212)

Employing organization: Solidarity and Action Against The HIV Infection in India (SAATHII), India

Location: Bhubaneswar, India

Date of Issue: December 21, 2011

Closing Date: December 25, 2011

About SAATHII:

SAATHII, a non-government organization founded in 2000, works to strengthen the capacities of individuals and organizations working on sexual and reproductive health (SRH) and HIV in India through information dissemination, networking, advocacy, research and technical assistance services.

It is known for innovative and multi-sectoral initiatives in the SRH, HIV and associated fields. SAATHII is registered as a tax-exempt charitable trust with offices in Chennai (Head Office), Kolkata, Hyderabad, Bhubaneswar, Jaipur, Imphal and Nagpur.

Job Descriptions:

SAATHII will implement a long term project titled “Project Pehchan: MSM, Hijra and TG Community Systems Strengthening”, in partnership with emerging and existing CBOs in the states of West Bengal, Orissa, Jharkhand and Manipur, with funding support from the Global Fund for AIDS, Tuberculosis and Malaria (GFATM), and technical assistance from India HIV/AIDS Alliance, New Delhi. Main objectives of this intervention are: a) To strengthen community systems that reach MSM, Hijra and transgender (TG) communities; b) To increase the number of beneficiaries reached by such systems; c) To strengthen the relevant health system resources and d) To increase knowledge and advocacy for MSM, Hijra and transgender concerns.

SAATHII is looking for suitable individual for the post Community Mobiliser – Odisha, Project Pehchan

Job Description of Community Mobiliser – Odisha, Project Pehchan:

The Community Mobiliser – Odisha position requires an individual from the MSM, Transgender or Hijra community who has broad knowledge and experience in issues related to HIV/AIDS, gender and sexuality along with leadership qualities.  The principal role of the Community Mobiliser will be to assist the project implementing partner CBOs in mobilizing MSM, TG and Hijra communities in specific areas to form groups, building capacity of the groups to construct the foundation of a CBO and provide assistance to establish the CBO through registration.  S/he will also interact with other project staff and India HIV/AIDS Alliance staff and provide necessary implementation assistance.


The Community Mobiliser – Odisha, Project Pehchan will report to the Project Manager, Project Pehchan

 Skills and Qualifications Required:

1.      At least three years of experience in working on HIV prevention, care, support, treatment programmes with MSM, TG and Hijra populations

2.      Involvement with MSM, TG, Hijra groups / networks as a leader or key member

3.      Graduation or equivalent degree from a reputed university or institute, preferably in social sciences or public health is desirable.

4.      Good command over Oriya, English and Hindi languages (written and spoken). Ability to speak and write in Bengali language will be considered an added qualification.

5.      Ability to work independently and in a team

6.      Demonstrated knowledge base and documentation skills in relation to gender, sexuality, human rights and HIV/AIDS communication

7.      Proficiency in computer usage (including Microsoft Office software and internet)

8.      Willingness to travel extensively in the project area mentioned earlier.

Monthly pay amounts:

Around Rs. 7000/- per month, plus provident fund (organizational contribution) at the prescribed rate.

A contract of nine months will be offered for the post.

People living with HIV candidates and candidates from gender or sexuality minority sections are encouraged to apply.

To apply:


Please submit a comprehensive CV in English with a supporting cover letter, including the names of three referees (preferably one should be a current or previous employer), as well as last salary earned, and whether able to join immediately or not.

Applications should be sent by courier or e-mail to the following contact address, and be clearly marked: “Application for the post of Community Mobiliser – Odisha, Project Pehchan”

Contact address:

Director, Kolkata Office

Solidarity and Action Against The HIV Infection in India (SAATHII)

229, Kalitala Main Road, Purbachal (North), Kolkata 700 078

E-mail: saathii.jobs@... (CVs sent to any other e-mail ID will not be entertained) 

Website: www.saathii.org  

Closing date for applications: December 25, 2011

Likely interview and written examination date and venue for short listed candidates will be intimated over phone.



#4772 From: subhasree raghavan <subhasree.raghavan@...>
Date: Mon Dec 26, 2011 4:55 am
Subject: Chennai- January 4: Public Lecture on Health Care for MSM, Sexual and Gender Minorities
subhasree_ra...
Send Email Send Email
 




Public lecture

 

Health issues of MSM and other sexual and gender minority populations, and the components of culturally competent care.

 

Speaker: Dr. Kenneth H Mayer

 

Infectious Disease Attending and director of HIV Prevention Research, Beth Israel Deaconess Medical Centre,

Visiting professor of Medicine, Harvard Medical School,

Medical Research Director, The Fenway Institute

 

 

4th January, 2012 at 3 pm

 

Organised by

 

                 Solidarity and Action Against The HIV Infection in India (SAATHII)

       Tamil Nadu State AIDS Control Society (TANSACS)

&

         National Institute for Research in Tuberculosis (NIRT)

 

 

 

Venue: Robert Koch Auditorium

National Institute for Research in Tuberculosis (Formerly TRC)-ICMR

No: 1 Satyamoorthy Road, Chetpet-600031

 

 

All are invited

 

 

Contact for Details: 044 – 28369513, +919840030951 




--
Dr. Sai Subhasree Raghavan
President, SAATHII 
India Mobile: 919840033302
Skype: Subhasree
http://www.saathii.org/orc
SAATHII-Chennai: 044 28173948
SAATHII-Calcutta: 033 23347329
SAATHII-Hyderabad:040 27674757

1 of 1 File(s)


#4773 From: SAATHII <saathii@...>
Date: Mon Jan 2, 2012 7:21 am
Subject: HIV/AIDS Factsheets in Indian Languages
saathii
Send Email Send Email
 
Dear All
 AIDS InfoNet is a project of the New Mexico AIDS Education and Training Center in the Infectious Diseases Division of the University Of New Mexico School Of Medicine. InfoNet was originally  designed to make information on HIV/AIDS services and treatments easily accessible in both English and Spanish for residents of New Mexico. Its mission has expanded for providing HIV/AIDS treatment information in non-technical language in various languages. The primary audience for InfoNet materials includes people living with HIV and their caregivers, especially nurses and other first-line treatment providers. Through collaborative agreements with AIDS service organizations in various countries, the InfoNet is expanding the range of languages in which its materials are offered.
Solidarity and Action Against The HIV Infection in India (SAATHII) is a national non-profit that has been working for over a decade towards universal access to health care in India through strengthening and scaling up HIV/AIDS, reproductive, sexual, maternal and child health and nutrition services. As a collaborative effort with AIDS Infonet, SAATHII has adapted factsheets on various topics of HIV/AIDS to the Indian context and translated into various Indian languages, including Hindi, Tamil, Telugu, Bengali and Manipuri.
The translated factsheets can be accessed at the web  links provided below:
 
 
 
 
 
 
 
 
Please do contact us through saathii@... if you have any queries or comments related to the translated factsheets.
Thanking you
Sincerely
Chitwant Tahalyani
Coordinator – Factsheet review,  translation and dissemination
 
 
 

#4774 From: Sughis Muhammad <sughism@...>
Date: Sat Dec 31, 2011 10:34 am
Subject: Final Call
sughism
Send Email Send Email
 
Call for articles for March 2012 Issue

Dear Professionals, 

We would like to invite you to submit your scholarly work for March issue of theHealth journal. theHealth entertains manuscripts from all domains of health sciences from pilot studies to review articles, from public health to health economics. You are invited to submit your scholarly work for upcoming issues.

Deadline for article submission for March issue is 15 January, 2012. For more information, please visit: www.thehealth.liphealth.pk

Regards,
_______________
Muhammad Sughis
Skype: sughis
________________________________________
For social and professional interaction,
Join Pakistani Students Abroad (PSA)
http://groups.google.com/group/psabroad

#4775 From: "siaap ." <siaap@...>
Date: Tue Jan 3, 2012 3:42 pm
Subject: South India AIDS Action Programme (Siaap) is interested in receiving applications for the following Senior Position.
siaap@...
Send Email Send Email
 
South India AIDS Action Programme (Siaap) is interested in receiving applications for the following Senior Position.

PROJECT OFFICER:

Project officer will report to the Programme Manager to implement strategies to attain the   outcome of a specific project. The officer will perform duties, make suggestions and follow guidelines in relation to the project. She/he will play an important role in implementation of the project.

A.     Job Requirements:

1.      Qualification: Graduates in any discipline with good command in English and Tamil both spoken and written. Knowing  Hindi would be an added advantage

2.      Experience: A minimum of 3 years experience preferably in nonprofit organizations. It would be preferable if he/she has worked with the teams independently.

3.      Skills: Person should be a team player who takes initiative and motivates the team.  The project officer must have strong verbal and written communication skills; should be organized, motivated and work individually as well as with a team. She/he also needs to understand the project scope; should be eager to work with the vulnerable  communities like Men who have sex with Men, Women in sex work and People living with HIV & AIDS.

4.      Travel: The project officer should be open to travel at least 15 days in a month.

B.     Emoluments: It shall commensurate with Experience.

C.     Last day of receipt of applications: All applicants are requested to send their complete resume by 15th  January 2012 by 12 noon (IST) .

Please send your resume to :   admin.siaap@..., admin.siaap@...

D.      Process of selection:  Short listed applicants shall be called for a written test and personal interview. They will be expected to join immediately. Preference will be given to persons belonging to sexual minorities and who actively work with and for their issues and rights.

#4776 From: "nirmala" <nirmaala@...>
Date: Fri Jan 6, 2012 11:39 am
Subject: Vancancy for the post of Research Officer/ Consultant
raji196
Send Email Send Email
 
Job Title: Research Officer/ Consultant
Duration of consultancy: February-April 2012 (Part time/full time)
Location: Hyderabad, with minimum 25 days travel in Andhra Pradesh
Reports to: Research Supervisor
Date of issue: 06 January, 2012
Closing Date: 16 January, 2012
__________________________________________________________________________
Background:
SAATHII is initiating a research study to capture data on current practices in
HIV counseling for PPTCT, and referral and patient tracking mechanisms in a
sampling of program sites in Andhra Pradesh. Two teams of two (one Research
Officer and one Program Officer each) will be deployed to program sites to
gather original data through interviews with site-level program administrators,
observation of counseling interactions, and surveys with counselors.
We are seeking a suitable candidate for a Research Officer position.
Position Summary:
We are looking for a highly motivated mid-level research officer to support
various aspects of the research study. Specifically, we are looking for the
following objectives to be met:
• Administering 15 -20 semi-structured half hour interviews with program
administrators in select program sites
• Transcription of same interviews
• Mentoring program officer and ensuring standardization of data collection and
data recording processes
• Verifying accuracy of data entry
• Supporting analysis of qualitative findings through assessing information for
reliability and identification of main ideas and themes,
• Supporting analysis of quantitative findings through use of basic statistical
methods, including simple logistic regression, generating descriptive
statistics, and cross tabulation.

All of these objectives will be met under the supervision of the project lead,
and with input from the program officers as required.
Extensive travel is required from this post, as all data will be collected
through field visits. A minimum of 25 days will be spent in the field. All
desk-based activities will be conducted out of the SAATHII office in Hyderabad.

Language Requirements:
• Written and conversational fluency in English and Telugu
• Written and conversational fluency in Hindi desired, but not required

Education and Experience Requirements:
• 1+ years experience developing and administering interviews for research
purposes
• 1+years in statistical data analysis is desired
• Basic understanding of HIV services; some knowledge of PPTCT counseling is
desired

Skills Needed:
• Excellent analytical skills
• Knowledge of CDC EpiInfo™
• Excellent communication skills/ excellent interviewing skills
• Self-motivated and highly organized
• Team-oriented and communicative (most decisions are made collaboratively, and
routine communication with the research team is expected)

Compensation:
• The consultant will be compensated based on previous experience.

Please contact Dasari Ramesh at rameshdasari@... and Rekha Viswanathan
at Rekha@... with a CV if you are interested.

#4777 From: "A.J. Hariharan" <fieldmaster2000@...>
Date: Wed Jan 11, 2012 11:07 am
Subject: “Calls to country’s first lesbian helpline on rise” /ICWO
fieldmaster2000@...
Send Email Send Email
 

 Calls to country’s first lesbian helpline on rise


Daniel George, TNN | Jan 8, 2012, 05.13AM IST

 

CHENNAI: Alternative sexuality may still be a topic discussed only in whispers in Chennai, but the number of city women calling up the first helpline for lesbians in the country has been going up considerably. 

The lesbian helpline (044-65515742) run by Indian Community Welfare Organisation (ICWO) in the city gets, on an average, more than a call every day. Last year the line got 400 calls, up from 150 calls in 2010. In 2009,the year when itwasestablished, the helpline got around 100 calls. 

Most of the calls are from women who are either in dilemma over accepting their sexual orientation or those facing insult and harassment for having spoken it out. "Constant fights at home, especially with the men, are a common complaint from women who callup tosaythey are lesbians," says A J Hariharan of ICWO. "We organise counselling and group discussions to support such people." 

 

Weblink:

 

http://timesofindia.indiatimes.com/city/chennai/Calls-to-countrys-first-lesbian-helpline-on-rise/articleshow/11408484.cms



With regards

A.J.HARIHARAN
Founder Secretary
Indian Community Welfare Organisation-I.C.W.O.
AP-216, 18th Main Road, 'I' Block, 6th Street,
Vallalar Colony, Anna Nagar West, Chennai - 600 040
Phone: 044-26184392, 65515742
Fax: 044-45536392
Mobile: 98401-88821
Email: fieldmaster2000@..., fieldmaster2000@...
Website: www.icwoindia.org

#4778 From: Santanu Pyne <santanu_pyne@...>
Date: Wed Jan 11, 2012 8:41 am
Subject: Vacancy: Post of Project and Finance Officer at Odisha, Project Pehchan
santanu_pyne
Send Email Send Email
 
Job title: Project and Finance
Officer – Odisha, Project Pehchan(Job
code BBSR-PEH-PFO-0112)
Employing organization:Solidarity
and Action Against The HIV Infection in India (SAATHII), India
Location:Bhubaneswar, India
Date of Issue:January 10, 2012
Closing Date:January 20, 2012
About SAATHII:
SAATHII, a non-government organization
founded in 2000, works to strengthen the capacities of individuals and
organizations working on sexual and reproductive health (SRH) and HIV in India
through information dissemination, networking, advocacy, research and technical
assistance services.
It is known for innovative and
multi-sectoral initiatives in the SRH, HIV and associated fields. SAATHII is
registered as a tax-exempt charitable trust with offices in Chennai (Head
Office), Kolkata, Hyderabad, Bhubaneswar, Jaipur, Imphal and Nagpur.
Job Descriptions:
SAATHII is implementing
a long term project titled “Project Pehchan: MSM,
Hijra and TG Community Systems Strengthening”,in partnership with
emerging and existing CBOs in the states of West Bengal, Odisha, Jharkhand and
Manipur, with funding support from the Global Fund for AIDS, Tuberculosis and
Malaria (GFATM), and technical assistance from India HIV/AIDS Alliance, New
Delhi. Main objectives
of this intervention are: a) To strengthen community systems that reach MSM,
Hijra and transgender (TG)
communities; b) To increase the number of beneficiaries reached by such
systems; c) To strengthen the relevant health system resources and d) To
increase knowledge and advocacy for MSM, Hijra and TGconcerns. The overall
project
entails development and strengthening of 200 CBOs across 17 states in Indiato
reach almost 453,750
targeted individuals with SRH and HIV messages and services over a period of
five years. SAATHII will be partnering 38 of these CBOs in four states.
SAATHII is
looking for a suitable individual for the postof Project and Finance Officer –
Odisha,
Project Pehchan.
Job Description:
The Project and Finance Officer – Orissa, Project
Pehchan, will be responsible for assisting the Project
Manager by providing programmatic, financial, technical and organizational
development support to the project implementing partner CBOs of MSM, TGand Hijra
communities
and other vulnerable populations in Odisha; and promoting documentation of good
practices. S/he will also be responsible to provide necessary support in
advocacy and training related issues for the partner CBOs.
Key responsibilities:
1.      Contribute to the development and implementation of appropriate
strategies for the project;
	 1. Support the implementation of project plan strategies and budgets (including
that of the partner CBOs working Odisha).
	 2. Contribute to the implementation of effective monitoring, review and
evaluation strategies and activities against agreed project deliverables
	 3. Support assessment processes within SAATHII and partner CBOs
	 4. Support the organizational development and capacity building plans of
partner CBOs
	 5. Monitor, review and evaluate (both programmatically and financially) the
progress and impact of capacity building programmes
	 6. Assist in managing any relevant external technical support that may be
required for the project and partner CBOs
	 7. Work with other members of the Project team to liaise with partner CBOs in
preparing and submitting programme and financial reports on a timely basis, as
required, for internal and external use
	 8. Provide timely feedback on project reports and other documents relating to
partner CBOs
	 9. Maintain up to date accurate records on all programme and financial
activities and that of partner CBOs
	 10. Support the compilation of information about Pehchan project, including
workshop reports, quarterly and annual reports and review and planning documents
12.  Establish, maintain and strengthen effective
relationships between India HIV/AIDS Alliance, SAATHII and partner CBOs
13.  Undertake other responsibilities such as
training, advocacy and other capacity building programmes for partner CBOs
along with other designated staff
The Project and Finance Officer – Odisha, Project Pehchanwill report to the
Senior Project Manager,Project Pehchan.
Skills
and Qualifications Required:
1.      At least three years of experience in health or
development sectors in managing programme and finance.
2.      Graduation
or higher degree from a recognized university in commerce or financial
management.
3.      Sound skills in usage of the ERP
version of Tally software.Proficiency in
computer usage - including use of Microsoft Office
software and the Internet.
4.      Excellent command over
English, particularly in writing technical reports and correspondence.
5.      Fluency in spoken English, Hindi and Odiya languages.
6.      Ability to
translate documents from English to Odiya and vice versa.
7.      Basic knowledge of
current health and development sector issues, particularly HIV/AIDS, gender,
sexuality, human rights and reproductive health issues.
8.      Experience of working with multiple stakeholders in civil society
and
the government at different levels
9.      Experience of providing
technical, financial and capacity building support to other organizations,
especially those working at the community or grassroots level
10.  Ability to work independently and as a team player in a
complex, multicultural environment, with demonstrated
leadership, communication, networking and presentation capabilities.
11.  Willingness to travel
extensively within Odisha and other states where Project Pehchan is being
implemented, as well as to Delhifor implementation of the
training and other project activities.
12.  Ability to work independently and as a team player in a
complex, multicultural environment, with demonstrated
leadership, communication, networking and presentation capabilities.
Monthly pay
amount:  Rs.19,500/-
per month as cost
to organization. An initial contract up to September 30,  2012  will be
offered, with an option for renewal.
People living with HIV, women
candidates and candidates from gender or sexuality minority sections are
encouraged to apply.
To apply:
Please submit a comprehensive CV in
English with a supporting cover letter, including the names of three referees
(preferably one should be a current or previous employer), as well as last
salary earned, and whether able to join immediately or not.
Applications
should be sent by courier or e-mail to the following contact address, and be
clearly marked: “Application for the post of Project and Finance Officer –
Odisha,
Project Pehchan”
Contact address:
Director, Kolkata Office
Solidarity and
Action Against The HIV Infection in India(SAATHII)
229, Kalitala Main Road, Purbachal (North), Kolkata 700 078
E-mail: saathii.jobs@... (CVs sent to any other e-mail ID will not
be entertained) 
Website: www.saathii.org  
Closing date for
applications:January 20, 2012
Likely interview and written examination date and venue for short listed
candidates will be intimated over phone.

#4779 From: "EMPOWER INDIA" <ttn_empower@...>
Date: Wed Jan 11, 2012 2:46 am
Subject: Global Fund Observer Issue 173
ttn_empower@...
Send Email Send Email
 

GLOBAL FUND OBSERVER (GFO), an independent newsletter about the Global Fund provided by Aidspan to nearly 10,000 subscribers in 170 countries.

Issue 173: 10 January 2012. (For formatted web, Word and PDF versions of this and other issues, see www.aidspan.org/gfo.)

+ + + + + + + + + + + + + + + + + + +
CONTENTS
+ + + + + + + + + + + + + + + + + + +

1. NEWS: Aidspan Guide to TFM Applications Now Available

The English-language version of "The Aidspan Guide to Applications under the Global Fund's Transitional Funding Mechanism" is now available. French-, Spanish and Russian-language versions should be posted by the end of January.

2. ANNOUNCEMENT: Aidspan Seeks Applicants for Three Staff Positions

Aidspan seeks applicants for three newly-established positions: Senior Research Officer, Senior Editor, and Editor/Writer. All three positions are based at the Aidspan office in Nairobi. The closing date for applications is 25 January 2012.

3. NEWS: Secretariat, OIG Agree on New Protocol

The Global Fund Secretariat and the Office of the Inspector General (OIG) have agreed on a new protocol that covers communications between the two entities and describes how they will collaborate on audits, diagnostic reviews and investigations conducted by the OIG.

4. NEWS: Global Fund Releases Additional Information on Changes to Grant Renewal Process

Additional information from the Global Fund on changes to the grant renewal process includes an eligibility list for 2012 renewals and an FAQ document.

5. NEWS: Numbers of Services Provided and People Reached Up Sharply Again in 2011

The Global Fund is continuing to experience solid growth in terms of services provided and the numbers of people reached through programmes supported by the Fund. Estimates of the full year numbers for 2011 were released on 1 December 2011.

6. NEWS: Global Fund Rated High in Transparency

The Global Fund has ranked second out of 58 aid-giving organisations on the subject of transparency, according to a report published by "Publish What You Fund." The Global Fund ranked just behind the World Bank's International Development Association (IDA) programme.

+ + + + + + + + + + + + + + + + + + +

1. NEWS: Aidspan Guide to TFM Applications Now Available

The English-language version of "The Aidspan Guide to Applications under the Global Fund's Transitional Funding Mechanism" is now available at www.aidspan.org/guides. French-, Spanish and Russian-language versions should be posted by the end of January.The deadline for applications under the TFM is 31 March 2011.

The guide is designed to assist applicants with questions on the proposal form that may not be entirely clear, and to provide guidance on how responses to the questions can be structured and on what needs to be included to ensure a full response.

Unlike the guides Aidspan has produced for the last few rounds of funding, which were in two volumes, "The Aidspan Guide to Applications under the Global Fund's Transitional Funding Mechanism" covers everything we think applicants need to know in a single volume.Also, there is no separate version of the guide for multi-country applicants because the proposal forms for single- and multi-country applicants are almost identical.

The following is an extract from the guide's table of contents:

Chapter 1: Introduction

Chapter 2: What's New for Applications under the TFM?

Who Is Eligible to Apply under the TFM?

Duration of Funding

Two Pools of Funding

Prioritisation

Reprogramming

Health Systems Strengthening

Consolidated Proposals Mandatory for Some Applicants

Single Stream of Funding Agreements and Grant Consolidation

Changes to the Proposal Form and Guidelines

Chapter 3: General Information on the TFM Applications Process

Guidelines for Proposals

Eligibility Criteria and Counterpart Financing Requirements

Information Notes and FAQs

Versions of the Proposal Form

Documents that Form Part of Your Application

Process for Submitting a Proposal

The TRP Review

Some Key Concepts Used in All Proposals

General Guidance on Filling Out the Proposal Form

Chapter 4: Guidance on Specific Sections of the TFM Proposal Form

Chapter 5: Guidance on the Attachments

+ + + + + + + + + + + + + + + + + + +

2. ANNOUNCEMENT: Aidspan Seeks Applicants for Three Staff Positions

Aidspan, independent watchdog of the Global Fund and publisher of GFO, seeks applicants for three newly-established positions: Senior Research Officer, Senior Editor, and Editor/Writer. All three positions are based at the Aidspan office in Nairobi. The closing date for applications for all three positions is 25 January 2012.

The Senior Research Officer will support, and partially lead, a new programme of research and analysis designed to make Aidspan the world's foremost repository of knowledge about the Global Fund. Applicants must have a history of high-quality research publications in the field of international health, and superb analytical and writing skills.

The Senior Editor will lead Aidspan's production of news, analysis, commentary, guides and reports on the Global Fund, and will become Editor of GFO. Applicants must have superb analytical, writing, editing and mentoring skills, backed by a proven track record of articles and reports that are clear and free of jargon. Knowledge of international health issues is preferred but not required.

The Editor/Writer, who will report to the Senior Editor, must have credentials of a similar nature, and will increasingly take the lead on various projects.

For further information, please visit www.aidspan.org/jobs.

As reported in GFO Issue 172, Aidspan is also seeking applicants for the position of Executive Director (see article).

+ + + + + + + + + + + + + + + + + + +

3. NEWS: Secretariat, OIG Agree on New Protocol

Protocol describes how the two entities will collaborate on audits, diagnostic reviews and investigations

Process and timelines for audits spelled out

The Global Fund Secretariat and the Global Fund's Office of the Inspector General (OIG) have agreed on a new protocol that describes how the two entities will work together. The protocol covers communications between the Secretariat and the OIG, and outlines how the two entities will collaborate on audits, diagnostic reviews and investigations conducted by the OIG. The protocol also describes the steps involved in conducting audits and diagnostic reviews, complete with timelines.

(A diagnostic review is less extensive than an audit; for example, the accounts of sub-recipients [SRs] are routinely examined in an audit, but are usually not included in a diagnostic review.)

According to the protocol, the Executive Director and the Inspector General will meet every two weeks or more often if needed. Focal points have been identified to handle day-to-day communications. The focal points are:

  • on the OIG side: the directors of the Audit and Investigations units; and
  • on the Secretariat side: the Director of the Country Programs Cluster for grant-related audits, reviews and investigations;and the Director of the Corporate Services Cluster for internal audits.

Audits and diagnostic reviews

The protocol describes the steps involved in preparing for an audit or review, conducting the audit or review, finalising the report, organising debriefing sessions and publishing the final report. The following is a partial list of the steps:

  • Two months prior to the start of an audit or review, the OIG sends notification letters to all parties involved.
  • Six weeks before the start of an audit or review, the Secretariat, CCM and principal recipients (PRs) provide the OIG with information concerning shortcomings, potential irregularities and risks of which they are aware.
  • At least four weeks before the audit or review starts, the OIG calls a planning meeting with the Secretariat in which the Secretariat shares any concerns or issues that it believes should be pursued.
  • The OIG provides the Secretariat with preliminary key findings and recommendations of an audit at least two days before the OIG's debriefing meeting with in-country officials (or, in the case of a diagnostic review, at least one day before).
  • Within 12 weeks following the finalisation of OIG field work, the OIG provides the Secretariat with a first draft of the report. The Secretariat has 15 working days to provide comments.
  • Following integration by the OIG of the comments from the Secretariat, the Secretariat shares the revised draft with the subjects of the audit or review, requesting them to submit comments within 15 working days.
  • Following integration by the OIG of these latest comments, the OIG shares the latest draft of the report with the Secretariat, which has 10 days to comment.
  • A meeting is then held between the OIG and the Secretariat to resolve any outstanding issues.

The final report will note any remaining areas of disagreement between the OIG and the Secretariat and between the OIG and the subjects of the audit.

The protocol notes that if the above timelines are met, the OIG will strive to produce audit reports within six months of the completion of field work. Less time will be required for reports on diagnostic reviews.

As mentioned above, the OIG holds debriefing meetings with stakeholders - e.g., CCMs, PRs, SRs, relevant governmental entities - once its draft report is ready. The protocol says that the OIG will give consideration to meeting first with a limited number of key stakeholders in order to collect information on possible misunderstandings or misrepresentations before debriefing a wider audience. In addition, the protocol says that findings about the Secretariat and LFA should not be presented at the debriefing meeting with CCMs.

The protocol says that the Secretariat, CCM and PRs will receive an advance copy of the final report from the OIG before it is publicly released.

Investigations

With respect to investigations, the protocol says that allegations concerning PRs or SRs received by the OIG directly from whistle-blowers will not be disclosed to the Secretariat (in order to protect the whistle-blowers). In addition, according to the protocol, unlike as is done for audits and diagnostic reviews, the OIG does not provide a country debriefing following the completion of field work for an investigation. This is due to concerns about confidentiality and due process.

To ensure due process, the subject of the investigation is given an opportunity to provide its perspective once the investigation is complete, and prior to the finalisation and release of the report. However, when cases are referred to law enforcement agencies and not immediately published, subjects are not notified of the OIG's investigation outcomes, so that the investigations by these agencies are not compromised.

The protocol says that once the OIG has prepared its draft investigation report, the Secretariat has 15 working days to provide comments. After integrating these comments, the OIG seeks comments from in-country partners and the subjects of the investigation. The OIG integrates these latest comments into the report, noting any remaining disagreement, unless disclosure of these comments would prejudice law enforcement efforts.

Once an investigation report is deemed final by the OIG, the report goes first to the Board's Audit and Ethics Committee and then to the Board. When it is sent to the Board, copies are sent to the Secretariat and in-country stakeholders. All of these steps occur before the report is publicly released.

Recommendations

With respect to recommendations made by the OIG as a result of an audit, diagnostic review or investigation, according to the protocol the Secretariat provides the OIG with an action plan and a timeline for the implementation of the recommendations prior to the release of a final report. The Secretariat provides an explanation for recommendations it does not accept; the protocol says that the OIG and the Secretariat will normally share this explanation with the Board.

Internal audits

With respect to audits of internal Secretariat procedures, the OIG provides detailed reports to the Global Fund's Executive Director. The detailed reports are not provided to the Board and are not published. However, a redacted summary report is sent to the Board and is published. ("Redacted" means that some sensitive information, such as the names of persons under suspicion, are blacked out.)

Grant management following preliminary evidence of misuse

The protocol says that the OIG "normally" informs the Secretariat, preferably through a confidential verbal briefing, of preliminary evidence of misappropriation of grant funds identified in the course of an audit or investigation, so that the Secretariat can make appropriate grant management decisions. However, because any action taken by the Secretariat as a result of receiving this information can have significant repercussions for the OIG's continuing work on the case in question, the OIG may decide not to inform the Secretariat, or may decide to provide only partial information, depending upon the circumstances of the audit or the investigation, and whether actions based on any disclosure would "interrupt investigation efforts and cause due process issues."

The protocol says that in instances where the OIG makes a preliminary disclosure that is acted upon by the Secretariat before the completion of the OIG's work, the Secretariat should ensure that this action does not impede the pursuit of the audit or investigation effort.

Noting that the full or partial denial of access by the OIG to the documentation it needs to undertake an audit, review or investigation constitutes a breach of the grant agreement, the protocol says that the Secretariat shall support the OIG when it encounters a lack of cooperation from the subjects of its enquiries.

The undated protocol between the OIG and the Secretariat is not yet available on the Global Fund website. We have posted a copy on the Aidspan website; it is available for direct download here.

+ + + + + + + + + + + + + + + + + + +

4. NEWS: Global Fund Releases Additional Information on Changes to Grant Renewal Process

The Global Fund has posted on its website information on changes to the grant renewals process as a result of decisions made at the November 2011 meeting of the Board. The information is available here.

Most of the information on the website was included in a GFO article in Issue 169, published on 5 December 2011. However, some of the information is new.

The Global Fund has now published an eligibility list for grants renewals in 2012. The list is organised by country and, within each country, by component (i.e., HIV/AIDS, TB, malaria, health systems strengthening). For each component, the list shows whether the country is eligible to apply for renewal and, where the country is eligible, what the focus of proposal requirements are and what the counterpart financing minimum threshold is. The eligibility list can be accessed from the Fund's website, and can also be downloaded directly here.

The Global Fund has also published an FAQ document on the changes to grant renewals. The document can be accessed from the Fund's website, and can also be downloaded directly here.

In addition, the Global Fund has produced a chart depicting the new requirements for grant renewals by income category. The chart can be accessed from the Fund's website, and can also be downloaded directly here.

The Global Fund Secretariat is in the process of updating its request for renewal package. The package includes an application form and guidelines. The formal name of the request for renewals is "request for additional financial commitment," though the Fund uses several different terms on its website. According to the Fund's website, the Global Fund Secretariat will communicate with all applicants that are in the process of submitting their request, or that have already submitted their request, and whose request is scheduled to be reviewed after 1 January 2012. This communication will provide detailed information on the applicant's situation, and may state that the applicant is required to resubmit its request or provide additional information to the Secretariat.

The website also states that more information on different scenarios regarding requests for additional financial commitment will be communicated to affected countries as soon as it is available, "which should be no later than January 2012."

The Global Fund says that specific questions should be directed to fund portfolio managers, and that general inquiries should be sent to Grant.Renewals@....

+ + + + + + + + + + + + + + + + + + +

5. NEWS: Numbers of Services Provided and People Reached Up Sharply Again in 2011

The Global Fund is continuing to experience solid growth in terms of services provided and the numbers of people reached through programmes supported by the Fund, even as reduced estimates of available resources are forcing the Fund to tighten its belt.

The Global Fund released estimates of the full year numbers for 2011 in time for World AIDS Day on 1 December 2011. The number of people who received antiretroviral treatment (ART) in 2011 was 3.3 million, an increase of 10% compared to the 3.0 million people who received ART in 2010. The number of mothers treated to prevent them from transmitting HIV to their babies rose to 1.3 million in 2011, from 1.0 million in 2010, up 30%. The number of HIV testing and counselling sessions rose 27% to 190 million in 2011, compared to 150 million in 2010.

The number of tuberculosis cases detected and treated rose to 8.6 million in 2011 from 7.7 million in 2010, an increase of 12%.

The numbers for malaria were also up sharply:

  • 70 million bed nets were distributed in 2011, an increase of 43% over 2010;
  • indoor residual spraying was carried out in 43 million homes in 2011, an increase of more than one-third over 2010; and
  • the number of malaria cases treated with effective anti-malaria drugs also jumped by more than a third, to 230 million in 2011 from 170 million in 2010.

The Global Fund supports around half of all patients receiving HIV treatment in poor countries, and provides two-thirds of international funding to fight tuberculosis and malaria. The Global Fund estimates that it will disburse between $9.5 and $10 billion to programmes it supports in the period 2011-2013.

The Global Fund announced in November 2011 that because of a sharply deteriorating economic situation, which is placing severe pressure on the budgets of donor countries, the Fund will not be in a position to finance new grants before the end of 2013. The Global Fund's Executive Director, Professor Michel Kazatchkine, appealed to donors to increase funding, saying that while the latest results showed that programmes supported by the Global Fund were delivering remarkable results, far more could be achieved with additional resources. "The poor and the vulnerable must not be made to pay the price for the global financial crisis," Kazatchkine said.

Note: As indicated above, these accomplishments are attributable to programmes that the Global Fund has supported. This does not mean that the Global Fund alone can take credit for this; many of these programmes have also been supported by national governments and other donors. Information for this article was taken from a Global Fund press release.

+ + + + + + + + + + + + + + + + + + +

6. NEWS: Global Fund Rated High in Transparency

The Global Fund has ranked second out of 58 aid-giving organisations on the subject of transparency, according to a report published by "Publish What You Fund," which describes itself as a "global campaign for aid transparency." The Global Fund ranked just behind the World Bank's International Development Association (IDA) programme.

The online, undated report said that most international aid donors are still not open enough about their aid programmes, and that some offer no information at all.

Publish What You Fund was launched at the 2008 Accra High Level Forum on Aid Effectiveness by a coalition of governance, aid effectiveness and access to information organisations.

Organisations were ranked against a series of transparency indicators, using a numerical scoring system. On the basis of total scores, organisations were rated as "good," "fair," "moderate," "poor" or "very poor." No organisation scored high enough to be rated "good." Nine organisations were rated "fair," nine "moderate," 25 "poor" and 15 "very poor." Some of the organisations rated fair (in addition to the Global Fund and the World Bank) were the African Development Bank, the Netherlands and the U.K. Department for International Development.

The report said that the Global Fund performed particularly well on the organisation and activity level indicators; that information on the organisation and its activities is provided in a comprehensive project level database on the Global Fund website; and that the information can be downloaded in Excel. The report said that there is a very high level of information provided for all projects, including agreements and other project documents.

The report from Publish What You Find is available here.

"Reproduced from the Global Fund Observer Newsletter (www.aidspan.org/gfo), a service of Aidspan."

  Forwarded by:

---------------------------

 Yours in Global Concern,

 A.SANKAR

Executive Director- EMPOWER  INDIA - Professional Civil Society Organisation

Founder and General Secretary - Confederation of Indian Civil Society Organisation’s (CICSO)

National Convener- National Alliance for Health, Environment and Rights ( NAFHER)

107J / 133E, Millerpuram

TUTICORIN-628 008, TN, INDIA

Telefax: 91 461 2310151; Mobile:   91 94431 48599: www.empowerindia.org

·         You are invited to join an E FORUM AIDS-TN. To join this free E  Forum kindly send an e  mail    to AIDS-TN-subscribe@yahoogroups.com

·           This e Forum moderated by   EMPOWER, a Non-profit, Non-Political, Voluntary and Professional Civil Society Organisation.

P

 cid:image001.gif@01CC1D41.432C53C0             Please don't print this e-mail unless you really need to.

             S.v.p. ne pas imprimer ce courriel Ă  moins d’en avoir vraiment besoin.

 

 


#4780 From: Prashanth Kumar <gpk.nfi6@...>
Date: Thu Jan 12, 2012 12:04 pm
Subject: Maan AIDS Foundation :Vacancy Announcement:4 Job title : Finance Officer -Pehchan
gpk.nfi6
Send Email Send Email
 
Maan AIDS Foundation :Vacancy Announcement:4
Job title : Finance Officer -Pehchan
Employing Organisation : Maan AIDS Foundation
Location: National Office, Lucknow, India
 
Date of Issue: 12th January 2012
 
Closing Date: 20th January 2012
 
Maan AIDS Foundation is strongly committed to ensuring diversity within our organisation. We strongly welcome applications from sexual minority communities (MSM, Hijra and TG). Maan AIDS Foundation does not discriminate against applicants or employees based on their HIV status, Sexual orientation, or gender identity.
 
Position Description:
The  Finance Officer ‹ Pehchan, will be responsible for assisting the Project‹ Manager by providing , financial, technical and organizational development support to the project implementing partner CBOs of MSM, TG and Hijra communities and other vulnerable populations; and promoting documentation of good practices. s/he will also be responsible to provide necessary support in Financial management & programme  related issues for the partner CBOs.
 
Summary of Responsibilities:
 
·       Contribute to the development and implementation of appropriate strategies for the project;‹
·       Support the implementation of project plan strategies and budgets (including that of the partner CBOs ).‹
·       Contribute to the implementation of effective monitoring, review and evaluation strategies and activities against agreed project deliverables‹
·       Support assessment processes within Maan AIDS Foundation and partner CBOs‹
·       Support the organizational development and capacity building plans of partner CBOs‹
·       Monitor, review and evaluate (both programmatically and financially) the progress and impact of capacity building programmes ‹
·       Assist in managing any relevant external technical support that may be required for the project and partner CBOs‹
·       Work with other members of the Project team to liaise with partner CBOs in preparing and submitting programme and financial reports on a timely basis, as required, for internal and external use‹
·       Provide timely feedback on project reports and other documents relating to partner CBOs‹
·       Maintain up to date accurate records on all programme and financial activities and that of partner CBOs‹
·       Support the compilation of information about Pehchan project, including workshop reports, quarterly and annual reports and review and planning documents‹
·       Establish, maintain and strengthen effective relationships between India HIV/AIDS Alliance, MAAN AIDS FOUNDATION and partner CBOs‹
·       Undertake other responsibilities such as training, advocacy and other capacity building programmes for partner CBOs‹ along with other designated staff ‹
 
 
Skills and Qualifications required
 
·       At least three years of experience in health or development sectors in managing  programme and finance.‹
·       Graduation or higher degree from a recognized university in commerce or financial ‹management. ‹
·       Sound skills in usage of the ERP‹ version of Tally software. Proficiency in computer usage –including use of Microsoft Office software and the Internet.
·       Excellent command over English, particularly in writing technical reports and correspondence.‹
·       Fluency in spoken English, Hindi languages.‹
·       Ability to translate documents from English to Hindi and vice versa.‹
·       Basic knowledge of current health and development sector issues, particularly HIV/AIDS, gender, sexuality, human rights and reproductive health issues.‹
·       Experience of working with multiple stakeholders in civil society and the government at different levels‹
·       Experience of providing‹ technical, financial and capacity building support to other organizations,‹ especially those working at the community or grassroots level‹
·       Ability to work independently and as a team player in a complex, multicultural environment, with demonstrated leadership, communication, networking and presentation capabilities.‹
·       Willingness to travel extensively within North India where Project Pehchan is being implemented, as well as to Delhi for implementation of the training and other project activities.‹
·       Ability to work independently and as a team player in a complex, multicultural environment, with demonstrated leadership, communication, networking and presentation capabilities.
·        
Reports to Programme Manager –Pehchan & Finanace Manager - Parallel Reporting
 
Application are welcomed and encouraged from candidates from sexual / gender minorities with required skills and qualification
 
Remuneration
Salary package will be 2.34 Lakhs per annum
 
To Apply:
Interested candidates should send in their CV with a cover latter and photograph to applications@... & ishrat@... clearly mentioning the subject line and location as Finance Officer -Pehchan ,lucknow
Contact address:
Employment
Maan AIDS Foundation,
39/2,KHA,
21 B Clyde Road
Behind Times of India office,
Lucknow-226001
India
 
Likely interview for the short listed candidates will be intimated via email

#4781 From: "genvp ." <genvp@...>
Date: Sat Jan 14, 2012 9:17 am
Subject: Vaccancy Announcement
genvp@...
Send Email Send Email
 
Gramin Evam Nagar Vikas Parishad (GENVP) is a NGO working in different
districts of Bihar State. The organization is one of the leading
organizations in the field of Health Interventions in Bihar. The
organization is lounging a project “Link Worker Scheme” on HIV/AIDS in
Nawada district.

GENVP is inviting applications for the following posts:

1. DISTRICT RESOURCE PERSON (PROGRAMME)
No. of Post : 1

Eligibility Criteria:
• Should possess a Master’s degree in any discipline (preferably in
Social Science) from a recognized university.
• Should have a minimum of 3-5 years experience of development work,
preferably in programme management.
• HIV positive people, especially positive women, with the required
qualifications and experience should be given preference.
• The individual must have sensitivity of working with marginalized
groups, including people affected by HIV/AIDS and high-risk groups,
hands on experience of working on social mobilization and community
based projects and experience of working with varied partners.

Key Skill Areas:
Programme management – Ability to draw up action plans, work plans for
different cadres with prioritization, review programme implementation,
provide inputs to programme design tailored to the district situation
and provide supervisory inputs to the different cadres of personnel in
the scheme.2

Linkages – Competence to work with different departments in the
government at the district level, civil society partners including
positive networks, PRI members and other divisions under NACP-III at
the district level.

Reporting – Capability to interpret reports and feed back into
programme implementation, share results in an easy to understand
manner with Supervisors and Link Workers, compile programme updates
and share highlights and challenges.

Fund management – Know-how to work with allocated funds, supervise M &
E cum accounts assistant on submission of accounts and budget
preparation.

Responsibilities of DRP (Programme):

1. Ensure mapping activities are conducted in identified villages in
coordination with the SACS/lead NGOs and the mapping agency.

2. Manage selection of Supervisors during the mapping activities.

3. Coordinate development of the District Implementation Plan based on
the mapping data.

4. Ensure selection of Link Worker based on processes defined in the
Operational Guidelines.

5. Coordinate development and implementation of the District
Implementation Plan activities described in the Operational
Guidelines.

6. Review, monitor and supervise the work of Supervisors and Link Workers.

7. Ensure training of staff at all levels in coordination with Lead
NGOs/ SACS/DAPCU.

8. Ensure establishment of systems for fund management, programme
management, information flow and monitoring and supervision.

9. Ensure timely reporting of financial and programme performance to
Lead NGOs/SACS/ DAPCU.

10. Coordinate field visits to handhold the Supervisors and Link
Workers for effective implementation of the scheme.

11. Support the development of communication campaigns at the district
level and their effective implementation with a focus on creating an
empathetic and non-abusive environment.

12. Coordinate with Lead NGO to develop a set of villages as demonstration site.

13. Coordinate with Lead NGO to create networking with allied
government departments- Department of Women & Child Development, Rural
Development, Social Justice and Empowerment, Education, etc. Promote
convergence with ongoing programmes of different ministries, such as
Adolescent Friendly Health Services being envisaged under RCH-II. This
will help to create a better environment for networking care and
support of HRIs and vulnerable young men and women

14. Establish linkages with promotion and availability of condoms.

15. Establish connectivity with Red Ribbon Clubs wherever possible.
29
16. Compile Supervisors’ reports and provide necessary data to DAPCU/NGO.

17. Coordinate analysis and use of information generated by the scheme
to address gaps.

18. Play a strong role in advocacy and in creating an enabling
environment at the district level

19. Ensure implementation of protocols of outcome studies.



Honorarium for the DRP (Programme): Rs. 20,000/- per month.

Apply on or before 18 January 2011 with your CV to Gramin Evam Nagar
Vikas Parishad at hr.genvp@...


2. DISTRICT RESOURCE PERSON (TRAINING)
No. of Post : 1

Eligibility Criteria:

• Should possess a Master’s degree in any discipline (preferably in
Social Sciences) from a recognized university § Must have proficiency
in the local language and dialects.

• Should have a minimum of 2 years experience in training and pedagogy
especially in social sectors like SHG movement, watershed movement,
literacy etc.

• HIV positive people, especially positive women, with the required
qualifications and experience should be given preference.

• The individual must have sensitivity of working with marginalized
groups, including people affected by HIV/AIDS and high-risk groups,
hands on experience of working on social mobilization and community
based projects and experience of working with varied partners.

Key Skill Areas:
Ability to draw up training plans, prepare reports, conduct training
on needs assessment, hand hold and mentor, design training sessions
and coordinate its implementation.
30
Responsibilities of DRP (Training):

1. Ensure training of in-house staff e.g. M & E cum Accounts
Assistants, Supervisors and Link Workers.

2. Ensure training activities are conducted as per the plan defined in
the Operational Guidelines.

3. Ensure development of training reports and sharing with the Lead NGO.

4. Maintain rapport with local health units and facilitate access to services.

5. Coordinate with the Supervisors in their work.
31
6. Conduct orientation training of local health functionaries like
ANM, ASHA, AWW, VHSC members etc.

Honorarium for the DRP (Training): Rs. 15,000/- per month.








3. MONITORING & EVALUATION cum ACCOUNTS ASSISTANT
No. of Post : 1

Eligibility Criteria:

• Should possess a Bachelor’s degree in Commerce/ Financial Accounting
from a recognized university, with proficiency in computers.

• Must have proficiency in the local language and dialects.

• Should have a minimum of 2 years of experience in handling accounts
, MIS data entry and ease in working with NGOs.

• HIV positive people, especially positive women, with the required
qualifications and experience should be given preference.

Key Skill Areas:

Ability to draw up budgets, document financial activities and maintain
books of accounts, consolidate district reports and data entry.

Responsibilities of M & E cum Accounts Assistant:

1. Ensure consolidation of information generated in the mapping
activities and sharing with M & E officer at Lead NGO level.

2. Ensure timely collection of reports, data entry and preparation of
analytical reports for action.
32
3. Ensure timely submission of reports to Lead NGO/ SACS/NACO/DAPCU.

4. Ensure orientation of Supervisors and DRPs on the indicators
outlined in the Operational Guidelines.

5. Ensure procurement process is followed as per the requirements of the scheme.

6. Orient district level and in-house staff on the requirements of
procurement, fund tracking, financial documentation.

7. Ensure proper financial documentation i.e. maintaining books of
accounts, regular bank reconciliation, submission of audit reports,
utilization certificates.

8. Ensure administrative budget is utilized as per requirement of the programme.

Honorarium for the M & E cum Accounts Assistant: Rs. 10,000/- per month.


4. SUPERVISOR

No. of Post: 4 (Four)

Eligibility Criteria:
• Must be a resident preferably of the Nawada district or neighbouring district,

• Must have proficiency in the local language and dialect and command
over local situation.

• Must be at least 10th class pass.

• Must have 3-5 years of experience in the development sector as a
grassroot worker with at least 2 years of experience of working in
programmes at the community level in a supervisory or mentoring
capacity.

• The individual must have sensitivity of working with marginalized
groups, including PLHA and HRG, hands on experience of working on
social mobilization and community based projects and experience of
working with varied partners.

Key Skill Areas:
Supervision – Ability to supervise and mentor groups of people.

Team player – Work as a team and motivate others.

Drive for results - Understand goals and objectives of the programme
and ability to explain the implementation activities at the grassroots
level.

Responsibilities of Supervisor:

1. Undertake responsibilities of Link Worker in a smaller geographical area.
2. Participate in district level village mapping exercise.
3. Guide the Link Workers in the village level household mapping and
other mapping exercises.
4. Ensure regular supply/availability of condoms.
5. Coordinate orientation of ANM, MPW, AWW and ASHA on HIV/AIDS.
6. Maintain rapport with local health units and facilitate access to services.
7. Facilitate and strengthen STI related work being undertaken by
other basic health functionaries.
8. Facilitate formation of condom depots. Ensure timely supply of
condoms in intervention areas.
9. Support the functioning of youth corners.
10. Establish linkage for services and work towards convergence at the
block level with health, education and Panchayati Raj institutions.
11. Establish networking with Government departments to link families
for social entitlement support.
12. Ensure stigma and discrimination is addressed in planned activities.
13. Coordinate with Link Workers in formation of RRCs and SHGs.
14. Receive and compile reports of work done by Link Workers.
15. Monitor and assure a minimum standard of output expected of Link Workers.

Honorarium for the Supervisor: Rs. 5,500/- per month.

Apply on or before 18 January 2011 with your CV to Gramin Evam Nagar
Vikas Parishad at hr.genvp@...

#4782 From: "EMPOWER INDIA" <ttn_empower@...>
Date: Tue Jan 17, 2012 1:21 pm
Subject: Civil Society Questionnaire on Scaling up and Improving the Quality of Health Profession​al Education
ttn_empower@...
Send Email Send Email
 

 Dear all,

Last week, you received a message asking for your assistance in the completion of a survey that addresses civil society views on transformational education for health professionals.  We would like to express our gratitude to those that have responded to the request for completion of the survey.  Your responses have been very positive thus far.

We would also like to express our sincere gratitude to our colleagues in the Middle East for calling our attention to an error that limited your participation. We offer our apologies once again, and ask that you kindly observe that the error has been rectified in the second of the survey links provided below.

To those that have not had a chance to take the survey yet, we would appreciate your reading the message below and kindly request that you complete the survey before the deadline date of January 23rd, 2012.

The WHO Secretariat has embarked on an initiative that seeks to address the current shortage of health professionals, and transform medical education to bridge the misalignment between skill, competence, clinical experience and population health needs.  WHO seeks the active engagement of CS in this activity with the goal to ensure that the guidelines take on board the views of CS and advocacy foci important to the CS constituency engaged in HRH advocacy at country, regional and global levels.

WHO has worked with CHESTRAD to develop this survey and  to seek guidance and suggestions from CS as this process moves forward.  Most importantly, the WHO Secretariat is seeking information based on your current professional capacity and taking into account your specific/local context. Your responses will be used to develop a report which will be taken to the Southern Civil Society meeting in Abuja, Nigeria in February or March 2012 and will be used as the basis for planning how CSOs and WHO can work together to implement this initiative from 2012 onwards.

 The questionnaire can be accessed on these SurveyMonkey links:

  https://www.surveymonkey.com/s/BVVCW7T (General)

  https://www.surveymonkey.com/s/7P7VYD9  (Middle East)

 Please kindly share the links with other civil society organizations and networks to enable them contribute to this important activity.

 Many thanks and kind regards,

Angela Mazimba

Programme Officer- Research and Evaluation

CHESTRAD International  

   Forwarded by:

---------------------------

 Yours in Global Concern,

 A.SANKAR

Executive Director- EMPOWER  INDIA - Professional Civil Society Organisation

Founder and General Secretary - Confederation of Indian Civil Society Organisation’s (CICSO)

National Convener- National Alliance for Health, Environment and Rights ( NAFHER)

107J / 133E, Millerpuram

TUTICORIN-628 008, TN, INDIA

Telefax: 91 461 2310151; Mobile:   91 94431 48599: www.empowerindia.org

·         You are invited to join an E FORUM AIDS-TN. To join this free E  Forum kindly send an e  mail    to AIDS-TN-subscribe@yahoogroups.com

·           This e Forum moderated by   EMPOWER, a Non-profit, Non-Political, Voluntary and Professional Civil Society Organisation.

P

 cid:image001.gif@01CC1D41.432C53C0             Please don't print this e-mail unless you really need to.

             S.v.p. ne pas imprimer ce courriel Ă  moins d’en avoir vraiment besoin.

 

 

 


#4783 From: Prashanth Kumar <gpk.nfi6@...>
Date: Thu Jan 12, 2012 7:09 am
Subject: Maan AIDS Foundation :Vacancy Announcement:1 Job title : Assistant Programme Manager - Pehchan
gpk.nfi6
Send Email Send Email
 
Maan AIDS Foundation :Vacancy Announcement:1
Job title : Assistant Programme Manager
Employing Organisation : Maan AIDS Foundation
Location: National Office, Lucknow, India
 
Date of Issue: 12th January 2012
 
Closing Date: 20th January 2012
 
Maan AIDS Foundation is strongly committed to ensuring diversity within our organisation. We strongly welcome applications from sexual minority communities (MSM, Hijra and TG). Maan AIDS Foundation does not discriminate against applicants or employees based on their HIV status, Sexual orientation, or gender identity.
 
Position Description:
The Assit. Programme Manager will be primarily responsible for Assiting the Programme Manager in the programmatic implementation of the Global Fund-supported Round 9 Pehchān project of India HIV/AIDS Alliance with the MSM, Transgender and Hijra communities. The project entails development and strengthening of 30 CBOs across 4 state/s (Bihar, New Delhi, Punjab and Uttar Pradesh)  in India to reach MSM/TG/Hijra individuals with HIV messages and services over a period of five years.
The Assitant Programme Manager will thus be responsible for Assistance tp PM in managing and providing programmatic, technical and organisational development guidance and support within Maan AIDS Foundation as the sub -  recipient and programme implementing partners; supporting and managing programme development and capacity building; promoting innovation and documentation of good practice in HIV/AIDS programming for MSM/TG/Hijra and other vulnerable populations; and, actively representing and contributing to planning and policy work on behalf of Pehchān Project.
1.     Programme Management and Development
Objective: To effectively Assit Programme Manager to implement and manage the Global Fund Round 9 programme and the programme components.
·      Assist, support the development and implementation of various programme implementation plans and budgets including the SSRs.
·      Contribute to the development and implementation of effective monitoring, review and evaluation strategies and activities for the programme against agreed project deliverables.
·      Work with other members of the Pehchān Project, especially those working on M&E, Finance, Advocacy and Capacity Building to liaise with SSRs in preparing and submitting programme and other reports to Alliance India, SACS & TSUs on a timely basis, as required, for internal and external use.
·      Assist Review, analysis and provide timely feedback on programme reports and other documents relating to programmes and SSRs.
·      Assist Analysis and document the progress, impact, challenges and lessons learned of programmes.
·      Maintain and coordinate effective relationships with SACS, TSUs, DAPCUs and/or any other development partners in the region.
2.     Capacity Building and Technical Support to SSRs
Objective: To Assist in developing the programmatic and technical capacity of programmes, Maan AIDS Foundation, SSRs and team members to effectively manage and deliver quality HIV/AIDS programmes.
·      Assist Identify and develop capacity building plans for needs identified that particular entails community mobilisation, CBO formation and functioning
·      assist in the development of capacity building packages for the partners as well as CBOs.
·      Provide and facilitate the delivery of technical assistance and capacity building support for strengthening the programme and organisational development of SSRs through relevant Staff.
·      Assist Programme Manager with the Finance & Administration team review partner financial systems and procedures and facilitate specific technical support in areas including overall programme budgeting, financial management, internal control systems and grants management.
·      Identify, procure and manage any relevant external technical support that may be required for the programme and SSRs.
·      Monitor, review and evaluate the progress and impact of capacity building programmes.
·       In conjunction with Finance and Administration team assess, identify and develop individual capacity building needs of Maan AIDS Foundation team members, and develop staff training plans.
 
3.     Team Planning and Development
Objective: To effectively work as a team player in implementation of Pehchan in Maan AIDS Foundation
·       Contribute to the planning, co-ordination and implementation of the Pehchān Project workplan.
·       In collaboration with the senior management develop strategic direction and work plans (as appropriate) for the Pehchān Project.
·       Work closely with other members of the Pehchān Project team to develop and implement appropriate programme and technical support strategies.
·       Assist Programme Manager in Leading the team, through continuous encouragement, setting clear work /activity plans and close monitoring on the quality aspects of the deliverability through a lead by example approach.
 
4.     Miscellaneous
 
·       Undertake other responsibilities not outlined above which are commensurate with a role of this nature in the charitable sector and which have been discussed and agreed between the line manager and the post holder.
 
 Person Specification
Required experience/skills/qualities:
·    Master’s degree in social sciences, health or development field (or equivalent)
·    At least 3 to 5 years of relevant project management experience in the health or development sectors, including at least 3 years’ middle management experience.
·    At least 3 years working in HIV prevention programmes, including experience working with MSM/TG/Hijra populations.
·    Demonstrated knowledge and understanding of development issues and the HIV epidemic(s) in India, particularly in relation to MSM/TG/Hijra populations and other vulnerable populations.
·    Demonstrated knowledge and understanding of donor environment, donor relations and donor M&E and reporting systems
·    Demonstrated experience of project proposal development and budget preparation.
·    Excellent analytical, writing and verbal communication skills.
·    Experience of working with multiple stakeholders in civil society and the government at different levels.
·    Experience of providing technical support to and capacity building of organisations, especially those working at the community or grassroots level.
·    Ability to work effectively in teams as well as independently.
·    Ability and willingness to undertake extensive travel, primarily within India.
·    Strong commitment to HIV/AIDS and sexual and reproductive health and rights
·    Fluent in English, Hindi and/or (any other regional languages)
 
Reports to Programme Manager -Pehchan
 
Application are welcomed and encouraged from candidates from sexual / gender minorities with required skills and qualification
 
Remuneration
Salary package will be 2.64 Lakhs per annum
 
To Apply:
Interested candidates should send in their CV with a cover latter and photograph to applications@... & ishrat@... clearly mentioning the subject line and location as Assistant Programme Manager ,lucknow
Contact address:
Employment
Maan AIDS Foundation,
39/2,KHA,
21 B Clyde Road
Behind Times of India office,
Lucknow-226001
India
 
Likely interview for the short listed candidates will be intimated via email

#4784 From: Prashanth Kumar <gpk.nfi6@...>
Date: Thu Jan 12, 2012 7:31 am
Subject: Maan AIDS Foundation :Vacancy Announcement:6 Job title : Advocacy Officer - Pehchan
gpk.nfi6
Send Email Send Email
 
Maan AIDS Foundation :Vacancy Announcement:6
Job title : Advocacy Officer -Pehchan
Employing Organisation : Maan AIDS Foundation
Location: National Office, Lucknow, India
 
Date of Issue: 12th January 2012
 
Closing Date: 20th January 2012
 
Maan AIDS Foundation is strongly committed to ensuring diversity within our organisation. We strongly welcome applications from sexual minority communities (MSM, Hijra and TG). Maan AIDS Foundation does not discriminate against applicants or employees based on their HIV status, Sexual orientation, or gender identity.
 
Position Description:
The Advocacy Officer will be responsible for the Maan AIDS Foundation advocacy work and for informing, influencing and documenting advocacy work within the GFATM Round 9 Pehchan Project.  S/he will work closely with the Programme Manager, to coordinate state and district level advocacy work, capacity building of partners and external stakeholders and will liaise with other teams to ensure the participation and emphasis on the role of community participation.
 
Summary of Responsibilities:
 
·      Under the supervision of the Programme Manager, lead the strategising, planning and co-ordination to build and successfully implement advocacy initiatives under the Pehchan Project.
·      In coordination with the Programme Manager, develop strategies to ensure information and initiatives from all SSRs.
·      In coordination with programme and technical staff, identify key areas for development of advocacy work with SSRs.
·       Develop, document and disseminate good advocacy practices, working in close consultation with the Programmes team and SSRs.
·       Participate in relevant programme activities at state and district level to inform and guide cross state learning policy development and best practices in advocacy.
·       Provide technical assistance to build the capacity of SSRs in advocacy, both by distant and on-site support.
·       Facilitate state and district level engagement by Maan AIDS Foundation and SSRs with indigenous civil society networks, both with each other and with other state level partners.
·       Participate and contribute to learning and support networks for developing excellence in advocacy. 
·       Develop, collate and disseminate advocacy resources, and provide advocacy guidance to the Programmes team.
·       Take responsibility for day-to-day management of advocacy projects, in close liaison with other Alliance India teams, in particular the technical team.
·       Manage processes for sharing lessons and drawing out experience from field programmes, including synthesising learning from monitoring and evaluation, and responding to advocacy opportunities emerging from Maan AIDS Foundation.
·       Establish, maintain and strengthen effective relationships with relevant stakeholders, including state and district government agencies, SSRs.
·       In consultation with the Programme Manager, represent Maan AIDS Foundation in appropriate state and district level forums.
·       Undertake other responsibilities not outlined above which are commensurate with a role of this nature and which have been discussed and agreed between the line manager and the post holder.
 
Skills and Qualifications required
 
·       Proven Knowledge on MSM, HIV/AIDS and sexual health issues(essential)
·       Proven Advocacy skills and good communication abilities in HIV/AIDS prevention, care and support, sexualities, gender, human rights.
·       Proven experience of working with MSM and sexual health issues in CBO setting
·       Knowledge of MSM , masculinities , gender and rights issues in India and developing countries (desirable)
·       Educated to degree level
·       Experience in writing reports (essentials)
·       Computer literate with a very good working knowledge of windows Microsoft office products
·       Excellent writing skills (Essentials)
·       Fluency in English  (essential) knowledge of other Indian language would be useful
·       2 to 3 years experience in sexual health or development sector (desirable)
·       Demonstrated competence to assess priorities and meet deadlines with attention to details and quality
·       Experience in writing and producing reports
·       Ability to work independently and as a team player with demonstrated leadership skills, communication and networking capabilities
 
Reports to Programme Manager –Pehchan & Country Director - Parallel Reporting
 
Application are welcomed and encouraged from candidates from sexual / gender minorities with required skills and qualification
 
Remuneration
Salary package will be 1.99 Lakhs per annum
 
To Apply:
Interested candidates should send in their CV with a cover latter and photograph to applications@... & ishrat@... clearly mentioning the subject line and location as Advocacy Officer ,lucknow
Contact address:
Employment
Maan AIDS Foundation,
39/2,KHA,
21 B Clyde Road
Behind Times of India office,
Lucknow-226001
India
 
Likely interview for the short listed candidates will be intimated via email
 

#4785 From: "EMPOWER INDIA" <ttn_empower@...>
Date: Wed Jan 25, 2012 7:06 am
Subject: Global Fund Observer Issue 174
ttn_empower@...
Send Email Send Email
 

GLOBAL FUND OBSERVER (GFO), an independent newsletter about the Global Fund provided by Aidspan to nearly 10,000 subscribers in 170 countries.

Issue 174: 24 January 2012. (For formatted web, Word and PDF versions of this and other issues, see www.aidspan.org/gfo.)

+ + + + + + + + + + + + + + + + + + +
CONTENTS
+ + + + + + + + + + + + + + + + + + +

1. NEWS: Global Fund Executive Director Michel Kazatchkine To Resign

Michel Kazatchkine announced today that he will "step down" as Executive Director of the Global Fund by mid-March. He said that his planned resignation resulted from a decision by the Global Fund Board two months ago to appoint a General Manager who will supervise many Global Fund activities and who will report direct to the Board. GFO understands that this decision by the Board to transfer many of Dr Kazatchkine's responsibilities to someone else arose from the Board's concern that the Fund's managerial leadership was not sufficiently effective.

2. NEWS: National NGOs Serving as PRs Excluded from the Global Fund's Policy on Percentage-Based Overhead Costs

Concerns have been expressed that the Global Fund's new policy on percentage-based overhead costs for international NGOs, adopted in April 2011, excludes national NGOs, except in very limited circumstances, and that there is no equivalent policy for national NGOs.

3. NEWS: Demonstrators Rally to Urge African Leaders to Spend More on Health

The Global Fund's decision to cancel Round 11 was a hot topic at the International Conference on AIDS and Sexually Transmitted Infections in Africa (ICASA) held in Addis Ababa, Ethiopia on 4-8 December 2011. Demonstrators called for more spending on health from African governments.

4. COMMENTARY: The Transformation of the Global Fund - Concerns and Opportunities

"This is a significant and even bewildering time for the Global Fund," says Dr David McCoy. "It is undergoing not just a financial and fiduciary crisis, but also a process of transformation. And multiple agendas are in play... While it is too early to predict the final impact of all the changes, given their unclear (and, at times, contradictory) nature, there is still opportunity to shape the eventual outcomes of the transformation."

5. ANNOUNCEMENT: Aidspan Releases Revised Version of Its Guide to TFM Applications

The new version incorporates some minor changes to the text.

+ + + + + + + + + + + + + + + + + + +

1. NEWS: Global Fund Executive Director Michel Kazatchkine To Resign

Board Had Concerns Regarding Managerial Leadership

Gabriel Jaramillo, Brazilian Banker, to Serve as General Manager

Michel Kazatchkine announced today that he will "step down" as Executive Director of the Global Fund by mid-March. He said that his planned resignation resulted from a decision by the Global Fund Board two months ago to appoint a General Manager who will supervise many Global Fund activities and who will report direct to the Board. GFO understands that this decision by the Board to transfer many of Dr Kazatchkine's responsibilities to someone else arose from the Board's concern that the Fund's managerial leadership was not sufficiently effective.

"For the last ten years, the Global Fund has been my passion and my most important undertaking," Prof. Kazatchkine said in a statement to staff. Simon Bland, Global Fund Board Chair, responded by saying, "Few individuals have played a more central role in the creation and evolution of the Global Fund than Michel."

The Global Fund also announced today that the General Manager will be Gabriel Jaramillo, a prominent banker from Latin America who was one of the members of the High Level Panel that extensively evaluated the work of the Global Fund during 2011. Mr Jaramillo spent three days last week meeting senior staff at the Global Fund.

The Global Fund said that Mr Jaramillo will take up a 12-month appointment on 1 February. The Fund did not specify whether Mr Jaramillo will serve as Acting Executive Director once Dr Kazatchkine leaves, but it implied that he will when it said, in a Q&A document sent to Board delegation members, that Mr Jaramillo will "take over all of the management responsibilities of the Global Fund Secretariat." A spokesman told GFO that the Global Fund will launch a search for a new Executive Director "in due time."

Mr. Jaramillo, a native of Colombia and a citizen of Brazil, is a former Chairman and Chief Executive Officer of Sovereign Bank. Since he retired a year ago, he has served as a Special Advisor to the Office of the Special Envoy for Malaria of the Secretary General of the United Nations. Mr Bland said in a press release that Mr Jaramillo "is an outstanding choice, and exactly what we need at this time: an excellent manager and a proven financial leader who can direct change and improve performance in a large institution during a time of transition."

Background regarding Board concerns

On 21 November 2011, the first day of the Global Fund's two-day Accra board meeting, the twenty voting Board members and their alternates met in executive session to review a detailed performance assessment of Dr Kazatchkine. Such an assessment is automatically carried out each year by external professionals under the guidance of the Chair and Vice-Chair; it draws upon responses received to questionnaires that are submitted to dozens of people. According to several Board members, this year's assessment praised many aspects of Dr Kazatchkine's work, but it contained strong criticisms of his effectiveness as a manager - criticisms that echoed those made in the assessment that was conducted a year earlier.

On the second day of the Accra meeting, the Board decided, again in executive session, to appoint a General Manager. This decision was announced by the Fund the following day, as reported by GFO here. However, at that time, the Global Fund specified only that the General Manager would work "alongside" the Executive Director, adding that the General Manager would "help to take the organization through its transformation phase over the next twelve months."

Jon Liden, the Global Fund's Communications Director, clarified the situation earlier this month in the course of responding to questions from GFO. He said that all of the Fund's senior managers (including the Deputy Executive Director) who then reported to the Executive Director would instead report to the General Manager, and that the General Manager would report to the Board, not to the Executive Director. Mr Liden added that the person to serve as General Manager would be chosen by the Chair (Simon Bland, a U.K. government official) and Vice-Chair (Mphu Ramatlapeng, Minister of Health of Lesotho), in full consultation with the Board. Finally, he stated that the responsibilities of the Executive Director once the General Manager was in place were "to be determined."

It was against this context that Dr Kazatchkine announced today that he will resign by mid-March.

Speculation in French magazine

Earlier this month, there was speculation in the popular French magazine Marianne that certain procurements by the Global Fund were mishandled, and that this was of concern to the Board. The Chair has informed GFO that these allegations were not true and were not a factor in the Board's decision to appoint a General Manager. The procurements related to services to support the Born HIV Free campaign in 2010, in which Carla Bruni-Sarkozy, the Global Fund's unpaid Ambassador for Protecting Women and Children Against AIDS, and wife of the President of France, featured prominently. The Global Fund responded with a detailed accounting of the procurements in question, and stated emphatically that all Global Fund procurement procedures had been handled correctly and that this had been confirmed through an external audit specially commissioned by the Chair. (The Global Fund's statements in response to the Marianne article are available here and here.)

Dr Kazatchkine

Dr Kazatchkine, 65, has been Executive Director of the Global Fund since April 2007. Prior to then he served the Global Fund as the first Chair of the Technical Review Panel, then as Board member representing France, then as Vice-Chair of the Board. He is an immunologist who has been working in the field of AIDS since 1983. In 1988 he became the director of the French National Research Agency on AIDS (ANRS), the world's second largest AIDS research program, and he has also served as France's Ambassador on HIV/AIDS and Transmissible Diseases.

Further background information regarding Dr Kazatchkine is available in his bio, his Huffington Post blog entries, a 2007 interview with GFO, a 2007 Boston Globe profile, his report to the 2011 Accra board meeting, and various interviews and speeches.

+ + + + + + + + + + + + + + + + + + +

2. NEWS: National NGOs Serving as PRs Excluded from the Global Fund's Policy on Percentage-Based Overhead Costs

Policy covers primarily international NGO PRs

Some concerns that the policy is being applied inconsistently

Concerns have been expressed that the Global Fund's new policy on percentage-based overhead costs for international NGOs excludes national NGOs, except in very limited circumstances, and that there is no equivalent policy for national NGOs.

On 18 April 2011, the Global Fund adopted a new policy on percentage-based Headquarters overhead charges for international NGOs (INGOs) serving as principal recipients (PRs) and sub-recipients (SRs). The policy applies to INGO PRs and SRs that have certain services provided by their "Headquarters" (including regional offices) located in another country. The INGO PRs and SRs have to be able to demonstrate strong Headquarters involvement in their operations.

According to the policy, for services provided by Headquarters, an INGO PR can charge a maximum of 3% of the costs of procuring health products; up to 7% of other costs incurred by the PR directly; and up to 5% of the funds managed by SRs. These maximums are reduced in certain instances. For example, if a procurement agent is used, an INGO PR can only charge 1% of the costs of procuring health products (not 3%).

INGOs serving as SRs are entitled to charge a maximum of 3% of the costs of procuring health products; and can charge up to 5% of other costs incurred by the SR directly.

The policy states that the services provided by Headquarters for which a percentage-based overhead fee can be charged include financial accounting, treasury management and reporting support; management support and oversight; human resources administration support; legal support; IT support; internal audit; routine technical assistance and capacity building of in-country staff and structures; and procurement services.

The policy states that it specifically excludes national NGOs and U.N. agencies serving as PRs and SRs. Despite this, the policy includes a section on national NGOs. It says that national entities may not charge percentage-based overhead fees, but should be able to "directly charge" any support provided by Headquarters "using a reasonable basis of apportionment." Further, the policy states that in exceptional cases, where a national entity is managing multiple programmes and apportionment is not practical due to the low value of the Global Fund grant compared to other funding sources, a percentage-based charge may be applied.

Many national NGOs are upset about the fact that they are not permitted to charge percentage-based overhead costs in most situations. A spokesperson for one national NGO PR told GFO that in order to include any Headquarters cost as a direct cost in the programme budgets, detailed and tedious justifications are required. "One may say this brings about accountability," the spokesperson said, "but this does not assist the national NGO to grow beyond what it is today. Costs that go directly towards strengthening the governance structure of the organisation or increasing office space would be questioned by those [in the local fund agent and in the Secretariat] carrying out the review."

The Civil Society Principal Recipients Network (CSPRN), a network of 46 international and national PRs, expressed concern about the exclusion of national NGOs from the overhead policy. "As with INGOs," the CSPRN said, "national NGOs incur costs that are not directly related to Global Fund implementation but that have an overall impact on organizational effectiveness." The CSPRN formally recommended to the Global Fund that it develop an indirect cost recovery policy for national NGO implementers. The CSPRN said that such a policy would reduce conflict and delays during grant negotiations and would reinforce the Global Fund's objective of country ownership.

The CSPRN has set up a task force to advocate for a new policy on overhead costs for national NGOs or, alternatively, for the extension of the INGO policy to cover national NGOs.

The CSPRN also said that the new policy implemented in April 2011 has sometimes been misunderstood, misinterpreted and inconsistently applied by various stakeholders involved in grant negotiation processes. The CSPRN cited as examples the fact that there have been contradictory messages from local fund agents and fund portfolio managers concerning how the policy should be interpreted, and the fact that there have been instances of treating direct implementation costs as Headquarters support costs.

One member of the CSPRN told GFO that the Global Fund is attempting to apply the policy to grants signed before the policy came into effect. The member said that this is a violation of the signed agreements for these grants.

The Fund's policy on overhead costs for INGOs is contained in an operational policy note in Section 6.1.5 of "The Global Fund's Operational Policy Manual," available here. Some of the information for this article came from a paper describing the recommendations and meeting outcomes from a CSPRN meeting held in October 2011, on file with the author.

+ + + + + + + + + + + + + + + + + + +

3. NEWS: Demonstrators Rally to Urge African Leaders to Spend More on Health

Concerns expressed that cancellation of the Global Fund's Round 11 will have devastating consequences

Editor's note: This is the first article written by the Key Correspondents (KC) Team to appear in GFO. We hope to publish additional KC articles in future. See the note at the end of this article for more information on the KC Team.

Medicins Sans Frontieres (MSF) Health Policy Analyst Dr Mit Phillips described the cancelation of the Global Fund's Round 11 as a "catastrophe," as protesters demonstrated to call on African leaders to commit more internal resources to the HIV response. Dr Phillips said the cancelation will have devastating consequences on millions of people who are yet to access ARV drugs.

"The Global Fund is the main instrument. Don't take it away; more people need treatment. It is not right for the Global Fund to pull out. Africa has invested so much energy and time and more people need treatment," Dr Phillips said during a media briefing organised by the Global Fund at the International Conference on AIDS and Sexually Transmitted Infections in Africa (ICASA) in Addis Ababa, held on 4-8 December 2011.

Prior to the media briefing, AIDS activists from 40 African civil society organisations marched around the conference centre, chanting and displaying messages, reading "Where is the money for HIV and AIDS?"

The demonstrators were campaigning to get African leaders to commit resources to health. On the march was James Kamau a representative from the Southern African Treatment Access Movement (SATAMO), a network of AIDS advocacy organisations. Mr Kamau described the move taken by the Global Fund as "a reverse gear," and said countries in Africa should learn from Kenya, which has come up with a sustainable health financing programme with support from UNAIDS, the National AIDS Control Council and civil society organisations. The Kenyan government has introduced a tax levy on mobile phones, Mr Kamau said; subscribers pay 10 cents per phone call and the money generated from the tax levy is allocated to health.

At the press conference, Dr Phillips said that by 2013 an estimated 86,000 people in Zimbabwe will not be receiving antiretrovirals (ARVs) if the Global Fund doesn't reverse its decision to cancel Round 11. In Malawi, people living with HIV who were on the ARV drug tenofovir will be switched to stavudine, which has severe side effects. In Mozambique, 15% of people in need of ARVs don't have access to them and those who are sick are told to wait until their CD4 count drops to 250 to receive treatment. Dr Phillips said that due to the cancellation of Round 11, Mozambique will not have resources for the prevention of mother-to-child transmission of HIV (PMTCT) programmes.

Dr Phillips said Africa has made some progress in putting people on life saving drugs, hence the need to sustain existing programmes and to scale-up in order to reach out to people that need treatment.

Also at the media conference was Lynette Mabote, from AIDS and Rights Alliance for Southern Africa (ARASA), who lashed out at African leaders for not keeping the promise of allocating 15% of their national budgets to health. She said that Africa was at a "critical moment" and that there was an emergent need for "an innovative financing mechanism to be put in place to finance the health sector."

Ms Mabote urged governments to be accountable to its people, citing the case of Zambia were social audit and expenditure budget tracking is being implemented to make leaders accountable and promote transparency in the health sector. She also bemoaned the lavish life that most African leaders live when others are without basic health services. Ms Mabote added: "The Global Fund was meant to fill up the gaps in health sector. We cannot entrust our health to the donors. Africa should start funding the health sector."

Nearly 50 organisations are part of a broad coalition of HIV/AIDS organizations working under the banner of the "Where Is the Money Campaign" to push African governments to do more and give more in the fight against HIV/AIDS and in promoting health and life.

Many organisations working in Africa are advocating for local health and HIV funding. They include the African Council of AIDS Service Organizations (AfriCASO), ARASA, the Global Network of People Living with HIV (GNP+), the International HIV/AIDS Alliance, the International Treatment Preparedness Coalition (ITPC), the Networking HIV/AIDS Community of South Africa (NACOSA), the Eastern Africa National Networks of AIDS Service Organizations (EANNASO) and the World AIDS Campaign. Along with many other NGOs and stakeholders working in the HIV/AIDS and health fields, the Where is the Money Campaign coalition is pushing for African governments to own, scale up and sustain funding for HIV and health in Africa.

This article was written by Dennis Chibuye, a member of the KC Team. KCs are "citizen journalists" whose network is supported by the International HIV/AIDS Alliance. By posting dispatches and engaging in debate on www.keycorrespondents.org - read by activists, health professionals, academics, policy makers and journalists - KCs are able to communicate the reality of health and development to key influencers as a way to advocate for political and social change. For more information, contact kcteam@....

+ + + + + + + + + + + + + + + + + + +

4. COMMENTARY: The Transformation of the Global Fund - Concerns and Opportunities

by David McCoy

It has been a year of turmoil for the Global Fund. Round 11 has been officially cancelled, preceded by months of negative publicity about corruption and fraud. But the turmoil is set to continue as the Fund undergoes a process of organisational transformation. A Consolidated Transformation Plan (CTP) consisting of six "transformation areas," 31 projects and 162 deliverables is being implemented. A new Strategy for 2012-16 ("the Strategy") has also been produced, setting the direction for the Fund's future evolution. With so much happening, it can be hard to "see the forest for the trees."

This commentary identifies seven elements of the Global Fund's future transformation and then discusses what they might mean for the Fund's mission.

SEVEN ELEMENTS OF TRANSFORMATION

Contraction and tighter rationing

If the first decade was the Global Fund's era of expansion (in terms of the number of countries supported by grants and annual levels of expenditure), the next decade looks likely to be an era of contraction. As aid budgets stagnate or shrink, and as donor commitment to the Global Fund weakens, and given the reality of scarce resources and unmet need, the Global Fund has little choice but to consider tighter eligibility criteria and a more explicit system of rationing. The original demand-driven model of funding will thus be transformed into one that is more supply-driven. Funding will become less about countries "pulling in" Global Fund grants, and more about the Global Fund "pushing out" money according to stricter eligibility criteria.

A more hands-on approach

The Global Fund is adopting a more hands-on approach to all aspects of the grant cycle, from the initial applications for funding through grant management and programme implementation, and including grant renewals. This is designed to allow grant-making and grant-management to be better tailored to the specific context and needs of a given country. The CTP and Strategy also suggest a more operational role for the Fund in the procurement and supply management of pharmaceutical and other health commodities. In order to support this change, the status, capacity and authority of fund portfolio managers will be increased, as will the number of countries that will be managed under the country team approach. In addition, the time spent by Global Fund staff within recipient countries is expected to rise, and efforts will be made to strengthen the capacity and effectiveness of local fund agents. These changes mark a significant departure from the original vision of the Global Fund as a quick and nimble, global-level financing agency with a minimal in-country presence.

Shorter cycles of funding

The Fund will be moving towards shorter cycles of funding. For example, in future, new grants will cover a three-year period rather than a five-year period; and applications to the Transitional Funding Mechanism are limited to a maximum of two years. Grant performance will also be subject to more rigorous (and possibly more frequent) assessments and performance management prior to semi-annual disbursements. These changes mostly run contrary to the principles of aid effectiveness and may aggravate the difficulties associated with unpredictable and uncertain aid flows.

More emphasis on results and performance based funding

A striking feature of both the CTP and the Strategy is the even greater emphasis on results and performance measurement than before. This appears to be part of a general trend of donors and international agencies seeking to calculate their impact, especially in terms of the ultimate outcome measure: lives saved. As a result, the CTP and the Strategy include a number of plans to improve the health and management information systems of recipient countries and to improve the methodologies for measuring and attributing "results" to funders and programmes.

More risk averse

One of the transformation areas of the CTP is entirely focused on the Global Fund's approach to risk management. A risk management framework and strategy will be established at both the corporate and operational level. They include hiring a new and senior Chief Risk Officer; strengthening the role and management of external auditors; and ranking countries according to some type of risk score. This also marks a significant departure from the way the Global Fund was originally conceptualised. Whilst previously, the Global Fund was positively encouraged to "sail the boat whilst it was being built," the message now is to only sail fully constructed boats which have been tested and declared fit by an independent boat safety agency!

Changing the balance of power

Part of the Global Fund's transformation is concerned with changes to the Fund's governance and management. This includes the restructuring of the Board's committees; a clearer delineation of the roles and responsibilities of the Board and the Secretariat; and the appointment of a General Manager who, apparently, will be accountable to the Board. At the same time, the Executive Management Team (EMT) has been subjected to much criticism, causing harm to its reputation and authority. Meanwhile, the Office of the Inspector General (OIG), which has been at loggerheads with the Secretariat, has escaped being subjected to "transformation" and has, in fact, emerged with a bigger budget. All this adds up to a change in the balance of power across the Board, the OIG and the EMT. It is harder to discern whether there have been changes in the relative power and influence across the different Board members.

More fundraising and appealing to donors

When first established, the Global Fund was described as a "war chest" to help fight the scourge of disease (especially HIV/AIDS). Donors were quick to back the Fund; and, in turn, the Global Fund adopted an ambitious programme of expansion. The Fund was cast as a new type of global agency - quick, reactive, pragmatic and free of red tape. If the need was there, the money would be found. The Global Fund is now experiencing life under a more austere financial climate. As a consequence, there will be a bigger onus placed on the Global Fund to persuade donors of its value - possibly increasingly so as the Fund competes with other recipients of government aid. Additionally, the Fund will be expected to increase the level of support from the private sector and from the general public (e.g., through individual donations or through mechanisms such as voluntary levies applied to purchases).

CONCLUSION

How these different elements of transformation will impact on the Global Fund is unclear. It depends on how each element is implemented and how the elements interact with each other. But it's worth thinking about what might or might not happen.

The shift towards a more country-specific and iterative approach to grant management is potentially a good thing because it enables programmes financed by the Global Fund to align better with national disease strategies, national planning cycles and broader health systems strengthening (HSS) efforts. It could also help ensure better harmonisation with programmes funded by other development partners and sources of external funding for health. The Global Fund has been working towards simplification of its grant-making system through single-stream funding and consolidated proposals; there is an opportunity for the transformation to add further impetus to these efforts.

On the other hand, the proposed changes could result in the Global Fund becoming yet another uncoordinated actor in an already crowded health landscape. Unless the Fund deploys staff with the right competencies and mandate to work effectively with country-level stakeholders, the potential for better alignment and harmonisation may not be realised. There is also a danger that shorter funding cycles and greater pressure to demonstrate "value for money" could result in a more top-down, donor-driven funding model that would undermine country ownership. It could make it harder to invest in things that may only have an indirect or long-term impact on health outcomes.

Shorter funding cycles could also aggravate existing problems associated with short-term and unpredictable aid, and increase the transaction costs associated with frequent and multiple negotiations over grant renewals. On top of this, an over-zealous concern with risk reduction - if it leads to, for example, continued or greater use of parallel donor-specific M&E frameworks and accounting systems - could aggravate existing problems even further.

While the need to employ tighter eligibility criteria and more explicit rationing are regrettable in many respects, there is a potential silver lining in that this could create an opportunity for resources to be better allocated according to the health and financial needs of countries and communities. However, this opportunity could be undermined if proposals to incorporate financial risk into the Global Fund's future resource allocation policy are also accepted. Although an assessment of financial risk should inform the steps to be taken to ensure adequate fiduciary control, it should arguably not be used to influence resource allocation. Resource allocation should be primarily based on need.

The notion of the Global Fund becoming more reliant on private sector financing would also have consequences that would need to be monitored. For example, a greater reliance on private sector funding could lead to a greater emphasis on the funding of pharmaceutical and other technologies. There are some views circulating that the Global Fund should become a more focused "commodities fund," concerned primarily with financing the purchase and price reduction of medicines and other technologies. Such views would be more likely to become policy if the private sector becomes more influential.

The changes to the governance and management of the Global Fund should also be monitored. Will the changes improve the overall functioning of the Global Fund? Or will they create conflicting or parallel lines of authority between the Board, the OIG and the EMT? And will the changes translate into a new balance of power between donors, recipient governments, business and civil society?

This is a significant and even bewildering time for the Global Fund. It is undergoing not just a financial and fiduciary crisis, but also a process of transformation. And multiple agendas are in play. Some of the changes appear good, but others are worrying. It is too early to predict the final impact of all the changes. However, given the unclear (and, at times, contradictory) nature of the changes, there is still some opportunity to shape the eventual outcomes of the transformation.

Dr David McCoy (david.mccoy@...) is a public health physician who is supporting the development of Aidspan's policy and research programme.

+ + + + + + + + + + + + + + + + + + +

5. ANNOUNCEMENT: Aidspan Releases Revised Version of Its Guide to TFM Applications

"The Aidspan Guide to Applications under the Global Fund's Transitional Funding Mechanism" has been revised to incorporate two minor changes to the text. The new version is dated 19 January 2012. The original version was issued on 10 January 2012. The guide is available at www.aidspan.org/guides. The changes are explained on the cover page of the new version.

Both English- and Spanish-language versions of the revised guide are currently available. French- and Russian-language versions will be posted shortly.

"Reproduced from the Global Fund Observer Newsletter (www.aidspan.org/gfo), a service of Aidspan."

  Forwarded by:

---------------------------

 Yours in Global Concern,

 A.SANKAR

Executive Director- EMPOWER  INDIA - Professional Civil Society Organisation

Founder and General Secretary - Confederation of Indian Civil Society Organisation’s (CICSO)

National Convener- National Alliance for Health, Environment and Rights ( NAFHER)

107J / 133E, Millerpuram

TUTICORIN-628 008, TN, INDIA

Telefax: 91 461 2310151; Mobile:   91 94431 48599: www.empowerindia.org

·         You are invited to join an E FORUM AIDS-TN. To join this free E  Forum kindly send an e  mail    to AIDS-TN-subscribe@yahoogroups.com

·           This e Forum moderated by   EMPOWER, a Non-profit, Non-Political, Voluntary and Professional Civil Society Organisation.

P

 cid:image001.gif@01CC1D41.432C53C0             Please don't print this e-mail unless you really need to.

             S.v.p. ne pas imprimer ce courriel Ă  moins d’en avoir vraiment besoin.

 

 

 

 


#4786 From: SAATHII <saathii@...>
Date: Fri Feb 10, 2012 10:30 am
Subject: HIV Shedding in the Oral Cavity
saathii
Send Email Send Email
 
 
SAATHII Electronic Newsletter
HIV/AIDS Updates
 
 
 
POSTED ON:       10.02.2012
 
COMPILED BY:  Dr. Sai Subhasree Raghavan and Manish Mudaliar
 
NOTE: This compilation contains news items about HIV/AIDS published in the International Electronic Newsletters. Articles in this and previous newsletters may also be accessed at http://www.saathii.org/orc/elibrary
--------------------------------------------------------------------------------------
HIV Shedding in the Oral Cavity
An Assessment of HIV Type, Immunovirologic, Demographic and Oral Factors
Patricia B Pavlinac; Stephen E Hawes; Geoffrey S Gottlieb; Awa Gaye; Charlotte F N'Diaye; Cathy W Critchlow; Papa Salif Sow; Qinghua Feng; Nancy B Kiviat
Abstract and Introduction
Abstract
Objective To quantify the prevalence and burden of HIV type 2 (HIV-2) and HIV-1 RNA in the oral cavity of antiretroviral therapy-naive HIV-infected Senegalese individuals and to identify correlates of oral HIV viral loads.
Design A cross-sectional study of 163 HIV-1 and 27 HIV-2-infected antiretroviral therapy-naive Senegalese adults.
Methods Participants received clinical and oral exams and provided blood and oral wash samples for viral load and plasma CD4 count ascertainment. Logistic and interval regression models were used to identify univariate and multivariable associations between presence and level of oral HIV RNA and various immunovirologic, local and demographic factors.
Results Presence of detectable oral HIV RNA was less common in HIV-2-infected compared with HIV-1-infected study participants (33% vs 67%, OR 0.25, 95% CI 0.11 to 0.59). HIV type was no longer associated with oral shedding of HIV when plasma viral load was considered. Detection of oral HIV RNA was associated with increased plasma viral load in both HIV-1-infected and HIV-2-infected individuals (HIV-1, OR 1.89, 95% CI 1.24 to 2.61; HIV-2, OR 1.93, 95% CI 1.1 to 3.39). Oral HIV-1 detection was also associated with periodontal disease (OR 3.02, 95% CI 1.16 to 7.87).
Conclusions Oral shedding of HIV-2 RNA is less common than HIV-1 RNA, a likely consequence of lower overall viral burden. Both systemic and local factors may contribute to shedding of HIV in the oral cavity.
Introduction
Shedding of HIV-1 and/or HIV-2 has been demonstrated in cervicovaginal fluid, semen, breast milk and anal–rectal mucosa.[1–6] While research has suggested that the virus is inactivated by inhibitory salivary factors, there is evidence that HIV-1 RNA is present at low levels in the oral cavity. The presence of oral HIV RNA may simply reflect systemic burden of the infection or may be a site of viral replication.
As with other anatomic compartments, HIV-1 DNA and RNA in the oral cavity are not detected in all infected individuals, HIV-1 RNA detection rates ranging from 42% to 100% and proviral DNA typically ranging from 0% to 50%.[3 4 7–12] Consistently across studies, salivary HIV-1 is positively associated with plasma HIV-1 viral load with Pearson's correlation coefficients ranging from 0.21 to 0.51.[4 7 11] Other factors commonly associated with plasma HIV levels, such as blood CD4 count, antiretroviral therapy (ART) and stage of disease, are inconsistently associated with oral shedding of HIV-1.[9 13 14] Associations between oral HIV-1 and dental parameters and/or oral lesions revealed similarly inconsistent associations.[9–12, 15]
To our knowledge, all studies looking at oral shedding of HIV are limited to HIV-1-infected participants. Compared with HIV-1, HIV-2 is characterised by reduced transmissibility, lower plasma and genital tract viral loads, slower decline in CD4 T cell counts and slower disease progression.[1 2 16 17] The current study aimed to evaluate the difference in oral shedding of HIV between HIV-1-infected and HIV-2-infected individuals in Senegal, West Africa. Among these patients, we also evaluated potential immunovirologic, periodontal and demographic factors associated with oral HIV shedding.

Methods

Study Setting and Participants

Between September 1994 and July 1998, ART-naive HIV-1-positive and HIV-2-positive men (≄18 years) and women (≄15 years) presenting to either the University of Dakar outpatient infectious disease clinic or an STD clinic in Mbour were asked to participate in a study of oral manifestations of HIV and in a subset of subjects, oral HIV shedding. Of 786 persons testing positive for HIV-1 and 150 testing positive for HIV-2, 163 HIV-1 and 27 HIV-2 individuals provided at least one oral wash sample. We excluded patients who were infected with both types of HIV. The study was conducted according to procedures approved by the University of Washington Institutional Review Board, University of Dakar Institutional Review Board and the Senegalese National AIDS committee.

Data Collection

Consenting participants were interviewed to obtain information regarding demographic characteristics, sexual behaviours and a standard medical history. Fifteen millilitres of peripheral blood was collected to determine the number of CD4 cells per microlitre of blood and qualitative and quantitative assays used to detect the number of HIV-1 and HIV-2 RNA copies per millilitre of blood as described previously.[18]
An examiner trained in Oral Medicine at the University of Dakar Dental Clinic examined the oral cavity of each study participant. Information on plaque index, gingival index, probing depth and clinical attachment loss was collected. Additionally, the examiner presumptively diagnosed the following types of oral pathology: candida pharyngitis, candida oesophagitis, perleche (angular cheilitis), hairy leukoplakia, other leukoplakia, ulcerations, oral herpes, aphthous ulcer, condyloma, Kaposi's sarcoma, other cancers, geographic tongue and other lesions. Periodontal disease was defined as the presence of linear gingival erythema, necrotising gingivitis and/or necrotising periodontitis. HIV-associated lesions were defined as presence of candida pharyngitis, angular cheilitis, candida oesophagitis, hairy leukoplakia, Kaposi's sarcoma, oral herpes and/or aphthous ulcers.
Subjects were given a small container containing 10 ml of sterile physiologic saline, instructed to swish the saline around the mouth and spit the saline back out into a sterile tube. Oral washes were collected from all patients and specimens centrifuged at 2000 rpm for 10 min at 4°C. The supernatant was decanted into a sterile tube from which 200 Όl was added to 600 Όl of lysis reagent containing 800 copies of either HIV-1 or HIV-2 IQS RNA. The samples were ethanol precipitated and the RNA pellet was suspended in 400 Όl of specimen diluent.
Quantitative and qualitative HIV-1 and HIV-2 RNA ascertainment in the plasma and oral supernatant were performed using PCR-based assays developed at Roche Molecular Systems (Pleasanton, California, USA) as described previously.[2 18 19] The amount of HIV RNA in each sample was calculated from the ratio of the total optical density at 450 nm for the HIV-specific well to the total optical density for the IQS-specific well and the input number of IQS copies and expressed as the number of HIV copies per millilitre of supernatant. The quantitative and qualitative HIV-1 assays provided reliable HIV RNA quantification at levels greater than 400 HIV RNA copies and 200 copies/ml, respectively, with a minimum detection limit of 80 and 40 copies/ml, respectively. The quantitative and qualitative HIV-2 assays provided reliable HIV-2 RNA quantification at levels >200 HIV RNA copies and 100 copies/ml, respectively, with a minimum detection limit of 40 and 20 copies/ml, respectively. All specimens were shipped to Seattle for laboratory analyses.

Statistical Analysis

In this analysis, complete cases were used to describe the patient characteristics by HIV type and to assess the association between HIV type and oral HIV viral load in the oral supernatant using a χ2 test of association and trend test. For all other analyses, missing values for plasma viral load, CD4 count, presence of periodontal disease, presence of HIV-related oral disorders and WHO-defined HIV disease stage were imputed based on the following set of covariates: HIV type, age, sex, smoking status, alcohol use, presence of gingival tattoos, presence of oral HIV RNA and non-imputed values of plasma viral load, CD4 count, presence of periodontal disease, presence of HIV-related oral disorders and WHO-defined HIV disease stage when non-missing. The range of imputed CD4 count and plasma viral load were set to match the range of non-imputed values.[20] Imputation model regression coefficients were estimated using a bootstrapped posterior predictive distribution, relaxing the assumption of multivariate normality on the distribution of regression coefficients. Ten data sets were created using Imputation by Chained Equations to multiply impute the missing values for model covariates.[20 21]
Regression analyses were performed on each of the 10 imputed data sets and regression coefficients averaged across the 10 to generate final coefficient estimations. Univariate logistic and interval regression models were used to estimate the ORs and slope coefficients (ÎČ) of presence and mean of log-transformed oral HIV RNA, respectively, associated with immunovirologic markers of HIV progression (CD4 cell counts and log10 plasma HIV RNA), oral local factors (periodontal disease and HIV-associated oral lesions) and demographic factors (age, sex and WHO-defined HIV disease stage). We created separate models for HIV-1 and HIV-2 because we believed that associations could differ by two types. We also adjusted the above analysis for log10 plasma viral load, the correlate of oral shedding identified, a priori, to be a potential confounding factor in all other associations. Interval regression was used instead of linear regression to accommodate non-censored, interval censored and left censored oral HIV viral load data due to the assay detection limits.[22] Robust SEs were used in both modelling techniques to relax the assumption of normal SEs in CI and p value calculations.
The midpoint of the detection range was imputed in subjects with oral and plasma HIV RNA levels below the limits of quantification or detection for the calculation of correlation coefficients, graphical displays and modelling in the case of plasma HIV RNA. Viral loads were transformed to their log10 values to satisfy the assumption of normality. In the case of multiple oral viral load measurements for a given individual, the earliest collection date was used in the analysis. In the case of non-contemporaneous collection of labs (plasma and CD4 counts) and oral exams, the data obtained on the date nearest the date of the oral viral load ascertainment were used.
All analyses were conducted using SAS V.9.1 and STATA V.10.1 with statistical significance criteria set at p≀0.05.

Results

Compared with HIV-2-infected persons at baseline, persons with HIV-1 tended to be younger (median age 33 vs 38, p=0.03) and were less likely to be female sex workers (16.9% vs 46.6%, p<0.01) (Table 1). Furthermore, compared with those with HIV-2 infection, participants with HIV-1 were more likely to have plasma viral loads ≄10 000 copies/ml (74.5% vs 22.2%, p<0.0001) and CD4 counts <200 cells/ÎŒl (49.1% vs 29.6%, p<0.01). Of the 142 HIV-1-infected patients and 19 HIV-2-infected patients with oral pathology data available, respectively, 21.7% and 3.7% were diagnosed as having linear gingival erythema, 4.4% and 0.6% as having necrotising gingivitis and 6.8% and 0.6% as having necrotising periodontitis. The median number of days between collection of oral samples (for oral viral loads) and blood samples (CD4 cell count and plasma viral load) as well as between oral sample collections and oral exams did not differ by HIV type. The oral sample was collected on the same day as blood for 58.9% of HIV-1 patients and 76.0% of HIV-2 patients and oral sample collected on the same day as the oral exam for 89.0% of HIV-1 patients and 95.0% of HIV-2 patients.
Presence of detectable oral HIV RNA was less common in HIV-2-infected compared with HIV-1-infected study participants (33% vs 67%, p=0.001) (Table 2). Complete case logistic regression revealed that the odds of detection were 75% lower in HIV-2-infected compared with HIV-1-infected patients (OR 0.25, 95% CI 0.11 to 0.59). However, this difference did not persist after adjustment for log plasma viral load (OR 0.92, 95% CI 0.29 to 2.95). Median levels of oral HIV RNA were significantly lower in HIV-2-infected (median: 0–20, IQR 0–20, 49) compared with HIV-1-infected patients (median: 40–80, IQR 0–40, 718, p<0.01).
We imputed values for the missing data for independent variables. The percent missing values by HIV type were as follows: CD4 cell count (HIV-1: 15.3%, HIV-2: 7.4%), plasma viral load (HIV-1: 14.1%, HIV-2: 18.5%), periodontal disease (HIV-1: 12.9%, HIV-2: 29.6%), HIV-related oral lesion (HIV-1: 10.4%, HIV-2: 25.9%) and WHO disease stage (HIV-1: 8.0%, HIV-2: 7.4%). HIV type, age and sex did not have any missing values.
Logistic regression was applied to the 10 imputed data sets to assess predictors of detection of oral RNA. Among HIV-1-infected participants, groups of patients with increased log10 plasma HIV RNA, presence of periodontal disease and WHO disease stage 3, compared with stage 1, were all significantly associated with detection of oral HIV in univariate analyses (Table 3). Among HIV-2-infected participants, log10 plasma HIV RNA level was significantly associated with detection and the risk estimate was similar, although slightly higher, to the risk estimate for HIV-1. Similar to HIV-1, there was a trend towards increased odds or oral RNA detection among the group of HIV-2-infected patients with higher levels of WHO-defined disease. However, periodontal disease had an inverse relationship, albeit not significant, with oral RNA detection among HIV-2 individuals. No other factors were significantly associated with detection of oral HIV-2. HIV-1-infected and HIV-2-infected patients with lower CD4 cell counts tended to have more oral RNA detected; however; the trend was not statistically significant when modelling CD4 count linearly, linearly with log transformation, nor categorically (which was the best-fitting model).
In analyses adjusting for log10 plasma HIV RNA, periodontal disease remained associated with oral RNA among HIV-1-infected (OR 2.79, 95% CI 1.08 to 7.24) but not among HIV-2-infected patients (OR 0.43, 95% CI 0.03 to 7.5). After adjustment for periodontal disease, log10 plasma HIV RNA remained significantly associated with oral RNA detection in both HIV-1-infected (OR 1.74, 95% CI 1.18 to 2.58) and HIV-2-infected patients (OR 1.98, 95% CI 1.08 to 3.62).
Interval regression was applied to the 10 imputed data sets to evaluate the association of viral, systemic, local and demographic factors with the quantity of HIV oral HIV RNA (Table 3). Similar to associations with presence of oral RNA, plasma viral load and periodontal disease were each associated with oral HIV viral load among HIV-1-infected persons, whereas only plasma viral loads were associated with oral viral loads among HIV-2-infected persons. After adjustment for log10 plasma viral load, the set of HIV-1-infected patients with periodontal disease had a mean oral RNA level that was 0.42 log10 higher, on average, than HIV-1-infected patients without periodontal disease (ÎČ=0.42, 95% CI 0.09 to 0.75). While there was a trend towards higher levels of oral RNA among patients with WHO-defined disease stage levels greater than 1, this positive association was only statistically significant among HIV-2 patients comparing stage 4 with stage 1 both in univariate and log10 plasma-adjusted models (adjusted ÎČ=1.73, 95% CI 0.93 to 2.53). All regression results using imputed data sets did not differ substantially from those using a complete case analysis (table 4, web only file).
For both HIV-1-infected and HIV-2-infected persons with non-missing values of plasma viral loads and detection limit midpoints used, plasma and oral viral loads were moderately correlated (Pearson's correlation coefficients: 0.33, p<0.001 vs 0.46, p<0.05) (figure 1). Using simple linear regression, log10 plasma HIV RNA was positively associated with log10 oral HIV RNA (HIV-1: ÎČ=0.26, 95% CI 0.13 to 0.39; HIV-2: ÎČ=0.20, 95% CI 0.02 to 0.38). When considering correlation coefficients using each of the 10 imputed data sets, coefficients ranged from 0.29 to 0.34 for HIV-1 and 0.36 to 0.46 for HIV-2.

Discussion

The present study is the first known assessment of oral HIV RNA shedding in HIV-2-infected individuals. In 67% of 163 HIV-1-infected and 33% of 27 HIV-2-infected ART-naive individuals, oral shedding of HIV was detected. The detection percentage of HIV-1 found in the present study is within the range presented among HIV-1-infected individuals in other studies (38–100%) that included participants both on and off ART.[3 4 7–10 24] Without considering other factors related to oral shedding, the current study found that detection was less common and levels of oral RNA lower in HIV-2-infected compared with HIV-1-infected individuals, a finding similar to differences in shedding in seminal and cervicovaginal fluids between the two virus types.[1 2 25] However, when considering plasma viral load, we found that HIV type was no longer independently associated with oral RNA. Therefore, differences in oral shedding between the two virus types may be a consequence of plasma viral load differences rather than fundamental difference between the two retroviruses.
We found that plasma viral loads were associated with detection and levels of oral HIV-1 and HIV-2. This association has been described across studies of HIV-1 oral shedding and observed with HIV-1 and HIV-2 shedding in other bodily fluids.[2 4 9 26] We found plasma and oral viral loads to be moderately correlated in both HIV-1-infected and HIV-2-infected individuals with levels in plasma being consistently greater than levels in the oral wash. Lower levels in the oral cavity may be due to oral factors that inhibit HIV replication such as mucins, thrombospondin and secretory leucocyte protease inhibitors.[8 27–30]
We found that HIV-1-infected patients with periodontal disease were more likely to have oral HIV detected than those without periodontal disease, an association that persisted after adjustment for log10 plasma viral load. We did not find this association in HIV-2-infected individuals, which may be the result of a small sample size or indicative of a different mechanism in HIV-2 individuals. Periodontal disease, and specifically linear gingival erythema, was also shown to be associated with HIV-1 oral shedding in previous studies.[9 24] The independent associations of higher plasma viral loads and periodontal disease shedding with oral HIV-1 suggest that the mechanism by which HIV-1 enters the saliva is likely multifocal, involving local and factors.
Unlike some studies of salivary and oropharyngeal HIV-1 RNA shedding, we did not find evidence of an association between CD4 cell count and oral HIV-1 or HIV-2 RNA.[13 24] Importantly, these studies were conducted in patients who were on and off ART, and presumably all patients with CD4 counts <200 were on ART. Because the data in the present study were collected before widespread use of ART, all patients were ART-naive and may represent the association between CD4 count and oral HIV in the absence of ART.
The present study was limited by its small sample size cross-sectional design. Despite the small sample of 27 HIV-2-infected patients, we did confirm that plasma viral load is associated with HIV-2 oral shedding. Because we analysed single evaluations of oral shedding and oral physical exams, we were not able to account for fluctuation in shedding and other biologic measures over time and we cannot infer the direction of causality between the factors of interest and oral shedding of HIV. Also, in some cases, measures of viral loads, labs and oral exams were not collected contemporaneously further complicating associations found between factors. However, in sensitivity analyses, including days between collection of oral viral loads and labs and days between oral viral loads and exams as covariates in the model did not alter the findings.
Despite these limitations, the present study was strengthened by the use of quantitative and qualitative assays to measure HIV RNA, decreasing the lower limit of detection. Further the regression technique used to model the dependent variable of oral HIV viral loads did not require imputations below detection limits. While we did impute values within detection ranges for plasma viral loads below the detection limits, cases of undetectable virus were much less common in the plasma (0.7% and 22.7% for HIV-1 and HIV-2, respectively) compared with the saliva (33.3% and 66.7% in HIV-1 and HIV-2, respectively). Furthermore, multiple imputation did not lead to conclusions that differed substantially from complete case analysis.
In summary, the present study confirms findings that plasma viral load and periodontal disease are associated with HIV-1 oral shedding and extends the plasma–oral shedding association to HIV-2-infected patients. The presence of oral HIV RNA shedding and the accessibility of the oral cavity for research and specimen collection over other sites of viral shedding make the oral cavity a particularly important site for research. Future studies addressing the mechanisms of oral HIV shedding may act as a model for understanding how local factors influence viral replication and harbouring.

#4787 From: L Ramakrishnan <lramakrishnan.lists@...>
Date: Sat Feb 11, 2012 7:38 am
Subject: APAC IFA: private sector facility assessment in Tamil Nadu
l_ramakrishnan
Send Email Send Email
 
APAC is inviting proposals for private health sector facility
assessment in three districts of Tamilnadu.  The invitation for
application (IFA) is available in APAC's website (www.apacvhs.org) .

  If you are interested, kindly send your proposals to APAC on or
before Thursday 16th Feb 2012.

#4788 From: SAATHII <saathii@...>
Date: Thu Feb 16, 2012 10:56 am
Subject: Scientific Updates on HIV/AIDS
saathii
Send Email Send Email
 
SAATHII Electronic Newsletter
HIV/AIDS Updates
 
 
 
POSTED ON:       16.02.2012
 
COMPILED BY:  Dr. Sai Subhasree Raghavan and Manish Mudaliar
 
NOTE: This compilation contains news items about HIV/AIDS published in the International Electronic Newsletters. Articles in this and previous newsletters may also be accessed at http://www.saathii.org/orc/elibrary
-------------------------------------------------------------------------------------------------------------------------------
 
The Achilles’ heel of HIV Treatment for Prevention
History of Sexually Transmitted Coinfections Among People Living With HIV/AIDS Receiving Antiretroviral Therapies
Seth C. Kalichman, PhD; Chauncey Cherry, MPH; Denise White, MA; Mich'l Jones, MA; Moira Kalichman, MSW
Posted: 02/13/2012; J Int Assoc Physicians AIDS Care. 2011;10(6):365-372. Â© 2011 Sage Publications, Inc.

Abstract

Background: Antiretroviral therapies (ARTs) offer promising new avenues for HIV prevention. Unfortunately, people infected with HIV who have co-occurring sexually transmitted infections (STIs) are more infectious than suggested by the amount of virus in their peripheral blood. We examined the history of sexually transmitted coinfections in people living with HIV.
Methods: People living with HIV/AIDS completed confidential computerized interviews that assessed history of STI, sexual behaviors, and STI knowledge.
Results: Among 414 men and 156 women currently receiving ART, 53% had been diagnosed with at least 1 STI since testing HIV positive; 24% women, 19% men, and 11% transgender persons had been diagnosed with an STI in the past year. History of STI was associated with younger age, greater STI knowledge, substance use, and ART nonadherence.
Conclusions: Aggressive strategies for detecting and treating STI in people receiving ART will be necessary to achieve protective benefits.

 

 

Introduction

HIV prevention priorities have shifted over the past decade, from reducing the risks of uninfected individuals contracting HIV, to treating persons already infected.[1] The rationale for targeting prevention to HIV-positive persons is in part based on the potential for reducing HIV infectiousness with antiretroviral therapy (ART).[2,3] Mathematical models project that implementation of universal HIV testing and treatment could have a significant impact on HIV incidence at the population level.[3-5] Although using HIV treatments for prevention poses significant challenges for generalized HIV epidemics in resource-constrained countries,[6-8] treatment for prevention is being implemented in the United States and Canada. For example, the San Francisco Health Department currently offers ART to all persons who test HIV positive. Similar initiatives are underway in the Bronx, New York, Washington, DC, and Vancouver, British Columbia. The potential for ART to reduce infectiousness and prevent new HIV infections led the Swiss Federal AIDS Commission to state that people living with HIV/AIDS who have effectively suppressed HIV replication, as demonstrated by repeated undetectable viral load test results, can be considered noninfectious; alleviating concerns about HIV transmission.[9,10] Research suggests that this policy shift has indeed resulted in less protected sexual behavior among men and women who are familiar with the Swiss policy and have undetectable viral loads.[11]
Although the potential for ART to prevent HIV infections is theoretically compelling, there are at least 2 behavioural factors that will undermine the use of HIV treatments for prevention: poor adherence to ART regimens and co-occurring sexually transmitted infections (STIs).[12] Specifically, poor treatment adherence results in nonsuppressive therapeutic levels of ART and therefore unchanged infectiousness. Even worse, nonadherence can lead to resistant virus that can subsequently be transmitted to others.[13,14]
Less obvious is the role of co-occurring STI in the infectiousness of genital secretions. Sexually transmitted coinfections increase HIV viral shedding in the genital tract, resulting in significant increases in HIV infectiousness.[15] Local inflammation activates HIV replication in the genital immune compartment independent of HIV in peripheral blood, such that a person can have a clinically monitored undetectable blood viral load while they are highly infectious in their genital tract.[15,16] Thus, people living with HIV and sexually transmitted coinfections are more infectious than they can possibly know from routine monitoring of blood plasma viral load.[17] A recent review of research on the correspondence between HIV concentrations in blood and semen found only moderate concordance; the mean correlation between blood plasma viral load and semen viral load was r = .44, accounted for at least in part by sexually transmitted coinfections.[17]
The overall median point-prevalence of confirmed STI in people living with HIV/AIDS is 12.4%, and the most common STI in people with HIV are those that cause HIV shedding, specifically syphilis (median 9.5% prevalence), gonorrhea (9.5%), chlamydia (5%), and trichamoniasis (18.8%).[18] Although STIs are frequently detected at the time of HIV diagnosis, reflecting the role of STI in HIV transmission, exposure to sexually transmitted pathogens persists long after HIV diagnosis. In addition, STI prevalence among individuals receiving HIV treatment is not appreciably different from their untreated counterparts.[19] Sexually transmitted coinfections have significant implications for people receiving ART, especially when ART is administered with the intent of preventing HIV transmission.
The purpose of the current research was to examine the history of co-occurring STI in a community sample of people living with HIV/AIDS who are receiving ART. We examined STI diagnoses during the time since testing HIV positive and STI diagnoses in the 12 months prior to assessment. To determine factors associated with sexually transmitted coinfections, we compared persons who had been diagnosed with an STI since testing HIV positive to those who had not been diagnosed with an STI on demographic, behavioral, and health characteristics. We hypothesized that people living with HIV/AIDS and receiving ART, who have a history of STI diagnoses would demonstrate a pattern of continued substance use and sexual behaviors that maintain risks of new STI, greater infectiousness, and HIV transmission.

Methods

Participants

People living with HIV/AIDS (N = 713) were recruited through community sampling to participate in a single-session survey.We used targeted venue and snowball sampling techniques to identify individuals in and out of care. Recruitment relied on responses to brochures placed in waiting rooms of HIV service providers and infectious disease clinics throughout Atlanta, Georgia, as well as an explicit systematic approach to word-of-mouth chain recruitment. Specifically, participantswere given recruitment brochures and encouraged to refer their HIV-infected friends to the study. These procedures were designed to extend recruitment beyond any one service setting in order to achieve a broad community sample.
Interested persons contacted our research program to schedule an assessment appointment. The study entry criteria were age 18 years or older and proof of positive HIV status usinga photo ID with either a matching ART prescription bottle, HIV clinic card, positive HIV test result, laboratory report, or any other proof of positive HIV status. Participants received $25 for completing the computerized interview (approximately 1 hour). Data were collected between December 2009 and March 2011. All study procedures were approved by the university institutional review board.

Measures

For the purposes of the current study, measures included STI history, demographic characteristics, substance use, STI knowledge, and sexual behavior. Measures were administered using audio-computer-assisted structured interviews (ACASIs) to reduce demand characteristics and socially evoked response biases.[20,21]
STI History. Participants reported whether they had been diagnosed with gonorrhea, chlamydia, syphilis, genital herpes, or trichomoniasis in 2 separate time frames. First, we asked the participants whether they had ever been diagnosed with any one of the STIs. Participants who had been diagnosed with an STI were asked for the approximate date of their last diagnosis. We used the date of STI diagnoses and date of their HIVpositive diagnosis to determine whether each STI had been diagnosed since testing HIV-positive. Specifically, we defined having been diagnosed with an STI after testing HIV positive if the difference in dates was 1 month or greater. We also used the dates to determine whether the diagnosis had occurred within the previous 12 months of the assessment session. We used the same format to assess the occurrence of genital ulcers, genital pain, and unexplained genital discharge to detect potentially undiagnosed STI symptoms. We did not, however, include these nonspecific symptoms in our definition of having contracted an STI.
Demographic and Health Characteristics. Participant characteristics including gender (including whether they were transgender), age, years of education, income, ethnicity, and employment status were collected. We assessed HIV-related symptoms using a previously developed and validated measure concerning the experience of 14 common symptoms of HIV disease.[22] Participants also indicated their most recent CD4 count and viral load. We asked the participants whether they were currently being treated with ART and those who were receiving treatment indicated whether they had missed any of their ART in the past week. Participants also responded to a single-item rating scale for assessing medication adherence. The adherence rating scale asked the individuals to indicate the point along a continuum showing how much of ARTs they have taken in the past month.[23,24] For the computerized administration, we adapted the response format by using a 100-point slide bar tool anchored by 0%, 50%, and 100%. The specific instructions read as follows ‘‘We would be surprised if most people take 100% of their medications. Below, 0% means you have taken no HIV medications the past month, 50% means you have taken half of your HIV medications the past month, and 100% means you have taken every single dose this past month. What percentage of your HIV medications did you take?’’ Participants indicated the percentage of medications taken by clicking their mouse anywhere on the 100-point slide bar continuum. The adherence rating scale has been found reliable and valid.[23,24]
STI Knowledge. We administered 14 items from a previously developed test of STI knowledge, reflecting a broad range of information about STI transmission, symptoms, and disease manifestations.[25] The specific items used in this study are shown in the results. Items were responded True/False and Do Not Know, with Do Not Know responses scored incorrect. The total score was obtained by calculating the percentage correct responses, Kuder Richardson-20 coefficient =.71.
Sexual Risk and Protective Behaviors. Participants responded to items assessing their number of male and female sex partners and frequency of sexual behaviors in the previous 4 months. Specifically vaginal and anal intercourse with and without condoms were assessed within HIV-seroconcordant and -serodiscordant partnerships. A 4-month retrospective period was selected because previous research has shown reliable reports for numbers of sex partners and sexual events over this time period.[26] Participants were instructed to think back over the past 4 months and estimate the number of sex partners and number of sexual occasions in which they practiced each behavior. The instructions included cues for recollecting behavioral events. Data were analyzed within seroconcordant and serodiscordant relationships with individual behaviors examined as well as behaviors collapsed across unprotected and protected aggregates. In addition, we calculated the percentage of intercourse occasions in which condoms were used by taking the ratio (condom-protected vaginal + condom-protected anal intercourse/total vaginal + total anal intercourse).
Data Analyses. All of the main analyses for this study focused on the participants who were currently taking ART. We first conducted descriptive analyses to determine the prevalence of sexually transmitted coinfections in the sample. We report STI diagnoses and symptoms for the time since testing HIV positive and in the past year, separately for men, women, and transgender persons. Based on this initial analysis, we identified participants who had and had not contracted an STI since testing HIV positive. Groups were compared using bivariate logistic regressions on demographic, health, substance use, STI knowledge, and sexual behaviors. Predictors found significant in bivariable models were selected for inclusion in the multivariable model. For all analyses, we performed logistic regressions, reporting odds ratios and 95% confidence intervals, with statistical significance defined as P < .05.

Results

Among the 713 persons screened for the study, 570 (79%) were currently taking ART. The final sample for analyses consisted of 415 men and 155 women, of which 26 men and 19 women identified as transgender. Table 1 shows the rates of STI since testing HIV positive and rates for having been diagnosed with an STI in the past year. Overall, 53% of participants had been diagnosed with at least 1 STI since testing HIV positive, 29% were diagnosed once, and 24% had 2 or more diagnoses. Genital pain and discharge since testing HIV positive were also reported. In terms of STI diagnoses in the past year, 26% women, 19% men, and 12% transgender persons had been diagnosed with an STI. The most common new STI diagnosis was genital herpes (7%), followedby gonorrhea (6%) and the least common was trichomoniasis (1%).

Demographic and Health Characteristics

Analyses showed that participant age differed between people living with HIV who were and were not diagnosed with an STI; persons diagnosed with a post-HIV STI were significantly younger. In addition, participants who had been diagnosed with an STI were significantly more likely to have a history of incarceration. The history of STI was not associated with gender, income, race, or employment status. In terms of healthrelated factors, individuals who had been diagnosed with an STI were significantly more likely to have missed their HIV medications in the previous week and were more likely to have taken less than 85% of their medications in the previous month (see Table 2 ).

Substance Use

Participants with a history of STI since testing HIV positive indicated significantly more alcohol and other drug use in the previous 4 months. Nearly 2 of 3 persons with STI diagnoses drank alcohol, half had used at least 1 illicit drug, and 30% were poly-drug users. In addition, having had an STI was associated with using drugs before sex in the past 4 months (see Table 2 ).

STI Knowledge

Results showed that most participants, regardless of whether they had an STI, did not have high levels of accurate information about STI transmission, symptoms, and treatment (see Table 3 ). Less than half of the participants were aware that genital herpes can be transmitted in the absence of genital ulcers and 1 in 3 believed that having gonorrhea resulted in an immunity against future infection. In addition, only 37% of participants knew that sexually transmitted coinfections increase HIVinfectiousness in genial fluids. Results also showed that individuals who had been diagnosed with an STI answered more STI knowledge items correctly compared to participants who had not been diagnosed with an STI.

Current Sexual Behaviors

The associations between having been diagnosed with an STI since testing HIV positive and recent sexual behaviors are shown in Table 4 . A total of 248 (43%) participants reported HIV-positive (seroconcordant) sex partners in the past 4 months and 193 (33%) had sex partners in that time period whose HIV status was negative or unknown (serodiscordant). Among the individuals with serodiscordant partners, 107 (55%) had engaged in unprotected vaginal or anal intercourse. Comparisons between groups demonstrated that individuals with a history of STI since their HIV diagnosis were significantly more likely to have HIV-positive (seroconcordant) sex partners in the past 4 months. Participants with a history of sexually transmitted coinfection were more likely to have engaged in unprotected anal intercourse and total unprotected intercourse, as well as significantly more occurrences of these behaviors.

Multivariable Model

To identify factors independently associated with history of STI since testing HIV positive, we tested a multiple logistic regression model predicting having been diagnosed with an STI since testing HIV positive (see Table 5 ). Results showed that younger age, more accurate knowledge about STI, drug use, and having missed ART in the past week were significantly associated with having had an STI.

Discussion

The current study demonstrates a history of post-HIV diagnosis of STI is common among people receiving ART. We found that more than half of the participants had been diagnosed with at least 1 STI since testing HIV positive. Among those who had been diagnosed with an STI, 24% had 2 or more STI diagnoses. More than 1 in 4 women and nearly 1 in 5 men receiving ART had been diagnosed with an STI in the previous year. The symptoms of STI were also common in the previous year. These STI rates are consistent with a recent review that found a median STI point prevalence of 12% among people living with HIV.[18] We confirmed our study hypothesis that people living with HIV who had a history of STI were at continued high risk of contracting new STI, increased infectiousness, and transmitting HIV. These results have implications for the use of ART to lower HIV infectiousness.
Local inflammation of the genital tract caused by sexually transmitted coinfections increases HIV viral shedding and therefore HIV infectiousness.[8] Although several ART regimens effectively penetrate the genital immune compartment, activation of HIV-infected CD4 cells spike HIV concentrations in genital secretions,[27,28] increasing infectiousness beyond what can be estimated from peripheral blood viral loads. We found that having contracted an STI was associated with poor ART adherence, posing an added challenge to using ART for HIV prevention. Multiple factors that can act as mediating variables may explain the association between sexually transmitted coinfections and ART nonadherence including the use of alcohol and other substances, health consciousness, and quality of health care.[29] Individuals who contract STI and are nonadherent to ART will likely remain highly infectious and undermine the preventive effects of using ART for HIV prevention.
We found surprisingly high levels of misinformation about STI in this sample of people living with HIV/AIDS. Similar to studies of other populations,[25] people living with HIV only knew about half of the STI knowledge items. Contrary to expectations, individuals who had been diagnosed with an STI since testing HIV positive had slightly better STI knowledge, possibly reflecting educational and counseling experiences related to their previous STI. Despite their greater STI knowledge, those who had been diagnosed engaged in substantially more risk behaviors. This finding suggests a need for STI education among people living with HIV but education alone will not be sufficient to prevent new infections.
The findings from this study should be interpreted in light of its methodological limitations. Our methods relied on selfreported health status and sexual behaviors which may have been affected by self-report biases, tendencies to underreport sexual behaviors and substance use,[30] as well as overreport medication adherence,[31] suggesting that the behaviors reported here should be considered lower-bound estimates. Our crosssectional study design also precludes any causal or directional conclusions. Our measures may have excluded important covariates that could have helped explain the results, such as quality of health care, stigmas associated with STI, and perceptions of infectiousness. Finally, our results are based on a convenience sample that is predominantly African American people living with HIV/AIDS in 1 southern US city. Although our results converge with other studies, caution is warranted before generalizing these findings to other populations of people living with HIV/AIDS. Acknowledging these limitations, we believe that our findings have implications for programs that seek to test and treat people for HIV prevention.
Co-occurring STIs are a significant threat to the potential for HIV treatments to reduce HIV infections. Indeed, mathematical models of infections averted by population scale-up of ART are unrealistically optimistic when they do not include estimates of sexually transmitted coinfections.[3,32] Although viral load in the genital tract is typically lower than viral load in blood plasma, this association is inverted when there are cooccurring STIs.[33] Implementing ART as a preventive strategy therefore requires aggressive STI detection and treatment. Patients taking ART should receive comprehensive information about STI as well as instruction in symptom detection, self-examination, and ability to attain sexual health services. Sexual history taking, STI screening, and risk-reduction counseling should be fully integrated with the routine care for people with HIV/AIDS. Failure to allocate adequate resources to stemming STIs and monitoring adherence in people receiving ART could render HIV treatment ineffective in preventing HIV transmission.
 

#4789 From: SAATHII <saathii@...>
Date: Fri Feb 17, 2012 7:38 am
Subject: Scientific Updates on HIV/AIDS
saathii
Send Email Send Email
 
SAATHII Electronic Newsletter
HIV/AIDS Updates
 
 
 
POSTED ON:       17.02.2012
 
COMPILED BY:  Dr. Sai Subhasree Raghavan and Manish Mudaliar
 
NOTE: This compilation contains news items about HIV/AIDS published in the International Electronic Newsletters. Articles in this and previous newsletters may also be accessed at http://www.saathii.org/orc/elibrary
 
The Effect of Injecting Drug Use History on Disease Progression and Death Among HIV-positive Individuals Initiating Combination Antiretroviral Therapy
Collaborative Cohort Analysis
M Murray; RS Hogg; VD Lima; MT May; DM Moore; S Abgrall; M Bruyand; A D'Arminio Monforte; C Tural; MJ Gill; RJ Harris; P Reiss; AC Justice; O Kirk; M Saag; CJ Smith; R Weber; J Rockstroh; P Khaykin; JAC Sterne
Posted: 02/12/2012; HIV Medicine. 2012;13(2):89-97. Â© 2012 Blackwell Publishing

Abstract

Background We examined whether determinants of disease progression and causes of death differ between injecting drug users (IDUs) and non-IDUs who initiate combination antiretroviral therapy (cART).
Methods The ART Cohort Collaboration combines data from participating cohort studies on cART-naĂŻve adults from cART initiation. We used Cox models to estimate hazard ratios for death and AIDS among IDUs and non-IDUs. The cumulative incidence of specific causes of death was calculated and compared using methods that allow for competing risks.
Results Data on 6269 IDUs and 37 774 non-IDUs were analysed. Compared with non-IDUs, a lower proportion of IDUs initiated cART with a CD4 cell count <200 cells/ÎŒL or had a prior diagnosis of AIDS. Mortality rates were higher in IDUs than in non-IDUs (2.08 vs. 1.04 per 100 person-years, respectively; P<0.001). Lower baseline CD4 cell count, higher baseline HIV viral load, clinical AIDS at baseline, and later year of cART initiation were associated with disease progression in both groups. However, the inverse association of baseline CD4 cell count with AIDS and death appeared stronger in non-IDUs than in IDUs. The risk of death from each specific cause was higher in IDUs than non-IDUs, with particularly marked increases in risk for liver-related deaths, and those from violence and non-AIDS infection.
Conclusion While liver-related deaths and deaths from direct effects of substance abuse appear to explain much of the excess mortality in IDUs, they are at increased risk for many other causes of death, which may relate to suboptimal management of HIV disease in these individuals.

Introduction

Injecting drug use (IDU) is one of the most frequent routes of HIV transmission in many industrialized countries[1] and is responsible for up to one-third of HIV transmission globally, outside of sub-Saharan Africa.[2] Since the introduction of combination antiretroviral therapy (cART) in 1996, mortality rates related to HIV infection have significantly decreased.[3–9] Rates of morbidity and mortality subsequent to initiation of cART are higher in HIV-positive IDUs than in other HIV-positive persons,[10–13] although some studies found only limited evidence for this effect.[6,14,15]
Several factors may contribute to the relatively poor response to treatment observed in HIV-positive patients who have a history of IDU. They have been shown to have decreased access to HIV care and treatment,[16,17] more comorbid conditions associated with drug use and addiction [such as hepatitis C virus (HCV) coinfection], poorer adherence to treatment,[18] and more adverse drug interactions.[19,20] They are also more likely to come from particular ethnic or racial groups that have historically been disadvantaged with respect to health outcomes.[21] In some studies, immunological or virological responses to cART appeared to be lower in HIV-positive IDUs than in other patients.[11,22] However, it is important to distinguish between those who are and are not actively injecting drugs, as the former will have additional risks from overdose, accidents and violence.
Given the high prevalence of IDU among HIV-positive individuals receiving cART, it is important to understand what factors affect disease progression and death in this group: for example, in order to design programmes to reduce disparities in health outcomes between IDUs and non-IDUs receiving cART. We examined determinants of disease progression and death among IDUs and non-IDUs initiating cART in participants in a large multinational collaboration of HIV treatment programmes, and compared causes of death in IDU and non-IDU populations.

Methods

Patient and Cohort Eligibility

The Antiretroviral Therapy Cohort Collaboration (ART-CC) is a multinational collaboration of HIV cohort studies. The collaboration has been described in detail elsewhere.[12,23,24] In brief, it was established in 2001, updated in 2004, 2006 and 2008, and includes cohort studies from Canada, Europe and the USA. Cohort studies were eligible to join if they had enrolled at least 100 HIV-1-positive antiretroviral-naĂŻve patients aged 16 years and over who initiated potent cART with at least three antiretrovirals, including nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), and nonnucleoside reverse transcriptase inhibitors (NNRTIs), with a duration of follow-up of at least 1 year. Fourteen cohort studies provided information on causes of death and were included in analyses presented in this paper.
All studies that joined the collaboration have been approved by their local ethics committees or institutional review boards, use standardized methods of data collection, and schedule follow-up visits at least once every 6 months.

Data Collection

Patient selection and data extraction were performed at the data centres of the participating cohort studies. Anonymized data from each cohort on a predefined set of demographic, laboratory and clinical variables were pooled and analysed centrally. Data managers checked for duplicated records, and ensured that patients included in more than one cohort had only one record in the combined data set.

Primary Outcome

The primary endpoint in this study was HIV disease progression, defined as (1) a new AIDS-defining disease [based on the clinical part of the 1993 US Centers for Disease Control and Prevention (CDC) revision of the AIDS case definition] or (2) death from any cause. We utilized an intent-to-continue-treatment approach, and therefore ignored changes to treatment regimen, including treatment interruptions and terminations. We measured time from the initiation of cART to the date on which the endpoints occurred. Patients who remained alive were censored at their last visit plus 50% of the average time between visits for that cohort. For example, if a cohort had, on average, 6 months between follow-up visits, patients who did not die would be censored at last visit plus 3 months. This allocates follow-up time in an unbiased way to those who did not die, as the average time from last follow-up to death in those who died is approximately 50% of the interval between scheduled visits.

Secondary Outcomes

The secondary outcomes in this study were causes of death. All deaths with International Classification of Diseases (ICD) version 9 or ICD10 or free text coding were reviewed by a computer program and also by a clinician and an epidemiologist and then reviewed in committee when discordant. Cause of death was determined utilizing a standardized protocol developed by the Copenhagen HIV Programme for coding causes of death in HIV-positive individuals.[25] Two cohorts participating in ART-CC [Italian Cohort of Antiretroviral-NaĂŻve Patients (ICONA) and the Veterans Aging Cohort Study (VACS)] did not provide causes of death and were omitted from analyses. The two cohorts from Germany did not provide cause of death prior to 2002 for patients in Frankfurt and prior to 2003 in Cologne and Bonn clinics. Patients enrolled in these cohorts prior to these years were excluded.

Prognostic Variables

Prognostic variables measured at baseline (initiation of cART) included gender, age (four categories, from 16 to ≄50 years), CD4 cell count (six categories, from <25 to >350 cells/ÎŒL), plasma HIV RNA (three categories, from 3 to ≄5 log10 HIV-1 RNA copies/mL), CDC HIV disease stage at baseline, first prescribed cART regimen (PI-based, NNRTI-based, three NRTIs, or other) and year of first therapy (three categories, from 1996 to 2006).

Statistical Analyses

Baseline variables in patients infected via IDU and non-IDU were compared using χ2 tests for categorical variables or the Wilcoxon rank sum test for continuous variables. Hazard ratios for progression to AIDS and death were estimated separately in IDUs and non-IDUs using Cox proportional hazards models, and were compared using Wald tests for interaction (assuming log-linear interactions for variables with more than two categories). We compared rates of death in IDUs and non-IDUs and estimated rate ratios stratified by CD4 count (<200 vs. ≄200 cells/ÎŒL) and time since starting cART (0–6 months, 6–12 months and 1–5 years) and tested for homogeneity across these strata,[26] Causes of death in IDUs and non-IDUs were compared using Fisher's exact test or χ2 analysis; and using Cox models adjusted for sex, age, prior AIDS diagnosis, baseline CD4 cell count, baseline HIV-1 RNA and year in which cART was started, and stratified by cohort. In models for specific causes of death, patients who died from other causes were censored at the date of death.
We estimated and graphed cause-specific cumulative incidence of deaths classified as AIDS-related, liver-related, violent (including suicide and overdose) and other (including unknown). The cumulative incidence function is similar to the Kaplan–Meier (KM) estimate, but accounts for censoring resulting from competing causes of death: the KM estimate is the cumulative risk of death from that cause conditional on having not died of another cause. Estimated cumulative incidence functions were stacked to illustrate the contribution of each specific cause to total cumulative mortality.[27]

Results

A total of 44 043 HIV-positive men and women were eligible for analyses. The majority of study participants were male (32 032; 72%), initiated PI-based regimens (26 345; 59%) and had CDC HIV stage A or B disease at baseline (33 868; 77%). At baseline, the median age was 37 years [interquartile range (IQR) 31, 44 years], the median CD4 count was 215 cells/ÎŒL (IQR 90, 345 cells/ÎŒL) and the median HIV-1 RNA was 4.94 log10 copies/mL (IQR 4.41, 5.40 log10 copies/mL).
Table 1 summarizes patient characteristics by IDU status: 6269 patients (14%) had a history of IDU. These patients were less likely to be female (23.8 vs. 27.9%, respectively; P<0.001), and started therapy earlier (median July 1999 vs. November 2000, respectively; P<0.001) compared with non-IDUs. There was little evidence of differences in the proportion of individuals with AIDS at baseline (22.4 vs. 23.2% in IDUs and non-IDUs, respectively; P=0.15). The median baseline CD4 count was slightly higher for IDUs compared with non-IDUs [218 cells/ÎŒL (IQR 97–360 cells/ÎŒL) vs. 214 cells/ÎŒL (IQR 88–341 cells/ÎŒL), respectively]. By contrast, at 6 and 36 months after initiation of cART, the median (IQR) CD4 count was lower in IDUs compared with non-IDUs [at 6 months, 297 (IQR 160–469) cells/ÎŒL vs. 323 (IQR 186–488) cells/ÎŒL, respectively; at 36 months, 405 (IQR 249–605) cells/ÎŒL vs. 462 (IQR 310–660) cells/ÎŒL, respectively]. The proportions of patients with undetectable viral load (defined as HIV-1 RNA ≀500 copies/mL) at 6 and 36 months after initiation of cART were also lower for IDUs compared with non-IDUs (at 6 months, 71.2 vs. 79.6%, respectively; P<0.001; at 36 months, 70.2 vs. 78.5%, respectively; P<0.001). In a subset of 15 238 patients with data on coinfection with hepatitis C virus at baseline, there was a strong association between IDU status and a positive test result: 2204 (88%) of IDUs were coinfected compared with 1518 (12%) of non-IDUs (P<0.001).
A total of 533 deaths (8.5%) were recorded in patients with a history of IDU, compared with 1564 (4.1%) among non-IDUs over the follow-up period: mortality rates were 2.08 [95% confidence interval (CI) 1.91–2.26] vs. 1.04 (95% CI 0.99–1.09), respectively, per 100 person-years (P<0.001). Rates of AIDS were also higher in IDUs than in non-IDUs [2.91 (95% CI 2.70–3.13) vs. 2.33 (95% CI 2.25–2.41), respectively, per 100 person-years; P<0.001]. The unadjusted mortality rate ratio (RR), comparing IDUs with non-IDUs, was higher for patients with baseline CD4 counts ≄200 cells/ÎŒL than for those with CD4 counts <200 cells/ÎŒL [2.67 (95% CI 2.26–3.15) vs. 1.76 (95% CI 1.55–2.00), respectively; P-value for homogeneity 0.0001]. Mortality RRs increased with time since start of cART, from 1.28 (95% CI 0.98–1.65) in the first 6 months to 1.48 (95% CI 1.08–1.99) in months 6–12 and 2.41 (95% CI 2.11–2.75) in years 1–5 (P-value for homogeneity <0.0001).
Table 2 shows hazard ratios for the association of patient characteristics at baseline with progression to death and AIDS (mutually adjusted for other variables in the table and stratified by cohort) in patients who were and were not infected via IDU, together with P-values for interaction (differences in hazard ratios in IDUs and non-IDUs). Lower baseline CD4 cell count, higher baseline HIV viral load, clinical AIDS at baseline, and later year of cART initiation were associated with disease progression in both groups, consistent with associations reported previously.[12,28] However, the inverse association of baseline CD4 cell count with subsequent rates of AIDS (interaction P<0.0001) and death (interaction P=0.092) appeared to be stronger in IDUs than in non-IDUs. By contrast, the positive association of baseline HIV-1 RNA with subsequent AIDS appeared stronger in non-IDUs than IDUs (interaction P=0.006). While the positive association of a diagnosis of AIDS before starting cART with mortality appeared stronger in non-IDUs than IDUs (interaction P=0.003), the association with AIDS appeared stronger in IDUs (interaction P=0.013). The association of baseline age with AIDS appeared stronger in non-IDUs than IDUs (interaction P=0.056).
Cause of death information was available for 1879 deaths: 452 (84.8%) of 533 deaths in patients infected via IDU and 1427 (90.4%) of 1564 deaths in non-IDU patients. Among these, causes of death could be assigned for 1600 (85%) deaths (379 IDUs and 1221 non-IDUs). Figure 1 shows percentages of deaths from specific causes in patients who were and were not infected via IDU. The risk of death from each cause was higher in IDUs than non-IDUs, with particularly marked increases in the risks of liver-related deaths, and deaths from violence and non-AIDS infection.
Click to zoom
Figure 1.
Numbers (below graph) and percentages (above bars) of specific causes of death in patients who were and were not infected via injecting drug use (IDU). Liver-related deaths include hepatitis and liver failure; violent deaths include accident, suicide and overdose; cardiovascular disease (CVD) includes myocardial infarction, ischaemic heart disease, stroke, heart failure/unspecified and other heart disease; 'Other' includes causes with fewer than 20 deaths overall. Unknown deaths are those for which there was insufficient information to assign a cause of death.
Figure 2 shows the estimated cumulative incidence of deaths from AIDS, liver-related disease (including hepatitis), violence (including suicide and overdose) and other causes up to 8 years after starting cART, separately for IDUs and non-IDUs. By 8 years after initiation of cART, the cumulative incidence of death was 16.3% in patients infected via IDU, compared with 7.3% in other patients. By the end of follow-up, the largest differences in the cumulative incidence of cause-specific death between IDUs and non-IDUs were in deaths resulting from hepatitis [0.72 vs. 0.08%, respectively; adjusted hazard ratio (AHR) 8.8; 95% CI 5.0–15.5], liver disease (0.38 vs. 0.09%; AHR 4.6; 95% CI 2.5–8.7) and substance abuse (0.54 vs. 0.04%; AHR 6.7; 95% CI 3.4–13.4). Mortality of unknown cause (1.46 vs. 0.60%; AHR 3.1; 95% CI 2.3–4.1) was also higher in the IDU group than in the non-IDU group. In the subset of patients with information on both HCV coinfection and causes of death (n=13 203), the hazard ratio for death from liver disease was attenuated from 4.08 (95% CI 2.24–7.44) to 1.02 (95% CI 0.50–2.09) on adjustment for coinfection with HCV.
Click to zoom
Figure 2.
Total cumulative mortality from the start of combination antiretroviral therapy (cART) in patients who were (a) and were not (b) infected by injecting drug use (IDU), partitioned by cause of death grouped as AIDS, liver-related, violent and other.

Discussion

In this analysis involving 14 cohort studies and 44 043 participants, individuals infected via IDU experienced higher rates of death and AIDS, compared with other patients, from the time that they started cART. Although associations for patient characteristics at initiation of cART with subsequent disease progression were largely similar between the two groups, the inverse association of baseline CD4 with subsequent disease progression appeared weaker in patients infected via IDU. By contrast, associations of baseline HIV-1 RNA and AIDS diagnosis before baseline with subsequent rates of AIDS appeared stronger in patients infected via IDU. Compared with other patients, those infected via IDU were at greater risk of all of the specific causes of death we examined, with the greatest differences seen for deaths as a result of hepatitis and liver failure and deaths as a result of substance abuse. The differences we observed were not explained by differences in baseline characteristics between IDUs and non-IDUs. However, the association with liver-related death appeared to be explained by coinfection with HCV.
Strengths of our study include its large size and wide geographic representation across Europe and North America, the consistency of methods used to ascertain AIDS events across the different cohorts, and the common methods used to assign causes of death.[29] This study also has a number of limitations, foremost among them being the lack of data on continuing IDU among individuals whose presumed transmission route for HIV acquisition was IDU; and adherence after starting cART, which may mediate some of the differences observed. Participating cohort studies in the ART-CC do not collect information on treatment adherence in a standardized manner. Unmeasured confounders may also account for some of these differences in progression rates in IDUs compared with non-IDUs. Further, a greater proportion of IDU deaths were of unknown cause, which may have biased our assessment of the relative importance of different causes of death.
Consistent with our results, most previous studies have shown higher rates of mortality in IDUs than in non-IDUs;[10,12] although some have not.[6,14,15] The IDU group was more likely to start cART in the earliest treatment period, an era that has been previously associated with an increased risk for mortality;[30] however, even with adjustment for this difference, higher rates of death and AIDS were seen among the IDUs.
The most important factors and behaviours contributing to the differences in disease progression we have observed are likely to be adherence to therapy and HCV coinfection. As explained above, we did not have data on adherence, but the poorer immunological and virological responses at 6 and 36 months after starting cART in IDUs compared with non-IDUs are consistent with a role for adherence. Previous studies have shown more rapid disease progression as a result of lower rates of virological response seen in IDUs.[31] Further studies have reported that poor virological outcomes and increased immunological failure on cART among IDUs are often attributable to lack of adherence to therapy.[14,17,22] When not actively using drugs, former IDUs have been shown to have the ability to be adherent to therapy and to achieve comparable benefits to non-IDUs on cART.[13,14,17,22,32] IDUs were also at increased risk for deaths from many diseases not typically thought to be related to HIV infection, such as heart and vascular disease and non-AIDS-related malignancies. Given that excesses of these deaths have been demonstrated in untreated individuals,[33] it is also possible that these deaths relate to suboptimal treatment of HIV infection in IDUs, as they may be more likely in some settings to remain off therapy for an extended period of time or be less likely to adhere to therapy. In British Columbia, however, IDUs who do adhere have similar outcomes to non-IDUs.[15]
IDUs are at increased risk of HCV coinfection,[10,12,34] which appeared to explain the excess of liver-related deaths in IDUs compared with non-IDUs. More than half of the approximately 5% difference in mortality between the groups can be attributed to three aetiologies, two of which could be attributed to HCV. Liver failure and hepatitis together accounted for a mortality rate of 1.1% in IDUs vs. 0.17% in non-IDUs (a difference of almost 1% between the two groups). Also, substance abuse-related deaths accounted for a 0.5% difference in mortality, and infection (both AIDS-related and -unrelated) accounted for a further 1.13% difference in mortality. In addition, there was a 0.84% difference between the two groups with respect to death from unknown causes. It is thus possible that the above-mentioned causes of death are in fact underrepresented in these numbers.
In summary, HIV-positive individuals with a history of IDU experienced higher rates of death and AIDS after starting cART, compared with individuals without a history of IDU. While liver-related disorders and deaths from the direct effects of substance abuse appeared to explain much of the excess mortality in IDUs, it also appeared that they were at increased risk for many other causes of death which are not typically thought to be related to IDU. These differences may relate to the suboptimal management of HIV disease in these individuals.
 

#4790 From: Sughis Muhammad <sughism@...>
Date: Thu Feb 16, 2012 11:41 am
Subject: theHealth Journal New Website
sughism
Send Email Send Email
 
Dear Professionals,

theHealth journal is published by LIPhealth (www.liphealth.pk) which also have other projects. To serve our readers better, we would like to bring it in your kind notice that the web address of theHealth journal is changed to: www.thehealthj.com. The old website (www.thehealth.liphealth.pk) will remain operational for few weeks and will be removed later on. For correspondence, please use the following new email addresses:

For editorial inquiries: @editor thehealthj.com
To submit articles: @submit thehealthj.com
For information: @info thehealthj.com

We would also like to invite you to submit your articles for June 2012 issue. We look forward for your scholarly contribution to theHealth journal.

For announcements and dissemination of information, we have also created a mailing list (weblink enclosed) to keep you well informed. We would like to invite you to join the mailing list: http://groups.google.com/group/thehealthj

Kindly forward the information among your peers. Should you have any questions, please do not hesitate to ask. Thank you for your understanding.

Regards,
for
theHealth Journal
_______________
Muhammad Sughis
Skype: sughis
________________________________________
For social and professional interaction,
Join Pakistani Students Abroad (PSA)
http://groups.google.com/group/psabroad

#4791 From: SAATHII <saathii@...>
Date: Thu Feb 23, 2012 6:10 am
Subject: Scientific Updates on HIV/AIDS
saathii
Send Email Send Email
 
SAATHII Electronic Newsletter
HIV/AIDS Updates
 
 
 
POSTED ON:       23.02.2012
 
COMPILED BY:  Dr. Sai Subhasree Raghavan and Manish Mudaliar
 
NOTE: This compilation contains news items about HIV/AIDS published in the International Electronic Newsletters. Articles in this and previous newsletters may also be accessed at http://www.saathii.org/orc/elibrary
 
IN THIS EDITION:
1. UK guidelines on treatment of HIV in pregnancy give green light to efavirenz
2. Increased risk of anal cancer for all groups with HIV
3. Cotrimoxazole prophylaxis reduces death rate by almost 60% in adults taking ART in low and middle-income countries
4. Tenofovir associated with increased risk of kidney disease
5. HIV treatment reduces risk of fractures

6. Neverapine and severe rash

1. UK guidelines on treatment of HIV in pregnancy give green light to efavirenz
Keith Alcorn
Published: 17 February 2012
New UK draft guidelines on the management of HIV infection in pregnant women recommend that efavirenz-based treatment should no longer be avoided in pregnant women or women who want to have a baby.
Pregnant women were previously recommended to avoid efavirenz treatment, as were women hoping to become pregnant, due to the theoretical risk of birth defects if the foetus was exposed to the drug in the first trimester of pregnancy.
But after rigorous review of the published evidence, the British HIV Association guidelines panel concluded: “there are insufficient data to support the former position [of avoiding the drug] and [we] furthermore recommend that efavirenz can be both continued and commenced during pregnancy.”
Women who conceive while taking an efavirenz-containing regimen should continue on it, and women taking any effective HAART regimen should continue on it even if it does not contain AZT (zidovudine), the panel recommends.
World Health Organization guidelines on antiretroviral treatment for the prevention of mother-to-child transmission in resource-constrained settings first recommended the use of efavirenz during pregnancy in 2009, but United States guidelines updated in 2010 recommend avoiding the drug during the first trimester of pregnancy.
The draft guidelines are available for comment until Friday February 24 at the BHIVA website.
Key recommendations from the guidelines
Women who need HAART for their own health
Women requiring HAART for their own health should commence treatment as soon as possible as per the adult treatment guidelines.
In terms of the NRTI backbone, there is most evidence and experience in pregnancy with zidovudine plus lamivudine. Tenofovir plus emtricitabine or abacavir plus lamivudine are acceptable alternatives.
In the absence of specific contraindications it is recommended that the third agent in HAART should be nevirapine if the CD4 count is less than 250 or efavirenz or a boosted PI.
No routine dose alterations are recommended for ARVs during pregnancy if used at adult licensed doses but consider third trimester TDM, particularly if combining tenofovir and atazanavir.
For women who do not need HAART for their own health
In the absence of specific contraindications it is recommended that HAART should be boosted-PI-based. The combination of zidovudine, lamivudine and abacavir can be used if the baseline viral load is <100,000 HIV RNA copies/ml plasma.
Zidovudine monotherapy can be used in women planning a caesarean section who have a baseline VL of <10,000 and a CD4 of >350. Women who do not require treatment for themselves should commence temporary HAART at week 14 if the baseline VL is >30K (Consider starting earlier if VL> 100,000). All women should have commenced HAART by 24 weeks.
A woman who presents after 28 weeks should commence HAART without delay. If the viral load is unknown or >100K a 3 or 4 drug regimen that includes raltegravir is suggested.
An untreated woman presenting in labour at term should be given a stat dose of nevirapine and commence fixed-dose zidovudine with lamivudine and raltegravir.
Women presenting in labour/ROM/requiring delivery without a documented HIV result must be recommended to have a HIV diagnostic point of care test (POCT). A reactive POCT result must be acted upon immediately with initiation of the interventions to PMTCT without waiting for formal serological confirmation.
ART can be continued in all women who commenced cART for MTCT with a CD4 count of between 350 and 500 cells during pregnancy.
ART should be discontinued in all women who commenced cART for MTCT with a CD4 count of > 500 cells unless there is discordance with her partner (see above) or co-morbidity.
Mode of delivery
Vaginal delivery is recommended for women on HAART with an HIV viral load <50 HIV RNA copies/ml at gestational week 36.
Delivery by pre-labour caesarean section (PLCS) is recommended for women taking zidovudine monotherapy irrespective of plasma viral load at the time of delivery and for women with viral load >400 regardless of ART.
Vaginal delivery is recommended for women on HAART with a HIV viral load <50 HIV RNA copies/ml plasma at gestational week 36.
Delivery by PLCS is recommended for women taking zidovudine monotherapy irrespective of plasma viral load at the time of delivery (Grading: 1A) and for women with viral load >400 regardless of ART.
Infant prophylaxis
Zidovudine monotherapy is recommended if maternal viral load is <50 HIV RNA copies/ml at 36 weeks gestation/delivery (or mother delivered by PLCS whilst on ZDV monotherapy), irrespective of the mother’s viral resistance pattern or drug history.
Infants <72 hours old, born to untreated HIV-positive mothers, should initiate three drug therapy immediately.
Three drug infant therapy is recommended for all circumstances where maternal viral load at 36 weeks gestation/delivery is not <50 HIV RNA copies/ml.
Three drug infant therapy is recommended for all circumstances where maternal viral load at 36 weeks gestation/delivery is not <50 HIV RNA copies/ml.
Neonatal PEP should be continued for 4 weeks.
Infant feeding
All mothers known to be HIV infected, regardless of antiretroviral therapy, and infant PEP, should be advised to exclusively formula feed from birth In the very rare instances where a mother who is on effective HAART with a repeatedly undetectable viral load chooses to breast feed, this should not constitute grounds for automatic referral to child protection teams. Maternal HAART should be carefully monitored and continued until one week after all breastfeeding has ceased. Breastfeeding, except during the weaning period, should be exclusive and all breastfeeding, including the weaning period, should have been completed by the end of 6 months
Prolonged infant prophylaxis during the breastfeeding period, as opposed to maternal HAART, is not recommended.
Intensive support and monitoring of the mother and infant are recommended during any breastfeeding period, including monthly measurement of maternal HIV plasma viral load, and monthly testing of the infant for HIV by PCR for HIV cDNA or RNA (viral load).
HIV DNA PCR (or HIV RNA testing) should be performed on the following occasions.
  • During the first 48 hours and prior to hospital discharge
  • 2 weeks post infant prophylaxis (6 weeks of age)
  • 2 months post infant prophylaxis (12 weeks of age)
  • On other occasions if additional risk (e.g. breast-feeding)
HIV antibody testing for seroreversion should be done at age 18 months.
-----------------------------------------------------------------------------
2. Increased risk of anal cancer for all groups with HIV
Michael Carter
Published: 08 February 2012
Gay men are not the only group of HIV-positive patients who have an increased risk of anal cancer, according to North American research published in the online edition of Clinical Infectious Diseases. The researchers found that incidence of the cancer was also significantly higher in non-gay HIV-positive men as well as HIV-positive women when compared to individuals in the general population.
“We confirmed that HIV-infected MSM [men who have sex with men] experienced the greatest risk of anal cancer,” write the authors. “We also found that both HIV-infected other men and women had substantially higher rates than HIV-uninfected men and women, and that HIV-infected other men and women had similar rates.” They believe that their findings may have implications for anal cancer screening strategies.
Thanks to improvements in HIV treatment and care the prognosis of many HIV-positive patients is now near normal. However, HIV-positive patients appear more likely to develop certain malignancies, including anal cancer, compared to their HIV-negative peers.
Understanding the incidence of anal cancer in the different populations affected by HIV can help develop strategies to prevent the cancer.
Therefore investigators from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) analysed findings from 13 US and Canadian studies. Their aims was to determine incidence of anal cancer in HIV-positive patients, who were divided into three categories – MSM, other men and women.
Rates of anal cancer in these HIV-positive patients were compared to those observed in HIV-negative men and women. Analyses were also conducted to see if there were temporal trends in anal cancer incidence, and if any specific risk factors for the malignancy in HIV-positive patients could be identified.
A total of 34,000 HIV-positive patients (55% MSM, 19% other men, 26% women) and 110,000 HIV-negative controls (90% men) were included in the study.
Data gathered between 1996 (the year effective HIV therapy first became available) and 2007 were examined by the investigators.
Incidence of anal cancer in MSM was 131 per 100,000 patient years. Among HIV-positive other men incidence of the malignancy was 46 per 100,000 years, and incidence in HIV-positive women was 30 per 100,000 person years. Incidence was therefore significantly higher in HIV-positive MSM compared to other men (p < 0.01). However, incidence rates for HIV-positive other men and women did not differ significantly.
Over the same period, the incidence of anal cancer in HIV-negative men was just 2 per 100,000 person years. There were no cases of the malignancy in HIV-negative women.
The investigators calculated that the risk of anal cancer was 80-times higher for HIV-positive gay men compared to HIV-negative men (RR = 80.3; 95% CI, 42.7-151.1). HIV-positive other men were almost 27 times more likely to develop anal cancer compared to HIV-negative men (RR = 26.7; 95% CI, 11.5-61.7).
“Our finding of high anal cancer incidence rates in HIV-infected MSM, other men, and women suggests the need for enhanced primary and secondary prevention efforts among all HIV-infected persons, as opposed to a targeted approach,” write the authors
Incidence of anal cancer increased significantly in HIV-positive gay men between 1996-99 and 2000-2003 (p < 0.03). However, new cases of the malignancy then stabilised. A similar trend was observed in HIV-positive other men and women. The investigators suggest that the initial increase was a function of the improved prognosis of HIV-positive patients, which allowed long-term cell changes caused by high-risk strains of human papilloma virus to become cancerous. In contrast, the levelling of cancer rate was attributed to the beneficial effects of antiretroviral treatment on the immune system.
HIV-positive MSM were significantly more likely to develop anal cancer than other HIV-positive men (RR = 3.3; 95% CI, 1.8-6.0). The risk of the cancer was near identical for HIV-positive other men and women.
Other risk factors for the malignancy included older age (RR per additional ten years = 1.3; 95% CI, 1.1-1.5).
A higher baseline CD4 cell count was protective against the development of the cancer (RR CD4 cell count above 500 cells/mm3 vs. 200 cells/mm3 = 0.2; 95% CI, 0.1-0.3).
There is currently disagreement about the value of anal cancer screening for HIV-positive patients. However, the investigators suggest that this is likely to be cost effective. They note “the New York State AIDS Institute guidelines
recommend anal digital rectal examination for all patients, anal targeted anal cytology for MSM, for individuals with a history of anogenital warts, and for women with a history of abnormal cervical or vulvar histology.”
Reference

Silverberg MJ et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis, online edition. DOI: 10.1093/cid/cir1012 (click here for the free abs

---------------------------------------------------------------------------

3. Cotrimoxazole prophylaxis reduces death rate by almost 60% in adults taking ART in low and middle-income countries
Carole Leach-Lemens
Published: 10 February 2012
Cotrimoxazole significantly reduces death among adults on ART in low and middle-income countries, according to a systematic review and meta-analysis published in the October online edition of the Bulletin of the World Health Organization.
Pooled analysis of seven studies showed that cotrimoxazole prophylaxis reduced the incidence of death by close to 60% (0.42, 95% CI: 0.29-0.61).
However, further research is needed to determine the optimum length of time for cotrimoxazole treatment in HIV-infected adults on ART. An on-going randomised double-blind placebo controlled trial involving 2000 individuals in Uganda is looking at this question, with results anticipated in 2014.
These findings together with those from a recent cost-effectiveness model lend further support to the World Health Organization’s (WHO) recommendations to scale up the use of cotrimoxazole in HIV-infected individuals starting or on ART.
Widespread implementation will importantly help reduce the high early death rate among HIV-infected individuals in low- and middle-income countries.
Those in low-income countries present at a more advanced stage of illness compared to those in high-income countries. Yet even when adjusting for differences in CD4 cell count at baseline death in the first few months remains higher among those in low-income countries. 
Cotrimoxazole is a cheap ($7 for each patient per year), widely available antibiotic, easy to use with no adverse side effects. Studies have suggested it is effective against common causes of death and risks of disease including malaria in people with HIV regardless of whether they are on ART or not.
Common causes of death among those on ART in low- and middle-income countries include sepsis, tuberculosis, meningitis, encephalitis, PCP, Kaposi’s sarcoma and diarrhoea.
Cotrimoxazole is a potentially important intervention in helping reduce the high early death rate of those starting or on ART.
In high-income countries it is given to those who present late for care primarily to prevent pneumocystis jirovecii (carinii) pneumonia (PCP). It is used in low- and middle-income countries for a wide range of bacterial and fungal infections and is not limited to those with advanced HIV.
.
WHO recommends its use in adults with WHO HIV clinical stage 2, 3 or 4 in settings with a limited health care infrastructure. Where HIV prevalence is high, however, the recommendation is for all HIV-infected adults to be treated since it reduces disease regardless of disease stage or CD4 cell count and makes distribution easier.
The authors undertook a systematic review of the effect of daily cotrimoxazole prophylaxis on death and disease in people on ART aged 13 or over.
In December 2010 they searched PubMed and Embase databases for randomised controlled trials and prospective and retrospective cohort studies comparing death and disease in HIV-infected individuals on cotrimoxazole and ART and on ART alone.
Selection, confounding and measurement bias was assessed. There was no evidence of publication bias.
Significant increased survival was seen when cotrimoxazole was continued at the start of ART, was begun at the same time as when ART was started or when starting cotrimoxazole when the patient was stable on ART.
Despite cotrimoxazole being widely available, cheap, safe and effective in helping reduce the high early death rate among people with HIV in low- and middle-income countries, its use remains limited.
The authors suggest reasons include: delays in the dissemination of the recommendations for its use; drug procurement and supply problems; poor health care infrastructure for managing patients before ART as well as inadequate monitoring and evaluation.
They suggest in addition to resolving these issues getting more adults on cotrimoxazole can be achieved by making its benefits known and using indicators to monitor its use globally and at the individual treatment programme level.
The authors highlight WHO’s priority (with UNAIDS) outlined in the Treatment 2.0 initiative of identifying, retaining and caring for people earlier in the course of HIV infection to improve both clinical and programme outcomes. They note currently over 50% of people are lost to care between diagnosis and starting ART.
They propose that providing free cotrimoxazole could help keep people in care and look at the individual’s ability to adhere to treatment as well as improve the survival of those not on ART.
Reduced early death rates as well as better retention could be further improved if intensified tuberculosis case-finding took place at every health visit and isoniazid given to those with tuberculosis without a cough, night sweats, weight loss or fever, the authors add.
Limitations include most studies had a short follow-up and none considered the effect on adults with a high baseline CD4 cell count; none looked at adherence to cotrimoxazole and ART; no study reported the cause of death so the exact mechanism by which cotrimoxazole improves survival is unclear. 
The authors conclude “although the data
were limited and results from an on-going trial
awaited, our findings support current WHO recommendations that the use of cotrimoxazole should be scaled-up in HIV-infected individuals starting or getting ART.”
Reference

Suthar AB et al. Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis. Bull World Health Organ 2012; 90:128-138C, doi:10.

-----------------------------------------------------------------------

4. Tenofovir associated with increased risk of kidney disease

Michael Carter
Published: 13 February 2012
Treatment with tenofovir is associated with a modestly increased risk of three key markers of kidney disease, US investigators report in the online edition of AIDS.
The large study involved over 10,000 patients who started antiretroviral therapy between 1997 and 2007. Patients treated with tenofovir were significantly more likely to develop proteinuria (high levels of protein in urine), experience a rapid decline in kidney function and have an estimated glomerular filtration rate below 60 ml/min/1.73 m3 (chronic kidney disease, or CKD). The risk of kidney disease also remained elevated for patients who discontinued tenofovir therapy.
“Even after accounting for demographics, HIV-related factors, comorbidities, and other antiretroviral drugs, tenofovir remained associated with an increased risk for each kidney disease outcome,” write the investigators.
The authors stress the drug’s association with proteinuria and CKD, noting “each is independently associated with cardiovascular disease and death in the setting of HIV infection.”
However, they also emphasise the importance of tenofovir in HIV treatment and that the risk of kidney disease associated with the drug should be balanced against its potential benefits. Moreover, the authors do not regard their research as definitive and call for further research.
Patients with HIV have an increased risk of kidney disease. The exact causes are controversial, but appear to include the effects of HIV itself, traditional risk factors such as hypertension and diabetes, co-infection with hepatitis C, and possibly the side-effects of some antiretroviral drugs.
The research exploring the association of tenofovir (Viread, also available in the combination pills Truvada and Atripla) with kidney disease is contradictory. Although some studies found an association between the drug and kidney dysfunction, this was not the case with others.
Differences in patient populations, limited sample sizes and lack of access to the appropriate laboratory data could be the reason for the lack of concordance between studies.
It is important to establish if the drug does increase the risk of kidney disease. Tenofovir is widely used in first-line antiretroviral therapy and also has an important role in pre-exposure prophylaxis (PrEP) regimens. Moreover, kidney dysfunction is a risk factor for cardiovascular disease, which is an increasingly important cause of illness and death in patients with HIV.
Therefore investigators from the US Department of Veterans Affairs designed a study to determine the effects of tenofovir exposure on the risk of kidney disease.
Their study population comprised 10,841 patients who started antiretroviral therapy for the first time over a ten-year period between 1997 and 2007. A total of 4,303 individuals were exposed to tenofovir. There was no difference between the tenofovir-treated patients and the patients treated with alternative antiretroviral drugs in terms of the prevalence of diabetes and hypertension, hepatitis C co-infection, CD4 cell count and viral load. Prevalence of proteinuria at baseline was comparable between the two groups of patients.
The overall mean age was 46 years and 98% of individuals were men.
Mean duration of tenofovir therapy was 1.3 years. The investigators acknowledge that this short period of treatment was a limitation of their study.
The study did not report on the absolute risk of kidney disease. It is important to bear in mind that previous studies have consistently shown that kidney problems develop in fewer than one in 20 people who take the drug, and serious impairment has been seen in fewer than one in 100. The classic risk factors, such as diabetes, high blood pressure and untreated HIV infection, continue to be more important causes of chronic kidney disease in people living with HIV. Just like anyone else, people with HIV are also vulnerable to acute kidney injury due to inflammation, infection or medications that can damage the kidneys.
In the entire study population there were 3400 proteinuria events in 38,132 person-years of follow-up; 3,078 rapid declines in kidney function during 51,589 person years; and 533 CKD events in 56,416 person years.
In all the investigators’ models, both any use of tenofovir and cumulative exposure to the drug was strongly associated with a significant increase in the risk of all three markers of kidney disease (p = 0.0033 to p < 0.0001).
Therapy with tenofovir was also associated with the presence of both proteinuria and CKD (p  = 0.0014), a more stringent measure of kidney disease.
Multivariate analysis which controlled for other variables that could affect the risk of developing kidney disease showed that each year of tenofovir treatment was associated with a 34% increased risk of proteinuria (95% confidence interval 25% - 45%, p< 0.0001), 11% increased risk of rapid decline in kidney function (95% CI 3% - 18%, p=0.0033) and a 33% increased risk of chronic kidney disease (95% CI 18% - 51%, p<0.0001).
Patients who ceased tenofovir therapy continued to have an increased risk of CKD which was of borderline significance (HR = 1.22 per year; 95% CI, 0.99-1.50, p = 0.055).
“The effects of tenofovir on kidney disease risk were not reversible following discontinuation,” comment the authors.
However the presence of other risk factors for kidney disease did not increase the risk of kidney disease while taking tenofovir; indeed, the association between tenofovir treatment and kidney disease was significantly weaker in older people, diabetics and people with cardiovascular disease or hypertension when compared to younger people or those without these conditions.
Tenofovir was the only anti-HIV drug with significant associations for all three measures of kidney disease used in the study. Nevertheless, several other drugs increased the risk of individual measures of renal dysfunction. For instance, ritonavir (Norvir) increased the risk of proteinuria (p < 0.0001). Atazanavir (Reyataz) was associated with a rapid decline in kidney function (p = 0.0035), and indinavir (Crixivan) had a significant association with CKD (p = 0.0019).
The authors were well aware of the apparent significance of their findings and their potential to cause alarm among patients. They therefore believe it is important to balance the benefits and risks of therapy with the drug.
“Despite tenofovir’s association with progressive kidney disease, it is an important component of effective antiretroviral therapy that may be required in many patients to control viral load,” conclude the investigators. “The balance between its efficacy and probably adverse events requires further study.”
NOTE: this article was amended on 16.2.2012 to correct an error, which referred to a risk associated with abacavir. This should have read `indinavir`.
Reference
Scherzer R et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS, online edition. DOI: 10.1097/QAD.0b013e328351f68f, 2012 (click here for the free abstract).
------------------------------------------------------------------------------------
5. HIV treatment reduces risk of fractures
Michael Carter
Published: 14 February 2012
Treatment with antiretroviral drugs reduces the risk of low-impact fractures, according to a case-controlled study published in the on-line edition of AIDS. Investigators compared fracture incidence between patients taking HIV therapy and non-treated individuals.
Despite the overall beneficial effect of treatment, the investigators found a complex relationship between drug class and duration of therapy and fracture risk.
Although there are concerns that tenofovir (Viread, also in the combination pills Truvada and Atripla) causes reductions in bone mineral density, the investigators found no robust evidence that the drug was associated with an increased risk of fracture.
“Our study identified an overall reduced risk for fracture in persons treated versus not treated with antiretroviral drugs for HIV infection,” write the authors.
With the right treatment and care, the prognosis of many HIV-positive patients is excellent. However, there is an increased prevalence of low bone mineral density in patients with HIV. The exact causes are uncertain, but may include HIV infection itself, the ageing of the HIV-infected population, and the side-effects of antiretroviral therapy. Nor are the clinical consequences clear. Some studies have shown that patients taking HIV treatment have an increased risk of fragility fractures, but such findings have been contradicted by other research.
Because of this continuing uncertainty, investigators in the US designed a case-controlled study involving patients who received HIV care between 1997 and 2008. The incidence of  low impact fragility fractures was compared between patients who received HIV therapy lasting at least twelve months and individuals with no history of antiretroviral treatment. The relationship between specific classes of antiretrovirals, individual drugs and duration of therapy and fracture risk was also examined. Finally, because of tenofovir’s association with low bone mineral density, the investigators compared fracture incidence between patients taking this drug and that seen among individuals taking abacavir (Ziagen, also in the combination pills Kivexa and Trizivir).
Cases were matched with four controls of exactly the same gender who were exactly the same age.
The study included 2411 cases and 9144 controls. An increased risk of fracture was associated with behavioural characteristics such as excess alcohol intake and low levels physical activity (both p < 0.0001). Some health-related factors were also associated with a significant increase in fracture risk. These included low body weight and a prior history of fractures (both p < 0.0001). More advanced HIV infection was also revealed as an important risk fracture for fractures (p < 0.0001).
Overall, HIV treatment reduced the risk of fractures (p < 0.0001). Nucleoside reverse transcriptase inhibitors (NRTIs), non-NRTIs (NNRTIs) and protease inhibitors were also associated with a reduction in fracture risk (p < 0.0001; p < 0.0001 and p = 0.0001 respectively). A significant reduction in the incidence of fracture was seen with both shorter and longer duration of therapy.
However, a more complex picture emerged when the investigators examined fracture risk according to the use of specific antiretroviral drugs.
For instance, therapy with the protease inhibitors darunavir (Prezista) and saquinavir (Invirase) was associated with an increased risk of fracture (p = 0.043 and p = 0.002 respectively). This increase in risk was regardless of the duration of exposure.
Treatment with several antiretroviral drugs, including nevirapine (Viramune), ddI (Videx) an ritonavir (Norvir) was initially associated with and increased risk of fracture, but this association disappeared with longer duration of treatment.
A number of widely-used agents had a consistent relationship with a reduced risk of fracture. These included efavirenz (Sustiva, also in the combination pill Atripla), 3TC (lamivudine, Epivir, also in the combination pills Kivexa, Combivir and Trizivir), FTC (emtricitabine, most widely taken in the combination pills Truvada and Atripla), tenofovir and AZT (Retrovir, also combined in Combivir and Trizivir).
Atazanavir (Reyataz), fosamprenavir, and lopinavir (Kaletra) neither increased nor decreased the risk of fracture. This neutral association was also found for a number of older agents which are now rarely used or discontinued.
Combinations containing abacavir were associated with a 25% reduction in fracture risk (OR = 0.75; 95% CI, 0.64-0.88). This was comparable to the reduction in risk seen for non-abacavir regimens (OR = 0.61; 95% CI, 0.54-0.69).
Tenofovir-containing regimens were associated with a 37% reduction in the risk of fracture (OR = 0.63; 95% CI, 0.55-0.72). The reduction in risk as similar for non-tenofovir regimens (OR = 0.68; 95% CI, 0.59-0.78).
The investigators believe their results indicate an overall benefit of antiretroviral treatment for bone health.
They conclude: “Our findings contribute evidence to and support for future robust analysis of observational cohort data to assess and identify modifiable risk factors associated with aging and drug exposure–response relationships. Such comparative research efforts will be integral to optimizing incremental net health benefits and antiretroviral treatment in years to come.
Reference
Mundy LM et al. Overall benefits of antiretroviral treatment on the risk of fracture in HIV: nested casecontrol analysis in a health-insured population. AIDS, online edition. DOI: 10.1097/QAD.0b013e328351997f, 2012 (click here for the free abstract).
------------------------------------------------------------------------------------

6. Neverapine and severe rash

Carole Leach-Lemens
Published: 20 February 2012
The risk of severe rash when taking the antiretroviral drug nevirapine is greater in women who clear the drug from their bloodstreams slowly, and clearance of the drug appears to be slower in African women, according to a pharmacokinetic analysis of the relationship between drug levels and severe nevirapine side-effects in a recent large trial of first-line antiretroviral therapy in sub-Saharan Africa.
The findings from the ACTG 5208/OCTANE study are published online in advance of print in the journal AIDS.
This pharmacokinetic (PK) study from the ACTG A5208/OCTANE clinical trial showed that the odds of developing a severe rash were estimated to be 50% higher for every 20% decrease in the rate of nevirapine clearance (p=0.046), and clearance of nevirapine was approximately 40% slower than previously reported in studies carried out in the United States and the Netherlands, suggesting that African women may be genetically predisposed to slower clearance of this drug.
Nevirapine (NVP), a non-nucleoside reverse transcriptase inhibitor (NNRTI), is part of standard first-line ART in resource-poor settings. During the first weeks of ART NVP has been linked to a serious and sometime life-threatening rash and/or liver damage. NVP rash is seen more often in women than in men.
The precise cause of NVP toxicity is unclear. Studies suggest that there is a link between how NVP is absorbed (NVP PK) and an increased risk for toxicity. These findings, however, are from studies with a majority of male subjects. Yet, it appears that women are exposed to the drug for longer since it takes longer to clear. Other factors that may contribute to how the drug is absorbed include: body weight, ethnicity, pre-existing liver disease and pharmacogenetics (how genetic make-up affects the response to medications).
So the authors chose to undertake this study to try and clarify the link of NVP PK with increased risk of rash and/or liver damage among a large cohort of HIV-infected, but not pregnant, women from 10 sites in seven sub-Saharan countries who started NVP-based ART. And secondarily to see if there was a link between these adverse effects and pre-treatment CD4 cell count and weight.
All women enrolled in the trial had a CD4 cell count under 200 cells/mm3 before starting treatment, were ART-naĂŻve or had taken zidovudine or single dose nevirapine for PMTCT. They were randomised to get either lopinavir/ritonavir twice a day or NVP twice a day after a 14 day period of once daily NVP each in combination with tenofovir and emtricitabine (Truvada).  Those randomised to NVP were included in the PK trial. Single nevirapine blood samples were taken after randomisation at 14 (±7) days (before dose escalation to twice a day) and at 28 (± 7) days if no NVP doses had been missed in the previous three days. They were followed until the last woman randomised had finished 48 weeks of follow-up.
Toxicity was defined as rash and liver damage that happened during therapy or within seven days of the last dose of nevirapine and before starting another ART regimen.
Population pharmacokinetic analysis modelled NVP pharmacokinetics. The authors note since only a single NVP blood sample was taken at week 2 and week 4 for each subject a simple additive clearance (CL) model was used to capture any additional CL after week 2 (CLweek4=CLweek2+CL additional).
Among the 359 women, included in the analysis, at baseline median age was 33 years (IQR: 28-38); median weight 57 kg (IQR: 52-67); and median CD4 cell count 128 cells/mm3 (IQR: 80-176).
While the screening CD4 count had to be under 200 cells/mm3 there were no restrictions on the baseline CD4 count. 47 women with a CD4 count over 200 cells/mm3 were enrolled with a median of 262 cells/mm3 (IQR: 250-386).
Women weighing less than 50 kg compared to those at or over 50 kg were significantly younger (median 30 compared to 34 years, p=0.012)) had higher viral loads (median 199526 compared to 125893 copies/mL) and more advanced WHO stage 3 or 4 (44% compared to 28%), p=0.013.
54% (194) developed a rash of any grade of which 23% (82) had grade 2+ and 9 (3%) had grade3+ of which one had grade 3+ liver damage. The link between NVP PK exposure and a significantly increased risk of severe rash was seen at week 4 but not at week 2
Median clearance at 28 days (week 4) was 1.7L/hr for women with a severe rash (grade 3+) compared to 2.0L/hr for women without a severe rash, p=0.046.
Discontinuing nevirapine because of rash and/or liver damage was more frequent among women with CD4 cell counts over 250 cells/mm3 before starting treatment (p=0.003). 
The authors note this is is the first study to show a link between NVP exposure and grade 3+ rash. While other studies have shown a link between exposure and increased liver enzymes none have shown such a consistent relationship, they add.
The authors note these findings “add to previous data suggesting vigilance and close monitoring for NVP toxicity are required for all African women starting NVP at any CD4 count, but toxicity is more likely in those with CD4 cell counts at or above 250 cellsmm3.”
Limitations include a lack of pharmacogenetic data to link with the pharmacokinetic findings because patient consent was not initially obtained.
The authors suggest caution in interpreting the findings as they are based on the differences between screening and pre treatment CD4 cell counts of a small number of women and the potential for change within the subject between the two measurements.
Guidelines now recommend starting ART at a higher CD4 cell count leading the authors to stress the importance of further PK and pharmacogenetic studies; in particular in resource-poor settings, notably among African women, to determine the most effective dose of nevirapine to give the best results while minimising toxicity.
Reference
Dong BJ et al. Nevirapine (NVP) pharmacokinetics (PK) and risk of rash and hepatitis among HIV-infected sub-Saharan African women. Advance online edition AIDS 26, doi: 10.1097/QAD.0b013e328351a521, 2012.
 
 

#4792 From: Subhadip Roy <subhadip_roy_04@...>
Date: Wed Feb 22, 2012 7:12 am
Subject: Siddhartha Gautam Film Festival 2012 - First Announcement and Call for Entries
subhadip_roy_04
Send Email Send Email
 
Siddhartha Gautam Film Festival 2012
Jalpaiguri (March 11), Siliguri (March 24),
Kolkata (March 25)
 
First Announcement and Call for Entries

Siddhartha Gautam Film Festival 2012 is opening its call for entries for the eighth edition to be held in Siliguri, Jalpaiguri and Kolkata in the month of March. Mobile film shows in health settings will also be organized in Asansol, Haldia and Howrah. The festival is being co-organized by Northern Black Rose, Siliguri; Jalpaiguri Uttarayan, Jalpaiguri; Koshish, Kolkata; PLUS, Kolkata; Astitva Dakshin, Baruipur and Solidarity and Action Against The HIV Infection in India (SAATHII), Kolkata Office on behalf of the Coalition of Rights Based Groups, a state level advocacy forum to advance the health and rights of sexual minorities and people living with HIV in West Bengal.
The festival is organized annually in memory of the pioneering activist Siddhartha Gautam and seeks to generate awareness and dialogue on gender, sexuality, HIV, sexual and reproductive health, and human rights issues. SAATHII and its partner organizations first organized the festival in Kolkata in 2003. It was inspired by a similar festival organized by the Friends of Siddhartha group in New Delhi each year from 1993 to 2003.
Over the years, the festival has become a multi-venue, week long event that reaches out to audiences in both urban and rural West Bengal. This is the third year that the festival is being organized as part of the Coalition of Rights Based Groups’ efforts. The festival is also organized along similar lines in Odisha by sister coalition Sampark. The coalitions have provided the festival with a much wider ambit and reach than in the earlier years. The festival includes both theatre-based and mobile film screenings. The festival will make its debut in Jalpaiguri this year.
Festival theme: In its eighth edition, the festival aims to highlight a diverse set of cross-cutting and interlinked issues that Siddhartha Gautam worked on:
·                    Struggle for survival with dignity of people living with HIV and those involved in same-sex romantic relationships
·                    Challenges faced by transgender people in social, legal and economic spheres
·                    Protection of child rights
·                    Concerns of mental health and disability
·                    Stories of untiring activism to fight corruption and justice
 
The films will be seen by a diverse audience of lesbian, gay, bisexual, transgender, intersexed, Kothi, Hijra and other queer people; people infected or affected by HIV; social workers; health care providers; legal service providers; government officials; college and university students; and media persons. Families and friends of queer people and people living with HIV will be especially welcome.
Call for entries: Filmmakers interested in participating should send their films in DVD formats (compatible with Indian systems) together with the screening permission letter, synopsis (film title, genre, production/release year, duration, director and producers’ names, film summary and filmmaker profile summary), and full contact details. Please also submit one or two digital stills from the film, or computer soft copy of the film DVD cover.
Shorts, documentaries, docu-features and feature films of any length suitable to the festival themes will be welcome. We especially encourage films produced in India and those that focus on the Indian, Indian Diaspora and South Asian contexts. We will also be approaching a number of filmmakers whose productions are already available in SAATHII’s reference libraries in Kolkata and Bhubaneswar.
Please note that there is no entry fee for participation. All films will be subject to a selection process by the Film Festival Organizing Committee. SAATHII will be happy to include the films submitted in its reference libraries which together constitute a key resource in eastern India for material on sexual and reproductive health and rights.
Last date for submission: February 29, 2012
Films need to be submitted / couriered to: Sarika Kar, Knowledge Resources and Documentation Officer, SAATHII, 229 Kalitala Main Road, Purbachal (N), Kolkata 700 078. Phone: 033 2484 4835, 2484 5002
The festival programming and schedules will be announced on the SAATHII website and Facebook page in the coming days. Please also look out for further announcements.
For enquiries: Phone: Pawan Dhall 0 98312 88023; Souvik Ghosal 0 91262 07148; Dipankar Datta 0 98325 62550; Agniva Lahiri 0 98305 10527; Sanjay Ram 0 98300 23153; Sanjay Mandal 0 98308 37440; Sarika Kar 033 2484 5002
 
E-mail: saathii@... with cc to crbgadmsubcom@... and crbg377@...
In solidarity: Pawan Dhall, Souvik Ghosal, Dipankar Dutta, Agniva Lahiri, Sanjay Ram, Sanjay Mandal, Kunal Chowdhury, Sarika Kar – Film Festival Organizing Committee – on behalf of the Coalition of Rights Based Groups
Courtesy: Interact Worldwide, London; Department for International Development – Civil Society Challenge Fund, Glasgow; Alliance India, New Delhi; Global Fund for AIDS, Tuberculosis and Malaria

#4793 From: "EMPOWER INDIA" <ttn_empower@...>
Date: Tue Feb 21, 2012 3:13 pm
Subject: ITPC Spotlight: Zero children dying from tuberculosis by 2015 is possible, if...
ttn_empower@...
Send Email Send Email
 
Spotlight: Zero children dying from tuberculosis by 2015 is possible, if...

Hara Mihalea, PATH

**********************



[Mods note: To join the e-consultation on childhood TB, send an email to:
stop-TB-subscribe@yahoogroups.com . The below CNS article written by Hara
Mihalea, PATH, Thailand, is available online at:
http://www.citizen-news.org/2012/02/0-children-dying-from-tb-by-2015-is.html .
Comments are welcome. Thanks]

**********************



I like to start by sharing a real story which I experienced in one of my visits
in the field last year. I'm sure many of you working in the field have similar
stories to tell. During a monitoring visit for our PPM program I came across a
referral slip made out by a pharmacy staff referring a 36 year old woman to the
DOTS health center.



Looking at the symptoms circled on the slip one could tell that this was
certainly a pulmonary TB case; weight loss, fatigue, chest pain, fever, and
cough with blood. We traced the referral to one of the district health centers
where we found out that the woman had indeed gone for further evaluation, she
was checked, diagnosed, given medication and sent home. We were told by the
health center staff that since the first visit she came back twice, each time
sicker than before, and was again send home, no TB. We decided to visit her at
home where she lived with her husband, her in-laws, two small children and one
baby. We asked the district TB officer to join us so he could be able to
follow-up later on.



When we arrived in her small house we were taken up in her room, she was sitting
on a straw mat on the floor, baby on the breast, glassy eyes, face flushed with
fever. She repeated the same story that the health staff told us. She told us
how disappointed, sad, and scared she felt, she said she was getting worse by
the minute and no one could help her. She said she wanted to go back to the
health center but they didn't have any more money and no transportation. Each
time she coughed she hit on her chest to show us where it hurts. I will never
forget the pain on her face, the shortness of her breath when she tried to tell
us her story. I will never forget the fear I felt for the baby on her breast and
her other two children and thinking that this woman unless treated immediately
will soon die and leave these children orphans. The end of the story is that the
woman did have TB and the last we heard was that the district officer was trying
to get the children tested.



So what went wrong? why did this woman sought care three times and still was
send home with a bag of  antibiotics and vitamins? This is a very common story
and it's happening every day, many times a day around the world, especially in
high TB burden developing countries.



I shared this story with you because I truly believe that once again we might
not be able to reach our goal to Zero the numbers of children dying of TB in our
lifetime, left alone by the year 2015, if we don't take some drastic steps to
address the real problems that are preventing us from doing a good job. We can
have the guidelines and country operational plans for TB in children, we can
have the treatment algorithms however I strongly feel that these will not help
much, especially in limited resource setting where stories such as this are real
unless we start by:



(1) Holding governments accountable for the health and well-being of their
populations, especially the children; health is a right not a luxury and not
only for the few. Advocate governments for resource allocation that will
increase the salaries of the health staff and will motivate them to perform
their tasks in an appropriate manner; health staff in developing countries often
do not get their salary for 3-6 months.



(2) Strengthening the DOTS program. If we had a quality DOTS program the health
staff would have been able to accurately diagnose and successfully treat the mom
in the story.  They would have being able to prevent TB and the needless
suffering in her children.



(3) Integrating TB into the primary health care and sensitizing all health care
providers on TB.  Once sensitized health staff be able to screen children and
moms during immunization sessions, postnatal visits, reproductive health (RH)
visits or other consultations.



(4) Most importantly recognizing the symptoms of TB in children, creating
linkages and partnerships between communities, private providers and TB services



(5) Intensifying case finding and contact tracing when TB is suspected to all
family members, most importantly to children. The majority of the children get
TB from a family member.



(6) TB is a poverty disease, half of the children in the developing countries go
without meals, they are malnutrition which makes them even more vulnerable to
TB. Addressing the nutrition needs is of out-most importance.



(7) TB in a child that is already living with HIV is a double heartbreak and so
much more difficult to diagnose and treat.



I might sound to you pessimistic, I am a little bit because TB is very political
and things are moving very slowly; we cannot afford to move slowly anymore, we
should not allow it. We need to step up and step up very fast. What we should
all see at the end of 2015 is not just the numbers, the statistics showing fewer
deaths, we should see children, happy and smiley faces, children free of TB.
Where there is a will there is a way and collective voices will find the way.



Hara Mihalea CHE, MPH

PATH, Thailand



Online at:
http://www.citizen-news.org/2012/02/0-children-dying-from-tb-by-2015-is.html

**************************************************



[MODS NOTE: Join the e-consultation by sending an email to:
stop-tb-subscribe@yahoogroups.com . The guiding question (Theme 1) of the
time-limited online consultation on childhood tuberculosis (TB) in lead up to
the World TB Day is: "What can be done more (or less of) at the family,
community or your country level to prevent new TB infections in children?"



Have your say before 25th February 2012:
http://www.citizen-news.org/2012/02/theme-1-e-consultation-how-to-get-to.html .
Thanks]

**************************************************

   Forwarded by:
---------------------------
  Yours in Global Concern,
  A.SANKAR
Executive Director- EMPOWER  INDIA - Professional Civil Society Organisation
Founder and General Secretary - Confederation of Indian Civil Society
Organisation’s (CICSO)
National Convener- National Alliance for Health, Environment and Rights (
NAFHER)
107J / 133E, Millerpuram
TUTICORIN-628 008, TN, INDIA
Telefax: 91 461 2310151; Mobile:   91 94431 48599: www.empowerindia.org
‱         You are invited to join an E FORUM AIDS-TN. To join this free E 
Forum kindly send an e  mail    to AIDS-TN-subscribe@yahoogroups.com
‱           This e Forum moderated by   EMPOWER, a Non-profit, Non-Political,
Voluntary and Professional Civil Society Organisation.

                Please don't print this e-mail unless you really need to.
              S.v.p. ne pas imprimer ce courriel à moins d’en avoir vraiment
besoin.

#4794 From: paramesh wari <Parameshware@...>
Date: Fri Feb 24, 2012 2:43 pm
Subject: Scientific Writing workshop
Parameshware@...
Send Email Send Email
 



















Dear
All,
 
Please register for the workshop. Kindly see the attachment. Registration is extended till 28th february,2012
 
The TN Dr.MGR Medical University

1 of 1 File(s)


#4795 From: SAATHII <saathii@...>
Date: Mon Mar 5, 2012 11:37 am
Subject: Scientific Updates on HIV/AIDS
saathii
Send Email Send Email
 
SAATHII Electronic Newsletter
HIV/AIDS Updates
 
 
 
POSTED ON:       05.03.2012
 
COMPILED BY:  Dr. Sai Subhasree Raghavan and Manish Mudaliar
 
NOTE: This compilation contains news items about HIV/AIDS published in the International Electronic Newsletters. Articles in this and previous newsletters may also be accessed at http://www.saathii.org/orc/elibrary
-------------------------------------------------------------------------------------------------------------------------------

Race and CD4+ T-cell Count in HIV Prognosis and Treatment

From Future Virology

Amit C Achhra; Janaki Amin
Posted: 02/26/2012; Future Virology. 2012;7(2):193-203. Â© 2012 Future Medicine Ltd.
Abstract and Introduction
Abstract
CD4+ T-cell count is known to vary by race in HIV-negative individuals. While people of certain races, such as blacks and Asians, continue to be disproportionately burdened by HIV/AIDS, they remain under-represented in most HIV clinical studies. Recent studies suggest that CD4+ count evolution in HIV, before and after therapy, may differ by race. In this review, we summarize the evidence from prospective cohorts comparing CD4+ count trajectories by race, and whether it is of any clinical significance. We find that although minor differences in CD4+ count trajectories exist between people of diverse races, socioeconomic, cultural and environmental differences are far more important in predicting clinical outcomes than racial differences in CD4+ count. Furthermore, current evidence does not support the need for any race or ethnicity-specific CD4+ thresholds for ART and prophylactic therapy initiation. Future long-term trials in racially diverse populations are required to substantiate these findings.
Introduction
In HIV infection, the CD4+ T-cell count (henceforth CD4+ count) is used for prognosis of HIV disease, making decisions on initiating prophylaxis for opportunistic infections, and initiating combination antiretroviral therapy (cART).[1,2,101] Even after starting effective cART, CD4+ counts are known to be one of best predictors of mortality, AIDS and serious non-AIDS events,[3,4] and are therefore an important part of HIV disease monitoring.
Total lymphocyte and CD4+ counts are reported to vary between people from diverse racial and geographical backgrounds.[5–13] For example, several studies suggest that HIV-negative whites, on average, have higher CD4+ counts (~1000 [± 200] cells/”l),[14] as compared with HIV-negative Asians (~800 [± 250] cells/”l).[6–8,13–15] Reference range-finding studies on blacks from countries such as Kenya,[9] Botswana[5] and Ethiopia[12] have reported lower CD4+ counts as compared with whites; while studies from other African countries reported higher or comparable CD4+ counts to whites.[10] Furthermore, a few cross-sectional studies in HIV-infected individuals also suggested that CD4+ counts may vary by race/ethnicity at any given stage of HIV disease, especially at higher CD4+ strata.[16,17] Although several prospective clinical studies have evaluated changes in CD4+ counts before and after treatment, and their relationship to clinical events and treatment initiation; most of these studies have included predominantly white (Caucasian) populations in developed countries. The validity of generalizing these results to more diverse populations is unknown.
Globally, people from certain races continue to be disproportionately affected by HIV. Sub-Saharan Africa carries 60% of the global HIV burden.[102] South-east and east Asian countries contribute over 10% of HIV infections world-wide.[103] In the USA, up to 45% of incident HIV occurs in African–American (black) populations, which are also reported to have a higher mortality rate due to AIDS, as compared with whites.[18–20] It is therefore important, although difficult, to evaluate the contribution of race per se, rather than the more modifiable socioeconomic and environmental factors, to the course of HIV disease.
In this paper, we will provide a narrative of prospective clinical and epidemiological studies in adults evaluating the role of race/ethnicity in CD4+ count changes in HIV, as opposed to a systematic review on a defined risk factor and endpoint. Specifically, we will assess: the variations in CD4+ count evolution in untreated and treated HIV infection; evidence of variation by race in the relationship between CD4+ counts and clinical endpoints; and what these findings might mean for the design of future epidemiological studies and individual patient management of HIV-infected individuals from diverse races.

Race & Ethnicity in HIV Research

The terms 'race' and 'ethnicity' have been poorly defined, and are inconsistently used across studies.[21–23] While 'race' implies an individual's geographic region of origin, physical characteristics and genetic make-up, 'ethnicity' is a broader construct and considers an individual's cultural traditions and practices.[21,22] The classification scheme of race used in the 2000 US census, which is often used in biomedical research, includes blacks or African–Americans, whites, Asians, native Hawaiian or other Pacific Islander and American–Indian or Alaskan native.[21,22] However, this is further complicated by the fact that the terms such as 'black' or 'Asian' do not capture the diversity within the groups and could be too simplistic.[24] For example, the migration of African-descent populations (i.e., black populations) in Europe occurred relatively recently (after the 1950s) from former colonies (e.g., Zimbabwe, Kenya, Tanzania, Uganda or the West Indies); whereas in the USA, migration occurred from the West Indies, Haiti and other parts of Africa relatively much earlier than that in Europe.[24] In France, African-descent populations came mainly from west Africa, which, especially in the case of recent migrants, may also have the higher prevalence of HIV subtype-2.[25] Similarly, the term 'Asians' could include diverse groups such as those from Indian subcontinent (south Asians) and those from China and other parts of Asia.[24] This also makes comparing studies from different countries problematic. In HIV clinical-epidemiological studies, blacks (mostly in the USA) have been the most common non-white people studied. For this study we will be referring to literature that has described research using the terms 'race' or 'ethnicity' as 'race'.
Evaluating the role of race in HIV is difficult, as race is often associated with several factors that affect HIV disease management and progression such as education, access to healthcare, socioeconomic status, environmental differences, different HIV subtypes, adherence and cultural practices.[22,26] Cohort studies that include patients of diverse racial origins with equal access to care are therefore a valuable source of information. However, equal access to care may not translate to equal uptake. For example, in a large clinical-trial cohort of mixed ethnicity in a US setting, with equal access to care, poorer outcomes after antiretroviral therapy were noted for black populations and were largely explained by lower adherence, baseline characteristics such as coinfections and advanced disease at therapy initiation.[27] Furthermore, cohorts comparing migrants in western countries to the local populations may account for some environmental confounders, although these studies are subject to 'healthy migrant' biases, among others.[23]
Thus, evaluating the role of race independent of socioeconomic factors and environmental factors in prospective cohorts of diverse populations is challenging. In this review, we will focus on findings from studies that have accounted for some of these confounders (see Box 1 for search strategy).
Race & CD4+ T-cell Count Evolution in HIV Infection
Untreated HIV Infection
Although several studies have evaluated CD4+ count decline after HIV infection in therapy-naive individuals, relatively fewer studies have compared diverse races within a single study using identical methodology. Recent large prospective studies evaluating the role of race are summarized in Table 1.[28–37] Most studies have compared black and white populations (Table 1). These studies suggest that black individuals, on average, have a somewhat slower decline in CD4+ counts compared with the white population. Moreover, this difference was found to interact with current CD4+ count, meaning that at higher CD4+ counts (greater than 350 or 500 cells/”l), the difference in rate of decline is larger than that at lower CD4+ counts (less than 200 cells/”l). A large prospective cohort study comparing Swiss and Cape Town cohorts, suggested that irrespective of the geographical region, black individuals, compared with white individuals, had CD4+ decline ranging from 30 cells/”l/year slower at baseline CD4+ counts greater than 500 cells/”l to 5 cells/”l/year slower at baseline CD4+ count less than 200 cells/”l.[31] Similarly, Mekonnen et al. comparing Ethiopian blacks to Dutch whites, found slower decline in blacks by approximately 30 cells/”l/year at baseline CD4+ count greater than 350 cells/”l to 10–20 cells/”l/year at baseline CD4+ count less than 200 cells/”l.[30]
Seroconverter cohort data from the Eligibility for ART in Low-Income Countries (eART Linc) collaboration of African and Asian (Thai) cohorts shows faster progression to AIDS in a Thai blood donor cohort, although follow-up CD4+ counts were not available.[38] This difference was attributed to the lower socioeconomic strata and lack of access to healthcare of the selected Thai cohort. A retrospective analysis from an Asian cohort suggests that rate of CD4+ decline could be similar to that in white populations.[39] However, findings from this study are difficult to interpret as most patients had AIDS at baseline, and had only short follow-up commencing from the first available retrospective CD4+ count.[39]
It is unclear if time to cART eligibility (as defined by CD4+ count) differs significantly by race. If estimates of rate of CD4+ count decline were available for diverse population groups, they could be used to model time to disease progression or time to cART eligibility, to get more accurate race-specific estimates.[31,38,40] For example, Minga et al. used information about rate of CD4+ count decline from HIV seroconversion to estimate the number of people becoming eligible for ART as per standard guidelines, in a given time, in order to forecast the need for ART in a given geographical region.[40]
Several possible explanations for racial variation in rate of CD4+ count decline have been offered. One possible explanation is that baseline immune activation may vary by race.[30,31] It has been postulated that, due to a high prevalence of background infections in low-income countries such as many African nations or in lower socioeconomic strata of western societies, these populations may have been selected for their ability to survive despite chronic immune activation by maintaining a low immune-activation phenotype.[30,31] This hypothesis, however, has not been tested.
Another explanation is that CD4+ count response may vary by HIV-1 subtype (clade).[34,41] While HIV-1 clade B predominates in western countries, non-B clades are more common in other areas of the world. Clade C predominates in Asia, the Middle East, east–central and south Africa, while other clades, including circulating recombinant forms, are more prevalent in sub-Saharan Africa and Asia.[26,34,41] This hypothesis is not, however, supported by the Muller et al. study, which compared black and white populations infected with similar clades of HIV in the same geographical region and with equal access to care, and showed that HIV clade does not explain the slower decline of CD4+ counts in blacks.[33] Lastly, genetic factors or the interaction between genetic and environmental factors could explain these differences.[33,42]
It should be mentioned that comparing the results across studies is problematic, because most studies have the starting point of follow-up as first measured CD4+ count after enrollment, as opposed to a fixed time-point in HIV natural history, such as at HIV seroconversion (Table 1). The circumstances under which patients are enrolled and had CD4+ count measurement vary between patients and studies and this is difficult to measure and account for. In addition, such studies do not account for the duration of HIV infection, which is likely to be important in assessing the disease progression. However, seroconversion cohorts are especially rare in low–middle-income countries.[38]
Treated HIV Infection
In response to potent cART and achieving durable virological suppression, CD4+ counts are known to increase rapidly in the first 6 months following cART initiation, and continue to increase for at least 7–8 years towards normalization.[43–45] A recent review comparing long-term CD4+ count gain in populations with access to free cART from diverse populations including Asia, Africa and high-income countries, concluded that the rate of change in CD4+ counts was largely similar between high- and low–middle-income populations; and that any differences in CD4+ gain could be explained by lower CD4+ count at cART initiation.[46] In a large North American cohort comparing whites, blacks and Hispanics with equal access to care and adherence to treatment, the rate of CD4+ count change was similar, as was the virological response, in all races.[47] However, whites had higher CD4+ counts at cART initiation, and this difference was maintained, such that at the end of an 8-year follow-up, whites had a mean CD4+ count of 30 cells/”l higher than non-white individuals.[47] Analyses from a large Asia–Pacific cohort found that Asians had lower CD4+ counts at cART initiation, but gained CD4+ count at equal or faster rates as compared with whites, and had a mean CD4+ count of approximately 25 cells/”l lesser than whites at the end of 6–7 year follow-up.[48] Similarly, in a cohort from Denmark, which had minimal socioeconomic disparities, the rate of CD4+ count gain did not vary by race.[49] Other studies have reached a similar conclusion.[50,51] Conversely, two North American cohorts with identical access to care for black and white populations suggested that blacks had higher rate of virological failure, which was most likely explained by lower adherence to treatment as compared with white individuals.[27,32] These observations suggest that race by itself is an unlikely determinant of immunological or virological response after therapy initiation, and that factors such as socioeconomic, environmental and cultural differences (including differences in adherence) and late initiation of cART are likely to explain any observed disparities between the races.
The CD4+ count evolution for whites and non-whites, from HIV infection to cART initiation and post-cART is illustrated in Figure 1. The disparity in CD4+ count responses (higher in whites than in non-whites) evident in this figure could be due to late initiation of cART in non-white groups.[32,48] Alternatively, a recent study suggested that with long-term effective antiretroviral therapy, the immune system seeks to attain the previous equilibrium dictated by the earliest CD4+ count at or before seroconversion.[52] This suggests that the maximum attainable CD4+ count by any group may be similar to their baseline (pre-therapy) CD4+ count (irrespective of the CD4+ count at therapy initiation), which might be slightly lower for non-whites (Figure 1). We will next discuss whether these differences translate into any clinical significance.
Click to zoom
Figure 1.
CD4+ evolution in HIV infection before and after combination antiretroviral therapy, by race. A schematic representation of the CD4+ count trajectories after HIV seroconversion and after start of antiretroviral therapy in whites and non-whites (predominantly blacks). The figure assumes the rate of loss of CD4+ counts after HIV seroconversion at approximately 100 cells/”l/year in whites (and ~70–80 cells/”l/year in non-whites) at CD4+ counts above 500 cells/”l and approximately 50 cells/”l/year in whites at CD4+ counts less than 500 cells/”l (and ~30–40 cells/”l/year in non-whites) until the start of cART [30,31]. After the start of cART, the rate of gain in CD4+ count is similar between whites and non-whites (~100 cells/”l/year in the first year, 40–50 cells/”l/year up to 5–6 years after start of antiretroviral therapy and stabilizing thereafter) [45,46]. The figure shows: higher CD4+ counts at HIV seroconversion, and slightly faster initial decline in CD4+ counts in whites compared with non-whites, before cART; typical delayed initiation of cART in non-white groups; and similar rate of CD4+ gain after cART in whites and non-whites. Importantly, large variations at the individual and population level exist.
cART: Combination antiretroviral therapy.
Clinical Significance of the Differences in CD4+ Count Evolution by Race
The clinical significance of the differences in CD4+ count decline before cART, or CD4+ gain after cART, is not clear. Studies reporting slower CD4+ decline pre-cART in black individuals, did not find a difference in rate of AIDS or death by race, especially in populations with equal access to care.[30,36,53] Mekonen et al. suggests that although blacks, compared with whites, have lower CD4+ counts at HIV seroconversion, their excess risk of AIDS or death may have been offset by a proportionately slower decline after seroconversion.[30] In a large multicenter North American cohort following over 2000 seroconverters, white individuals had lower rates of AIDS as compared with non-whites only in southern regions, which are known to have greater health disparities between black and white populations; while the outcomes were similar in other regions.[37] Similarly, migrants from Africa and Asia in a European seroconverter cohort with equal access to care, had identical rates of AIDS or death as compared with white individuals.[36]
Several studies have also suggested that the risk of clinical events after effective cART is unlikely to vary by ethnicity. In a large population-based cohort study in Denmark where access to care is universal, people of non-white origin had similar risk of virological failure and AIDS as to those of white origin.[49] Studies that have found increased rates of virological failure and AIDS in non-white populations have attributed this excess risk to late initiation of cART, socioeconomic disparities, background infections (e.g., TB), inconsistent coverage and adherence to ART, multiple comorbidities and lack of health insurance in non-white populations.[27,32,50,53–59] For example, in the Women's Interagency HIV cohort in North America, white women overall had better immunological and virological outcomes after cART initiation. However, when the analysis was adjusted for socioeconomic and psychosocial factors such as lower income, current drug use, depression, and discontinuation of therapy after initiation; non-white women had similar outcomes as compared with white women.[57]
These observations argue against the role of race in influencing outcomes in HIV, and instead emphasize the role of other modifiable factors such as universal access to healthcare (or lack thereof), socioeconomic disparities, psychosocial factors and comorbidities.[58]
Implications for Therapy Initiation
Present HIV treatment guidelines are consistent in recommending cART initiation at CD4+ counts ≀350 cells/”l.[101,104,] Furthermore, the Department of Health and Human Services (DHHS) guidelines recommend treatment at 350–500 cells/”l and the consensus is divided about whether cART should be commenced at CD4+ counts more than 500 cells/”l.[104] Evidence for commencement at CD4+ counts ≀500 cells/”l comes from three large cohort analyses, one observational analysis of a clinical trial, and one clinical trial in Haiti.[60–64] All of the cohort studies were predominantly in North American and European populations of predominantly white and some black individuals.[60,62–64] Although they did not assess for any interaction between CD4+ counts and race (i.e., assess whether starting at any CD4+ threshold confers a different amount of risk by race); these studies did not find race to be an important confounder in multivariable analyses.[60,62–64] Moreover, a Haitian clinical trial, which predominantly recruited a black population, confirmed the CD4+ threshold of 350 cells/”l or less (compared with 200 cells/”l or less) to be an appropriate threshold for cART initiation, although it did not assess any benefit of starting at higher thresholds.[61] Lastly, the spectrum of AIDS events, by CD4+ counts, was not found to be different between whites, blacks and Hispanics, in a large North American cohort with access to cART.[65] Collectively, these observations suggest that the results from these studies are likely to be generalizable to black populations.
Fewer studies have included people of Asian or other races. As discussed in the previous section, the differences observed in CD4+ count decline pretherapy or gain after cART initiation by race, are only prominent at higher CD4+ counts, where clinical events are less likely to occur. Moreover, mortality rates in Asian populations are reported to approach those in white populations within a few months after cART initiation.[66–69] Furthermore, a large prospective analysis from the Asia–Pacific HIV cohort suggested that the magnitude of risk of AIDS or death, at any given CD4+ count, was not different between Asians and whites (Figure 2).[70] These observations suggest that the prognostic significance of CD4+ count is similar in Asians and whites and provide indirect evidence that the CD4+ thresholds for cART and prophylactic therapy initiation derived from white populations may be equally appropriate for Asian populations.[70] Although two studies from Hong Kong suggested that lower CD4+ thresholds for cART initiation may be appropriate among Asian populations, these studies were limited by small sample size, especially at CD4+ counts above 200 cells/”l and a small number of clinical endpoints (<30 in both studies).[71,72]
Click to zoom
Figure 2.
Risk of AIDS or death, by latest CD4+ counts, in Asians and whites. Incidence-rate, per 100 person-years, of AIDS or death, in Asians and whites, taken from Achhra et al.. [70]. Figure shows similar rate of AIDS or death events in Asians and whites, at any given latest CD4+ count strata.

Conclusion & Future Perspective

The decline in CD4+ counts after HIV seroconversion may vary by race, especially at higher CD4+ counts. Non-white races appear to have lower CD4+ counts at HIV seroconversion, and somewhat slower decline by approximately 20 cells/”l/year at higher CD4+ counts (above 350 or 500 cells/”l), although the clinical significance of this difference is unclear. Nevertheless, the estimates of the rate of CD4+ count decline in different races/ethnicities could be used to obtain more accurate results about time to ART eligibility, needed in forecasting demand for ART. Seroconversion cohorts from diverse populations, including low–middle-income countries, are likely to provide this information in future.
After therapy initiation, the rate of CD4+ count gain does not appear to be different between people of diverse races. However, non-white people tend to start cART at lower CD4+ counts, which may explain the slightly lower CD4+ counts in non-whites, as compared with whites, throughout the follow-up. Also, the maximum CD4+ counts attained by non-whites could be slightly lower than whites, reflecting their lower pre-seroconversion CD4+ counts.
These differences in CD4+ counts, however, do not appear to translate into differential risk of AIDS or death in people from diverse races. Any excess morbidity and mortality in non-white races appear to be related to modifiable factors such as socioeconomic and psychosocial differences, environmental factors such as background infections (e.g., TB), access to healthcare (or lack thereof), and late initiation of cART. Future studies should therefore focus on better understanding these modifiable factors, to achieve equivalent health outcomes in diverse populations. Furthermore, current evidence does not support the need for any race- or ethnicity-specific CD4+ thresholds for ART and prophylactic therapy initiation, and suggests that conclusions drawn on white populations could be broadly appropriate for other groups. It should be noted, however, that data on Asian and other non-white groups are remarkably scarce. The ongoing large-scale trial, evaluating strategic timing of initiation of anti-retroviral therapy (START),[105] is enrolling patients from diverse settings, including Asia and Africa. Results from such multinational trials, which can provide subgroup analyses by race, will be important in future to substantiate our conclusions.
 

#4796 From: "Dr. Nabeel M. K." <drnabeelmk@...>
Date: Mon Feb 27, 2012 7:02 pm
Subject: Oslo Declaration on HIV Criminalisation
drnabeelmk
Send Email Send Email
 


Oslo Declaration on HIV Criminalisation
Prepared by international civil society in Oslo, Norway on 13th February 2012

You can sign the declaration at http://www.hivjustice.net/oslo/oslo-supporters/

  1. A growing body of evidence suggests that the criminalisation of HIV non-disclosure, potential exposure and non-intentional transmission is doing more harm than good in terms of its impact on public health and human rights.[1]

  2. A better alternative to the use of the criminal law are measures that create an environment that enables people to seek testing, support and timely treatment, and to safely disclose their HIV status.[2]

  3. Although there may be a limited role for criminal law in rare cases in which people transmit HIV with malicious intent, we prefer to see people living with HIV supported and empowered from the moment of diagnosis, so that even these rare cases may be prevented. This requires a non-punitive, non-criminal HIV prevention approach centred within communities, where expertise about, and understanding of, HIV issues is best found.[3]

  4. Existing HIV-specific criminal laws should be repealed, in accordance with UNAIDS recommendations.[4] If, following a thorough evidence-informed national review, HIV-related prosecutions are still deemed to be necessary they should be based on principles of proportionality, foreseeability, intent, causality and non-discrimination; informed by the most-up-to-date HIV-related science and medical information; harm-based, rather than risk-of-harm based; and be consistent with both public health goals and international human rights obligations.[5]

  5. Where the general law can be, or is being, used for HIV-related prosecutions, the exact nature of the rights and responsibilities of people living with HIV under the law should be clarified, ideally through prosecutorial and police guidelines, produced in consultation with all key stakeholders, to ensure that police investigations are appropriate and to ensure that people with HIV have adequate access to justice. We respectfully ask Ministries of Health and Justice and other relevant policymakers and criminal justice system actors to also take into account the following in any consideration about whether or not to use criminal law in HIV-related cases:

  6. HIV epidemics are driven by undiagnosed HIV infections, not by people who know their HIV-positive status.[6] Unprotected sex includes risking many possible eventualities – positive and negative – including the risk of acquiring sexually transmitted infections such as HIV. Due to the high number of undiagnosed infections, relying on disclosure to protect oneself – and prosecuting people for non-disclosure – can and does lead to a false sense of security.

  7. HIV is just one of many sexually transmitted or communicable diseases that can cause long-term harm.[7] Singling out HIV with specific laws or prosecutions further stigmatises people living with and affected by HIV. HIV-related stigma is the greatest barrier to testing, treatment uptake, disclosure and a country’s success in “getting to zero new infections, AIDS-related deaths and zero discrimination”.[8]

  8. Criminal laws do not change behaviour rooted in complex social issues, especially behaviour that is based on desire and impacted by HIV-related stigma.[9] Such behaviour is changed by counselling and support for people living with HIV that aims to achieve health, dignity and empowerment.[10]

  9. Neither the criminal justice system nor the media are currently well-equipped to deal with HIV-related criminal cases.[11] Relevant authorities should ensure adequate HIV-related training for police, prosecutors, defence lawyers, judges, juries and the media.

  10. Once a person’s HIV status has been involuntarily disclosed in the media, it will always be available through an internet search. People accused of HIV-related ‘crimes’ for which they are not (or should not be found) guilty have a right to privacy. There is no public health benefit in identifying such individuals in the media; if previous partners need to be informed for public health purposes, ethical and confidential partner notification protocols should be followed.[12]
References
[2] UNAIDS/UNDP. Policy Brief: Criminalization of HIV Transmission. Geneva, July 2008; Open Society Institute. Ten Reasons to Oppose the Criminalization of HIV Exposure or Transmission. 2008; IPPF,GNP+ and ICW. Verdict on a Virus. 2008. See also: IPPF. Verdict on a Virus (documentary) 2011.
[3] GNP+/UNAIDS. Positive Health Dignity and Prevention: A Policy Framework. Amsterdam/Geneva, January 2011.
[4] UNAIDS/UNDP. Policy Brief: Criminalization of HIV Transmission. Geneva, July 2008.
[5] UNAIDS. (2012) Op. cit.
[8] UNAIDS. Getting to Zero: 2011-2015 Strategy. Geneva, December 2010.
[9] Bernard EJ and Bennett-Carlson R. Criminalisation of HIV Non-disclosure, Exposure and Transmission: Background and Current Landscape. UNAIDS, Geneva, February 2012.
[10] GNP+/UNAIDS (2011) Op. cit.
[11] Bernard EJ and Bennett-Carlson R (2012) Op. cit.







Messages 4767 - 4796 of 4842   Oldest  |  < Older  |  Newer >  |  Newest
Add to My Yahoo!      XML What's This?

Copyright © 2010 Yahoo! Inc. All rights reserved.
Privacy Policy - Terms of Service - Guidelines NEW - Help